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Executive Summary  
This guidance has been developed by the Centers for Disease Control and Prevention (CDC) and 
the Health Resources and Services Administration (HRSA) to assist persons who compile and 
interpret HIV prevention and care data for state, territorial, or local HIV epidemiologic profiles. 
The purpose of the document is to provide one set of guidance to help profile writers produce 
integrated epidemiologic profiles and advise them concerning how to interpret epidemiologic 
data in ways that are consistent and useful in meeting the planning and evaluation needs of both 
HIV prevention and care programs. Integrating prevention and care data should help to 
streamline the work of health department staff, HIV planning groups, and planning councils by 
reducing duplicated effort and by promoting consistency and comparability of data and terms in 
prevention as well as care planning.  
The guidelines are written in 5 chapters that (1) provide an overview of integrated HIV 
epidemiologic profiles, (2) outline what writers need to do to start creating a comprehensive 
profile, (3) address how to describe the burden of HIV in a jurisdiction, (4) describe the process 
of completing the profile, and (5) address special issues that may arise during the writing of the 
profile. Each chapter is organized into sections. Specific data and elements to meet the 
requirements of CDC and of HRSA are also addressed. Highlights of each chapter are as follows:  
• Chapter 1  
o Describes the purpose of the guidelines, identifies the audience for the document, and 
outlines what end users will learn  
• Chapter 2  
o Describes 3 core epidemiologic questions and 2 care-related questions that help to 
describe the burden of HIV in a jurisdiction and suggests analyses that may be used to 
answer each question. 
 Core Question 1: What are the sociodemographic characteristics of the general 
population in your service area?  
 Core Question 2: What is the scope of HIV in your service area?  
 Core Question 3: What are the indicators of risk for HIV infection in the 
population covered by your service area?  
 Care-related Question 1: Using epidemiologic and related public health data, what 
is the impact of the care and treatment services of the Ryan White HIV/AIDS 
Programs on people living with HIV?  
 Care-related Question 2: What are some things to keep in mind as a Ryan White 
HIV/AIDS Program grantee prepares the epidemiologic profile document for 
HRSA’s HIV/AIDS Bureau?  
 Outlines a 7-step process for developing the profile  
• Chapter 3  
o Describes the contents of the body of the profile, including  
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 supporting data to answer the core questions and the care-related questions  
 sources of, and caveats about, data 
• Chapter 4 
o Describes how to make the profile user-friendly and disseminate the profile  
• Chapter 5  
o Addresses confidentiality, special-needs populations, comorbidity, and areas with low 
morbidity and minimal data 
The guidance also includes appendices, terms, definitions, and calculations common to HIV 
epidemiologic profiles, and a list of references and suggested readings. The appendices consist of 
the following:  
• Appendix A: Sample Data Tables and Charts with Interpretation Associated with 
Chapter 3  
• Appendix B: Use of Tables, Charts, and Maps to Illustrate Data 
• Appendix C: Data Sources  
• Appendix D: Ryan White HIV/AIDS Programs  
• Appendix E: Preparing Oral Presentations of Your Profile  
• Appendix F: Planning Group Epidemiologic Profile Feedback Form 
• Appendix G: Terms, Definitions, and Calculations  
Epidemiologic profiles should be compiled, interpreted, and summarized by epidemiologists in 
the state or local health department in collaboration with interested planning group members. 
Planning group members should, at a minimum, assist in framing the questions to be addressed 
by the profile.  
Although input from planning group members is a valuable component of profile development, 
final editorial control should rest with the state health department. 
The data in an integrated HIV epidemiologic profile may be used for several purposes, including 
HIV planning, designing and implementing prevention activities and evaluation programs, and 
informing policy decisions and documenting care needs for underserved groups. Researchers, 
consumers, legislators, and the media also use the data.  
The information should be used as a starting point in the development of your profile. The 
recommended analyses represent the minimum data for an integrated profile. Depending on the 
need for HIV prevention and care services in a jurisdiction, additional analyses may be required. 
Technical assistance with analyzing, interpreting, and presenting prevention-related data and 
care-related data is available from CDC and HRSA, respectively.  
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Chapter 1. 
Introduction 
Section 1  Overview  
Section 2  Goals and Benefits of Integrated Guidance  
Section 3  Core Concepts  
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Section 1: Overview  
The epidemiologic profile is a document that describes the burden of HIV on the population of 
an area in terms of sociodemographic, geographic, behavioral, and clinical characteristics of 
persons with HIV. The profile is a valuable tool that is used at the state and local levels by those 
who make recommendations for allocating HIV prevention and care resources, planning 
programs, and evaluating programs and policies.  
The Centers for Disease Control and Prevention (CDC) and the Health Resources and Services 
Administration (HRSA) are 2 of the agencies that use HIV epidemiologic and surveillance data. 
Both agencies provide guidance and funding for programs for persons with, or at risk for, HIV. 
The goals of these programs are to prevent HIV infection and promote testing, care, and treatment.  
Purpose of the guidance 
The Integrated Guidance for Developing Epidemiologic Profiles is a joint project of CDC and 
HRSA. The purpose of the document is to provide guidance to help writers create integrated 
epidemiologic profiles and advice on how to interpret the data in ways that are consistent and 
useful in meeting the planning needs of both HIV prevention and care programs. Integrating 
prevention and care data should help to streamline the work of health department staff, HIV 
planning groups, and planning councils by reducing duplicated effort and by promoting 
consistency and comparability of data and terms in prevention as well as in care planning. 
HIV planning  
HIV planning is a process organized by the health department in which HIV prevention decisions 
(e.g., programs and services provided, funding allocations) within the jurisdiction are decided via 
a formal voting process by the HIV Planning Group (HPG), a specially selected group of 
community members reflective of the jurisdiction’s burden of disease. The epidemiologic profile 
is an essential document for this body, in that it informs the following:  
• Comprehensive HIV Prevention Plan—The HPG is responsible for developing a 
comprehensive HIV prevention plan. To develop the plan, the HPG should review and 
discuss information presented in the epidemiologic profile, such as geographical and 
demographic patterns of HIV cases in the jurisdiction. Other sources of information will 
be reviewed, but the most crucial are epidemiologic data.  
• Composition of HIV Planning Group—The HPG should be diverse and include 
representatives of persons living with HIV in the jurisdiction. The demographic 
breakdown of HIV prevalence and diagnoses presented in the epidemiologic profile is 
used to determine the composition of the HPG in order to create parity in the planning 
body. These statistics help to ensure that the health department meets this fundamental 
component of the cooperative agreement.  
Health departments that have produced profiles using methods that they find effective, but which 
may differ from the procedures presented here, should feel free to adapt the recommendations in 
this document on the basis of their own experience, community needs, and priorities.  
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Section 2: Goals and Benefits of Integrated Guidance 
Recognizing that epidemiologic profiles for HIV prevention and care share common purposes, 
data needs, and staff demands, CDC and HRSA agreed to create common guidance that will 
contribute to the following goals and benefits:  
Goal Benefit 
• Consistent epidemiologic profiles 
o common time frame  
o common data  
o core elements with specific sections 
to meet the individual requirements 
of CDC and HRSA  
o common data elements, definitions, 
categories, time frames  
• Increased usefulness and application 
• Enhanced sharing of information at all 
levels (federal, state, regional, and 
local) and in all organizations  
• Increased quality 
• Increased confidence in data validity 
because the data are being used for 
two processes  
• User-friendly epidemiologic profiles • Easy interpretation and application to 
local needs  
• Enhanced possibility that data will be 
used in planning 
• Flexibility to customize profiles to meet 
local needs 
• Enhanced quality and sharing of 
information while meeting local 
requirements 
• Shared resources for prevention and 
care 
• Reduced strain on local capacity 
• Reduced duplication of effort 
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Section 3: Core Concepts  
HIV epidemiologic profile goals 
An epidemiologic profile is designed to  
• provide a thorough description of HIV among the various populations (overall and 
subpopulations) in a service area in terms of sociodemographic, geographic, behavioral, 
and clinical characteristics  
• describe the current status of persons with HIV infection in the service area and provide 
some understanding of how the HIV distribution may look in the future  
• identify characteristics of the general population and of populations who are living with, 
or at high risk for, HIV in defined geographic areas and who need primary and secondary 
prevention or care services  
• provide information required to conduct needs assessments and gap analyses  
Users and uses of an epidemiologic profile 
Epidemiologic profiles have many users. The primary users are prevention and care planning 
groups, grantees, and applicants for funding. As you develop the profile, keep these end users in 
mind. Make the profile user-friendly to all planning group members, regardless of their 
experience with statistical data.  
Planning groups use the HIV epidemiologic profile to  
• set priorities among populations who need prevention and care services  
• provide a basis for determining or projecting future needs  
• develop requests for proposals to providers and subcontractors  
• increase general community awareness of HIV  
• disseminate data for providers  
• frame research and evaluation questions  
• apply for, and receive, funding  
• respond to public needs (e.g., educators, funding agencies, media, policymakers)  
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Profile end user Focus Specific uses 
CDC 
• HIV planning groups (HPGs) 




• Preventing and 
intervening to reduce 
transmission of HIV  
• Prioritize target 
populations and 
identify appropriate 
interventions for each 
priority population 
• Develop HIV 
prevention plan 
HRSA  
• Ryan White HIV/AIDS 
Program grantees  
• Ryan White HIV/AIDS 
planning bodies  
• Community-based 
organizations 
• Providing services 
and care for people 
living with HIV 
• Set priorities and 
allocate resources for 
care  
• Serve as source 
document for 
applications to HRSA’s 
HIV/AIDS Bureau 
The profile should also meet the program requirements of the end users. For example, if the 
planning group using the profile must address emerging communities at risk, ensure that the 
profile provides data on this topic.  
Using the profile to meet CDC prevention guidelines  
CDC prevention guidelines state that the HIV planning process should be used to develop a 
comprehensive HIV prevention plan. The plan is jointly developed by the health department and 
the HPGs and focuses on priority setting for target populations for which HIV prevention will 
have the greatest impact. The first step in HIV prevention planning is the development of an 
epidemiologic profile. State, local, and territorial health departments have the responsibility for 
providing an epidemiologic profile that describes HIV in the HPG's service area.  
Using the profile to meet the Ryan White HIV/AIDS Program legislative requirements  
As part of needs assessment, an epidemiologic profile is an important component of Ryan White 
HIV/AIDS Program planning as found in the Ryan White HIV/AIDS Treatment Extension Act 
of 2009 (Public Law 111-87, October 30, 2009). Legislative requirements and the expectations 
of HRSA’s HIV/AIDS Bureau differ by Part. In general, each Part calls for profile preparers to  
• determine the size and demographics of the population with HIV  
• determine the service needs of these populations, with particular attention to those who 
know they have HIV but are not receiving HIV-related services and to historically 
underserved persons and communities that are experiencing difficulties in obtaining 
services  
• identify populations with severe needs and comorbidities 
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Chapter 2. 
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Section 1  Determining the Scope  
Section 2  Determining the Content and Organization of the Profile  
Section 3  Development Process  
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Section 5  Analysis and Interpretation  
 
Starting the Process 
Page 15 of 132—8/25/2014 
CDC and HRSA Requirements for Developing a 
Comprehensive or Full Profile and an Update  
Although the data required are similar, CDC and HRSA have different requirements for 
producing and updating the HIV epidemiologic profile. Below are several suggestions:  
• The health department should produce at least one comprehensive epidemiologic profile 
in a funding cycle (5 years). Ryan White HIV/AIDS Program planning consortia and 
councils should follow their yearly program guidance from the HIV/AIDS Bureau.  
• Every year, the health department should update the executive summary and core 
epidemiologic data—including tables and figures—to ensure that planning groups can 
identify and set priorities among populations and their prevention and care needs. The 
yearly update can also be in the form of fact sheets, supplemental reports, slide sets, or 
any standardized reports utilized by the state.  
Consider including, as much as possible, the sociodemographic and socioeconomic information 
covering the entire service area. Updated profiles will then need to include only the data from 
those areas in which significant changes have occurred.  
Section 1: Determining the Scope 
The first step in preparing an HIV epidemiologic profile is to determine its scope. Scope refers to 
the boundaries, such as the time frame and geographic area, that define the extent of information 
in your profile. The scope should be broad enough to provide planning groups with the 
information and background data they need to identify and set priorities among HIV prevention 
and care services. At the same time, the scope needs to be narrow enough to meet specific 
requirements of prevention and care programs. Determining the scope of your epidemiologic 
profile is a collaborative effort that requires consultation with your planning groups and other 
potential stakeholders.  
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Checklist for Determining the Scope of an Epidemiologic Profile  
 Is the profile a comprehensive epidemiologic profile or an annual update?  
 What planning jurisdiction(s) or service area(s) should be included?  
 What years of data will be presented in the profile? 
 What specific questions for prevention and care planning should be addressed by this 
profile?  
Examples  
• special needs of populations at risk of becoming infected with HIV  
• trends that can be identified through a comparison of HIV and stage 3 (AIDS) 
prevalence data  
• setting priorities for prevention and care services among prioritized populations  
 What resources—time, personnel, and funds—are available to develop the profile?  
 What sources of information are needed to answer the profile’s epidemiologic questions?  
 What data are available to supplement the HIV surveillance data that describe the HIV-
positive population?  
 What information is already available? More information, which is readily available, may 
allow for a broader scope.  
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Section 2: Determining the Content and Organization of 
the Profile 
To be useful for prevention and care planning, a full epidemiologic profile should answer several 
core epidemiologic questions:  
• What are the sociodemographic characteristics of the general population in your service 
area?  
• What is the scope of HIV in your service area?  
• What are the indicators of risk for HIV infection in the population covered by your 
service area?  
It should also answer questions specific to prevention or care planning needs, such as the 
following: 
• Using epidemiologic and related public health data, what is the impact of HIV of the care 
and treatment services of the Ryan White HIV/AIDS Programs on people living with 
HIV?  
• What are some things to keep in mind as a Ryan White HIV/AIDS Program grantee 
prepares the epidemiologic profile document for HRSA’s HIV/AIDS Bureau?  
Profile sections and organization 
As is true of any good document, a well-organized profile is divided into logical sections:  
• Front matter  
• Introduction  
• Body  
• Appendices  
• Other back matter  
Front matter  
The front matter should consist of the following:  
• Contributors, a list that includes the names of writers and others who worked on the 
profile  
• Abbreviations, a list of the shortened names for terms and organizations that appear in 
the profile  
• Executive summary, a synopsis of the profile’s content. Although the executive 
summary is at the beginning of the profile, it is one of the last elements you should write  
• Table of contents, a listing of, and page numbers for, topics, tables, and figures  
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Introduction  
The introduction should include the following:  
• Background about the history and purpose of the profile  
• General description of data sources and their strengths and limitations to ensure that 
users understand what the profile can and cannot explain  
• Overall description of the profile’s strengths and limitations  
• Other sources of information beyond the profile. Links to MMWR articles, other 
reports, published work that includes data from your jurisdiction. 
Body  
The body of the profile includes the epidemiologic questions and the data that answer the 
questions.  
Data are typically presented in tables, graphs, pie charts, or maps. These presentations should be 
accompanied by a narrative that explains and expands upon the data.  
Appendices and other back matter  
The back matter should consist of the following:  
• Appendices contain information on data sources, supporting documentation, and a 
feedback form for end users to complete and return to the authors.  
• Other back matter (in addition to the appendices) includes items such as a glossary 
and a list of references or suggested readings.  
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Section 3: Development Process 
Recommended development process  
1. In collaboration with state and local surveillance staff and prevention and care planning 
groups, determine the specific and unique needs of the planning group. Determine the 
boundaries and the scope of the profile. Establish mechanisms to ensure collaboration 
throughout the process. 
2. Obtain core and supplemental data. Determine which of these data to include in the 
analysis. 
3. Analyze and interpret data. 
4. Present data in user-friendly formats. 
5. Draw overall conclusions and write an effective, useful narrative. 
6. Write remaining sections and compile complete epidemiologic profile. 
7. Prepare clear presentations for appropriate audiences. 
Here are some additional tips to help ensure a successful profile development process:  
• Realize that the process is a group effort; it cannot be done by one person  
• Expect that a full-time equivalent staff person will need at least several months to 
complete the profile  
• Have a knowledgeable person with technical expertise on local data sources review and 
proofread the document  
• Create a dissemination plan well before your profile is complete and ready for 
distribution  
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Section 4: Obtaining Profile Data 
General data considerations  
The following are considerations for reviewing data and data sources that you may use in the 
epidemiologic profile:  
• Completeness of the data: How well does the number of reported HIV cases reflect the 
true number of persons who have HIV infection and are thus eligible to be reported? For 
example, how well does the prevalence of HIV represent the true number of persons 
living with HIV in your service area?  
• Representativeness of the data: How well do the characteristics from a data source 
correspond to the characteristics of the overall population? For example, data from a 
hospital-based sample may not represent all HIV-infected persons or all HIV-infected 
persons in care in the area covered by the survey.  
• Age of the data: How old are the data that will be used for analysis? For example, a 
behavioral survey conducted in 1990 might not provide data that are sufficiently up-to-
date for current prevention activities.  
• Timeliness of the data: How long is the reporting delay between the diagnosis of HIV 
and the report to the health department?  
• Surrogate, or proxy, markers: A proxy variable is used as a marker for other variables 
when what we really want to measure is too difficult to measure directly. For example, 
some areas may use sexually transmitted disease (STD) data as a proxy when data on 
sexual behaviors are not available.  
• Reliability of the data: How accurate and complete are the data? For example, how well 
was information about age transcribed to the case report from the medical record (how 
accurate are the case report data compared with those in the medical record)?  
• Small numbers: Small numbers of cases need to be interpreted with caution because 
small absolute changes in the number of cases can produce large relative or proportionate 
changes in rates that may be misinterpreted by end users. Rates calculated from 
numerators smaller than 12 should be denoted in a footnote as unreliable. This case 
threshold was chosen to keep the relative standard error (RSE) below 30% (consistent 
with National Center for Health Statistics [NCHS] surveys). Suggested footnote may read 
“Reported numbers less than 12, as well as estimated numbers (and accompanying rates 
and trends) based on these numbers, should be interpreted with caution because the 
numbers have underlying relative standard errors greater than 30% and are considered 
unreliable.”  
Types and sources of data for epidemiologic profiles  
This section includes a description of commonly available data and their sources. Several of 
these sources directly report HIV cases and clinical conditions of persons with a diagnosis of 
HIV infection. Other sources are used to round out the picture of HIV in your service area. Other 
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sources also are used if no HIV data are available. See Appendix A for an expanded list of core 
and supplemental data sources.  
Type of data:  
HIV surveillance 
Description:  
HIV surveillance data include all persons with confirmed diagnoses of HIV infection (including stage 3 
[AIDS]) and have been reported to a state or local health department.  
HIV surveillance data  
• provide an estimate of the number of persons with a diagnosis of HIV infection whose test was 
confidential 
• identify emerging patterns of transmission 
• help detect trends in HIV infections among populations.  
HIV surveillance data also provide a basis for establishing and evaluating linkage to care, retention in care, 
and viral suppression. They can be used to anticipate unmet needs for HIV care. According to state 
evaluations, HIV infection reporting is estimated to be 80%–90% complete for persons who have tested 
positive for HIV. 
Where to obtain: 
All areas now conduct integrated, name-based HIV surveillance. Contact your state or local service area’s 
HIV surveillance coordinator. 
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Type of data:  
Behavioral surveillance 
Description:  
Data on behaviors that are relevant to HIV prevention, transmission, and medical care may be available 
from a variety of sources, including general population surveys, surveys of populations at risk for HIV, and 
surveys of persons with HIV. Behavioral data include 
• patterns of, or deterrents to, HIV testing 
• substance use and needle sharing 
• sexual behavior, including unprotected sex 
• sexual orientation 
• health-care–seeking behavior 
• adherence to prescribed antiretroviral therapies 
Where to obtain: 
National HIV Behavioral Surveillance (NHBS) coordinator for your state or jurisdiction 
Type of data:  
Clinical data 
Description:  
Clinical data refer to information on the condition(s) of persons with HIV. Clinical information is collected so 
as to understand 
• disease status at the time of diagnosis and later progression (e.g., CD4+ cell count, viral load, 
opportunistic infections) 
• type of medical care received 
• prescription of antiretroviral therapy 
• type of therapy received 
Patient surveys collect data on adherence to therapy and health-care–seeking behavior. Depending on the 
source, clinical data may represent all cases of reported HIV infection or only a fraction. Because clinical 
data rely on the extent of documentation in a medical record and an ability to locate the record, they may 
be incomplete.  
A lot of clinical data are reported to HIV surveillance. The data can be used to determine who was linked to 
care, retained in care, or virally suppressed. 
Where to obtain: 
Coordinators of Medical Monitoring Project (MMP) and HIV surveillance.  
Starting the Process 
Page 23 of 132—8/25/2014 
Type of data:  
Demographic data 
Description:  
Demographic data are used to describe social characteristics (e.g., gender, age, and race/ethnicity) of 
persons in the service area. 
Where to obtain: 
Available for state, metropolitan areas and counties from the Bureau of the Census. Also, states maintain 
census centers. Obtain these data from http://www.census.gov. 
Type of data:  
Hepatitis B and C surveillance 
Description:  
Data on hepatitis B and C virus (HBV, HCV) infections may represent markers for needle sharing and 
sexual behaviors, which can be risk factors for HIV transmission. Data on hepatitis B and C are used to 
• predict the likelihood and rate of spread of viral hepatitis and HIV infections in a community 
• monitor trends 
• identify needs for HIV prevention and care services 
Acute hepatitis B and C (i.e., clinical illness with laboratory confirmation) is reportable in all states; however, 
because of underreporting and asymptomatic infections, data are likely to be incomplete. 
Several states have registries for HBV and HCV infection, and most have laboratory reporting laws 
requiring reporting of positive serologic test results for HBV and HCV infection. Although serologic markers 
for HBV infection can distinguish between acute and chronic infection, laboratory reports of positive HCV-
antibody results cannot differentiate newly acquired infections from chronic or resolved infections, making it 
difficult to monitor disease trends for HCV. In addition, many registries are relatively new, and their 
usefulness has not been evaluated. 
Where to obtain: 
State health department and CDC. The quantity and the quality of surveillance data differ between states. 
Refer to CDC’s National Electronic Disease Surveillance System) and the CDC Division of Viral Hepatitis.  
Reference: CDC. Guidelines for Viral Hepatitis Surveillance and Case Management. Atlanta: CDC; 2005. 
Available at: http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm. 
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Type of data:  
Qualitative data 
Description:  
Qualitative methods are used to obtain data through observations, interviews, discussion groups, focus 
groups, and analysis of social networks. 
Where to obtain: 
Health department staff and local community researchers often use qualitative methods to conduct 
research. Planning group members may also be aware of local studies. Additional information can be 
obtained from the University of Texas—Southwestern (http://www.utsouthwestern.edu/education/school-of-
health-professions/programs/outreach-programs/CPIU/cpiu-toolbox.html). 
Type of data:  
Ryan White HIV/AIDS Program 
Description:  
The Ryan White HIV/AIDS Services Report (RSR) is comprised of three reports used to collect information 
annually from grantees and service providers funded under Parts A, B, C, D or F of the Ryan White 
HIV/AIDS Program. The RSR Grantee Report is completed online and collects basic information about the 
grantee organization including a list of provider service contracts. The Provider Report is also completed 
online and collects general information on provider and program characteristics, including the types of 
organizations providing services (e.g., ownership status), sources of revenue, expenditures, and paid and 
volunteer staff. Finally, the Client Report is submitted online as an electronic file upload using a standard 
format with one record per client served. This report provides client-level on demographic status (e.g., 
gender, race, age, HIV exposure category), household income and health insurance status, HIV medical 
and support service utilization, HIV clinical information including viral load and the client’s “eUCI,” an 
encrypted, unique client identifier.  
The RSR is the only source of Ryan White HIV/AIDS Program data that is available in all states and eligible 
metropolitan areas (EMAs). It provides demographic information and service utilization data on all Ryan 
White HIV/AIDS Program clients and can be deduplicated at the national, state, local or provider level. 
Unlike previous Ryan White data collection systems, the RSR Client Report can be used to generate 
demographic cross-tabulations. 
Where to obtain: 
All Ryan White grantees/providers have a copy of the RSR data they submitted to HRSA. 
Grantees/providers are encouraged to consult their source data. 
Starting the Process 
Page 25 of 132—8/25/2014 
Type of data:  
Sexually transmitted disease (STD) data 
Description:  
These data are used in reports of notifiable STDs such as syphilis, gonorrhea, chancroid, and chlamydia. 
Use STD surveillance data to obtain the number of cases and incidence of specific STDs. Demographic 
and clinical data are available from STD surveillance. They may serve as a surrogate marker for unsafe 
sexual practices in a specific risk population. STDs are reportable in all 50 states, District of Columbia, and 
U.S. territories Reporting of STDs from private-sector providers may be less complete. Although STDs are 
the result of unsafe sexual behavior, STDs are not necessarily good predictors of HIV infection. 
Where to obtain: 
Available in all 50 states, the District of Columbia, and U.S. territories. Contact the STD program manager 
in your service area for information. 
Type of data:  
Socioeconomic data 
Description:  
Socioeconomic data are census data that are used to describe characteristics (e.g., income, education, 
poverty level) of persons in the service area.  
Where to obtain: 
Available for state, metropolitan areas and counties from the Bureau of the Census and the Bureau of 
Labor Statistics. Additionally, states maintain census and labor statistics centers. Obtain these data from 
http://www.census.gov, http://www.bls.gov, and state census centers. 
Type of data:  
Special studies and surveys at the local level 
Description:  
Surveys and other data collected from community-based organizations, AIDS service organizations, 
universities, and special studies. Includes recurring surveys in at-risk populations. 
Where to obtain: 
Local researchers and universities 
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Type of data:  
Substance abuse data 
Description:  
Substance abuse data are obtained from population-based surveys, medical examiner records, correctional 
facilities, law enforcement agencies, and drug treatment centers. These sources describe the patterns, 
prevalence, and consequences of drug use in the general population and specific populations. 
Where to obtain: 
National Institutes of Health (http://health.nih.gov/topic/DrugAbuse); Substance Abuse and Mental Health 
Services Administration (http://www.samhsa.gov) for information from drug-use surveys and data on 
treatment and drug abuse. 
Type of data:  
Tuberculosis surveillance 
Description:  
All 50 states, the District of Columbia, Puerto Rico, and other U.S. jurisdictions in the Pacific and Caribbean 
report tuberculosis (TB) cases to CDC on a standard case report form. In 1993, in conjunction with state 
and local health departments, CDC implemented an expanded surveillance system to collect additional 
data to 
• better monitor and target groups at risk for TB  
• estimate and follow the extent of drug-resistant TB 
• evaluate outcomes of TB cases 
Although information on HIV status among reported TB cases is available, it may not be complete because 
of 
• confidentiality concerns that limit the exchange of data between TB and HIV programs 
• local or state laws and regulations that prohibit the HIV program and the TB program from sharing 
information about patients 
• reluctance of health care providers to report HIV test results to the TB surveillance program staff 
• a lack of counseling and HIV testing for some TB patients  
Where to obtain:  
Available in all 50 states, the District of Columbia, and U.S. territories. Contact the TB program manager in 
your service area for information. 
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Type of data:  
Vital records 
Description:  
Vital records contain information, as stipulated by state statutes, on all births and deaths in the 50 states, 
the District of Columbia, and U.S. territories. For example, death records include 
• the cause of death according to the rules of the National Center for Health Statistics and the 
International Classification of Diseases (ICD-9 or ICD-10) 
• date of death 
• demographics of the deceased 
Where to obtain:  
All states maintain registries of deaths. Contact the State Vital Records Registrar. 
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Section 5: Analysis and Interpretation  
Collecting and presenting HIV data are only part of the task. To be useful to planning groups and 
others, the data must be analyzed and interpreted.  
Analysis is the application of logic in order to understand and find meaning in the data. It 
involves identifying consistent patterns and summarizing the relevant details.  
The purposes of analysis in an HIV epidemiologic profile are to 
• identify populations that are infected with HIV and describe their key characteristics  
• understand the trends and the impact of HIV in a service area  
• identify groups or populations at risk of acquiring or transmitting HIV and identify their 
prevention needs  
• identify emerging populations and their needs  
The following are a few general guidelines for analyzing and interpreting data for the HIV 
epidemiologic profile. Also see Appendix G, Terms, Definitions, and Calculations. 
Descriptive analysis  
Descriptive analysis is concerned with organizing and summarizing health-related data according 
to time, place, and person. An example of descriptive analysis might be “The transmission 
category for X% of men diagnosed with HIV infection in the United States in 2010 was male-to-
male sex.”  
To carry out an effective descriptive analysis, become familiar with the data before applying 
analytic techniques. This initial examination should progress to summarizing the data with 
descriptive statistics, such as frequencies and percentages, in a table to explain the distribution of 
HIV in your service area.  
As you analyze and interpret your data, keep the following cautions in mind:  
• Be aware of the strengths and limitations of the data source. For example, HIV diagnosis 
data can include persons who have been infected for a long time and may not adequately 
represent persons recently infected. 
• Surveillance data reflect where a person lived when the diagnosis of HIV was made, 
which may or may not be where the person currently lives.  
• Confidentiality of public health data is a special concern when dealing with small 
numbers of cases because of the potential that a person can be identified.  
• Interpret surrogate or proxy data with caution (e.g., using STD data as a marker for HIV 
exposure or infection).  
• Concerns about lack of reliability mean that you should be careful about misinterpreting 
large percentage changes (increases or decreases) based on small numbers.  
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Example: You observe a 200% increase in cases in one group versus a 5% increase in 
another. However, the 200% increase represents a change from 2 cases in 2010 to 6 cases in 
2011; the 5% increase represents a change from 1,000 cases to 1,050 cases. This is an 
absolute difference of 4 versus an absolute difference of 50. The 200% increase could be due 
to fluctuations typical of small numbers. Or perhaps 2 of the 6 cases in 2011 should have 
been reported in 2010. If so, then 4 cases would have been diagnosed in each of the 2 years, 
and there would have been no increase.  
Also see Appendix G, Terms, Definitions, and Calculations. 
Triangulation  
Triangulation, or data synthesis, refers to comparing and contrasting the results of different kinds 
of data analyses that address the same topic. For example, you may want to see whether the same 
methods lead to similar findings (e.g., do biologic data and surveys indicate similar patterns in 
HIV prevalence). The similarity of results from very different data is referred to as convergent 
validity.  
When research findings from different studies or different methods are strong, profile writers 
have a firm basis for making credible statements about the reliability of their findings and 
conclusions. If HIV prevalence data, STD prevalence data, and surveys of risk behavior show 
consistent evidence of higher HIV risk in a population, then you can be much more confident in 
saying that this population should be given a high priority for prevention services than you could 
be if you have only one kind of data. This is why multiple indicators of risk that address different 
aspects of HIV risk and use different methods are useful. Besides providing another index of 
validity, convergent findings may be clearer and more convincing to planning group members, 
service providers, policymakers, and others.  
By the same token, different data may suggest contradictory findings. When this occurs, it is 
important for epidemiologists to account for the reasons that different studies have arrived at 
different conclusions. This process can be important in terms of identifying problems in data 
collection or previously undetected differences within populations. Surveys collected under 
poorly monitored conditions may yield results that are different from those in which the 
population is well characterized and sampling procedures are rigorously followed. Recent data 
such as HIV case reporting may reveal emerging populations at risk that are not evident from 
HIV case reporting. Survey studies of drug use may suggest that methamphetamine injection 
may be increasing in a particular population, but no change has yet been seen in HIV prevalence. 
This may mean that HIV infection has not yet entered the population, which would suggest the 
need to look specifically at risk practices of this population that have protected them from HIV 
infection and also look at “mixing patterns” (persons with whom they share drugs and persons 
with whom they have sex). The use of rapid assessment in such a population could lead to a 
better understanding of the epidemiology of a potential new burden of HIV infection. Divergent 
patterns like these also may suggest areas that should be investigated during the prevention needs 
assessment.  
The simplest way to triangulate, or synthesize, data in the profile is to look at the main 
demographic categories and see how they differ according to data sources. Hence, you may want 
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to look at similarities or differences across data sources by race/ethnicity, gender, geographic 
area, and age group. Summary statements based on triangulation of the data will be helpful to 
profile users in understanding how to integrate the large number of tables, figures, and findings 
that are typically included in an epidemiologic profile.  
Where to get technical assistance  
The person preparing the profile may want to seek the assistance of the HIV surveillance 
coordinator if the coordinator is not part of the team preparing the profile. The surveillance 
coordinator will be able to provide technical assistance in acquiring, analyzing, and interpreting 
core HIV surveillance data. Also consult with the HIV prevention or care programs in the health 
department about remaining questions or needs for technical assistance.  
If your technical needs cannot be addressed at the local level, technical assistance is available 
both from HRSA and CDC.  
Ryan White HIV/AIDS Program grant requirements 
For technical assistance needs that relate directly to Ryan White HIV/AIDS Program grant 
requirements, contact HRSA. All technical assistance requests must go through the project 
officer:  
Part A Part B 
HIV/AIDS Bureau  HIV/AIDS Bureau 
Division of Metropolitan HIV/AIDS Programs Division of State HIV/AIDS Programs 
Health Resources & Services Administration Health Resources & Services Administration 
5600 Fishers Lane, Room 9WH04 5600 Fishers Lane, Room 9WH04 
Rockville, MD 20857  Rockville, MD 20857  
301-443-9086  301-443-6745 
For prevention grant requirements  
For technical assistance needs that relate to prevention cooperative agreement requirements, 
contact the Prevention Program Branch at CDC:  
Chief, Prevention Program Branch  
Division of HIV/AIDS Prevention  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention  
Mailstop E-58  
1600 Clifton Road, NE  
Atlanta, GA 30329  
404-639-5230  
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For developing epidemiologic profiles for HIV prevention planning  
For technical assistance needs that relate to developing epidemiologic profiles for HIV 
prevention planning, contact the HIV Incidence and Case Surveillance Branch at CDC:  
Chief, HIV Incidence and Case Surveillance Branch  
Division of HIV/AIDS Prevention  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention  
Mailstop E-47  
1600 Clifton Road, NE  
Atlanta, GA 30329  
404-639-2050  
Other sources  
Other sources of technical assistance include researchers at local universities (such as those at 
schools of public health, programs in community health and education, and social science 
departments) and organizational entities, such as the American Psychological Association’s 
Behavioral and Social Scientist Volunteers Program.  
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Chapter 3. 
Describing the Burden of HIV 
Section 1  Core Epidemiologic Questions  
Section 2  Special Questions and Considerations for Ryan HIV/AIDS Program Grantees  
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Overview 
This chapter is divided into 2 sections:  
• Section 1: Core Epidemiologic Questions presents 3 epidemiologic questions that all 
HIV profiles should address. It describes the types of supporting data you can use to 
answer each question and where to find the data, presents recommended analyses, and 
provides caveats and explanatory notes, as appropriate.  
• Section 2: Special Questions and Considerations for Ryan White HIV/AIDS 
Program Grantees presents questions that are specific to epidemiologic profiles that will 
be used to plan HIV care programs. Profiles focusing on care as well as prevention issues 
should contain the answers to the core questions in Section 1 and the questions in 
Section 2.  
Throughout your profile, it is acceptable to conduct additional analyses or analyses different 
from the ones recommended here as long as you answer the core epidemiologic questions and 
provide an interpretation of your tables in the accompanying text. If you choose to conduct 
additional analyses, be sure to state in the text that you have done so.  
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Section 1: Core Epidemiologic Questions 
Whether you are preparing an HIV epidemiologic profile for prevention or care, you should 
answer 3 essential epidemiologic questions:  
 
Examining groups at risk for HIV infection and answering these core questions will help you 
understand the characteristics of the population in your service area, the distribution of HIV 
disease, and how the distribution of HIV may look in the future. The answers provide the basis 
for setting priorities among populations and then identifying appropriate interventions and 
services. Answering these core questions is the first step in developing your comprehensive HIV 
prevention and care plan. Answer the questions as completely as possible, basing your answers 
on the needs, available data, and resources in your area.  
The remainder of this chapter presents recommended analyses that will help you answer the 
questions. First, however, it briefly describes the importance of changes in HIV in the service 
area and HIV surveillance data and their potential effect on epidemiologic profiles.  
Changes in the HIV burden and data that affect profiles  
Describing the HIV burden in the United States relies heavily on surveillance data collected 
through the coordinated efforts of public health officials and private and public health care 
professionals throughout the country. States and territories collect data locally and share it with 
CDC. State, territory, and local health departments and CDC analyze and disseminate the data in 
a variety of formats for use by public health, prevention and care planning, and health 
communications and news organizations.  
Supplementing surveillance data with other sources of data will help provide a more 
comprehensive and in-depth picture of HIV in your service area. To provide a balanced and 
accurate description of the burden of HIV that incorporates the strengths and limitations of the 
data sources, you need to be aware of the changing nature of HIV and surveillance data.  
Keep the following points in mind as you develop your epidemiologic profile. Because of the 
successful effects of treatment and the expansion of surveillance data, you may see changes in 
the trends in HIV in your service area.  
• The number of persons reported as living with HIV does not include persons who were 
not tested, or persons who were tested anonymously. CDC estimates that at the end of 
2010, 1.1 million adults and adolescents were living with HIV infection; of these 15.8% 
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(180,900) were unaware of their infection. Thus, they are not benefiting from improved 
health and survival associated with antiretroviral therapy.  
• Of the persons with diagnosed HIV infection reported in 2011 in the United States and 6 
U.S. dependent areas, one-third received a stage 3 (AIDS) classification at the same time 
as their HIV diagnosis (these persons represent those who are tested late in the disease 
process).* Increased HIV testing early in the course of HIV disease and programs to link 
infected persons to ongoing care and prevention services are essential to reducing the 
number of new infections.  
• Surveillance data on new HIV diagnoses provide estimates of persons known to be 
infected. HIV diagnosis data may not reflect trends in HIV incidence (new infections) 
because the data are affected by when in the course of disease a person seeks or is offered 
HIV testing.  
• A trend in the number of new HIV diagnoses that is stable, increasing, or decreasing may 
reflect current or historical patterns in HIV incidence, or changes in testing behaviors in 
the geographic area.  
Question 1:  What are the sociodemographic characteristics of the general population in your 
service area?  
The general characteristics of the population in your service area provide an essential context. 
Supporting data will help you examine these characteristics from 2 perspectives:  
• Demographics  
• Socioeconomic status  
The information you develop will help you identify the risk factors associated with HIV 
infection—such as poverty level and lack of health insurance—and may indicate a greater need 
for providing prevention and care services.  
Compile and analyze demographic and socioeconomic characteristics of the populations in your 
service area to determine changes during the past 5 to 10 years. Present substantial changes; if no 
substantial changes have occurred, state that.  
Demographics  
Race and ethnicity  
Race and ethnicity are based on categories defined by the Office of Management and Budget 
(OMB); ethnicity (Hispanic/Latino or Not Hispanic/Latino) is often shown in tables with six 
                                                            
*  Centers for Disease Control and Prevention. HIV Surveillance Report, 2011; vol. 23. 
http://www.cdc.gov/hiv/library/reports/surveillance/2011/surveillance_Report_vol_23.html. Published February 2013. 
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categories of race: American Indian/Alaska Native, Asian, black/African American, Native 
Hawaiian/Other Pacific Islander, white/Caucasian, multiple racial categories or persons 
identifying themselves as having multiple racial background (e.g., black and white).* 
Hispanics/Latinos may be of any race. For surveillance purposes, Hispanic/Latino ethnicity is 
shown with race categories regardless of any specific race information entered for the person. 
For tables that include cumulative counts, an additional category may be presented: Legacy 
Asian/Pacific Islander. This category only includes cases that were reported prior to the 
application of the 1997 OMB-defined race and ethnicity categories. The enhanced HIV/AIDS 
Reporting System (eHARS) field, RACE, is calculated based on all race and ethnicity data 
entered for a person. If the only information available is based on the old race categories where 
Asian and Other Pacific Islanders were not separated, there is not enough information to know 
whether the person is either, and this Legacy category is used to identify them. There should not 
be any cases reported after 2003 that fall into this category. 
Age 
The following age groups are recommended:  
• <13 years  
• 13–14  
• 15–24  




• ≥65  
Other age groupings can also be used in the epidemiologic profile. Consider your local needs 
when deciding on the age groups to use.  
Recommended analyses 
• Number and percentage distribution of the population by  
o age group and sex  
o race/ethnicity and sex  
o race/ethnicity and geographic subunit (e.g., planning region, county, Eligible 
Metropolitan Area [EMA]) 
                                                            
*  Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. 
Federal Register 1997;62:58781–58790. http://www.whitehouse.gov/omb/fedreg_1997standards. Accessed February 7, 
2013. 
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Socioeconomic status (SES)  
Focus your analysis and presentation of socioeconomic data on the populations and geographic 
areas that are most adversely affected by HIV.  
Recommended analyses  
Percentage of  
• persons living below the poverty level in selected areas  
• persons with high school diploma or higher and persons with bachelor’s degree or higher  
• adults (aged 19–64) without health insurance, by race/ethnicity  
Data sources  
• U.S. Bureau of the Census  
• Kaiser Family Foundation  
• State government statistics offices  
Note. See Appendix A for a description of the U.S. Bureau of the Census data. 
Question 2: What is the scope of HIV burden in your service area?  
An examination of the extent and effect of HIV in broad population groups in your service area 
provides the basis for comparison with national data and allows a closer examination of the 
effect on specific groups, both of which will help your planning group better focus prevention 
and care services.  
Section 1-A: Using Data from the HIV Surveillance System 
CDC has developed SAS programs for creating epidemiologic profile tables using jurisdictional 
level HIV surveillance data in eHARS (refer to Creating Integrated Epidemiologic Profiles: 
User Guide, version 4.0). Note the same reporting delay standard applies to diagnoses, deaths, 
and prevalence, so that if deaths for the prior year are reported by the end of the following year 
and death ascertainment has been performed for the prior year, the same frozen December 
dataset can be used for diagnoses, deaths, and prevalence for the prior year (see Appendix G for 
reporting delay). 
Describing the Burden of HIV 
Page 38 of 132—8/25/2014 
Jurisdiction HIV reporting status and corresponding data tables 
Single year tables for diagnosed cases of HIV or stage 3 (AIDS) 
The first group of tables presents analyses of data for the full calendar year that is designated for 
the profile. Persons included in these tables meet the CDC surveillance case definition for HIV 
or stage 3 (AIDS) (see Appendix G) and were diagnosed with HIV or stage 3 (AIDS) during the 
designated year. 
For the most recent available calendar year: 
1. Number, % distribution, rates of cases (/100,000) by: race/ethnicity and sex 
2. Number, % distribution by: age group and sex 
3. Number, % distribution by: transmission category and sex 
4. Number, % distribution by: transmission category and race/ethnicity 
For TB morbidity: 
5. Number and % distribution of diagnosed HIV cases with TB by sex (by definition, any 
diagnosed HIV with a diagnosis of tuberculosis [M. tuberculosis, disseminated or 
extrapulmonary, or M. tuberculosis, pulmonary] is a stage 3 [AIDS] case). 
For mortality data: 
6. Number and rates of death/100,000 population among persons with diagnosed HIV 
infection, by race/ethnicity and sex 
If HIV infection is among the 10 leading causes of death in any group in your service area, you 
may also wish to present these analyses:  
7. Number of deaths by underlying cause among persons 25 to 44 years of age, based on 
vital statistics mortality data (see Table 3-4)  
8. Number and rates of death (per 100,000 population) by race/ethnicity and sex, based on 
vital statistics mortality data  
These analyses will enable you to determine the rank of HIV infection among underlying causes 
of death for the most recent year for which data are available.  
Data sources  
• HIV surveillance data  
• Vital statistics data  
• National Center for Health Statistics mortality dataset  
• National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
(NCHHSTP) Atlas 
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Note. Data in death certificates on specific causes of death may be of poor quality for several 
reasons. Stigmatized diseases may be underreported. In addition, the causes of death may be 
recorded incorrectly if, for example, they were limited to symptoms or immediate causes and did 
not include the underlying cause (in this instance, HIV infection). See Appendix A for a 
description of some of the data sources mentioned above. 
Recommended analyses for geographic areas with large case numbers 
If the number of cases is large enough (>20) to stratify by geographic region (see Chapter 5 on 
how to handle areas with low morbidity and a small number of cases), consider developing the 
following tables stratified by region:  
• Number and percentage distribution of cases by  
o sex 
o race/ethnicity  
o age group  
o transmission category  
• Case rates (cases per 100,000 population) by race/ethnicity for each geographic region  
• Case rates by race/ethnicity for each sex  
These analyses will be somewhat directed by the planning jurisdiction. For example, a regional 
HPG will need a regional profile. However, areas with a state planning group should stratify by 
geographic or public health area, whichever makes sense at the local level.  
Example Table Shell 
Table 3-1. Diagnoses of HIV infection, by sex and race/ethnicity, Year—Jurisdiction  
 Males  Females  Total 
Race/ethnicity No. % Ratea  No. % Ratea  No. % Ratea 
American Indian/Alaska Native            
Asian            
Black/African American            
Hispanic/Latino            
Native Hawaiian/Other Pacific 
Islander 
           
White            
Multiple race            
Unknown            
Total            
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. 
Source: 
a  Rates are per 100,000 population. 
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Five-year tables for persons with diagnosed HIV infection or stage 3 (AIDS) 
The second group of tables is for analyses that cover the designated profile year, as well as the 
four years that preceded it for diagnosed cases of HIV infection or stage 3 (AIDS) by year of 
diagnosis. The populations included in these tables are persons who have been diagnosed with 
HIV infection or stage 3 (AIDS) in the designated profile year or in one of the four years 
preceding it. Two cumulative columns are also provided: one for the time leading up to the five-
year period, and one for all cases. Overall counts are stratified by sex, race/ethnicity, age group, 
and transmission category.  
For the most recent five-year period: 
1. Annual number of diagnosed cases, by sex 
2. Annual number of diagnosed cases, by race/ethnicity 
3. Annual number of diagnosed cases, by age at diagnosis 
4. Annual number of diagnosed cases, by transmission category 
Example Table Shell 
Table 3-2. Diagnoses of HIV infection, by year of diagnosis and race/ethnicity, 2008–
2012—Jurisdiction  











American Indian/Alaska Native        
Asian        
Black/African American        
Hispanic/Latino        
Native Hawaiian/Other Pacific Islander        
White        
Multiple race        
Unknown        
Total        
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. 
Source: 
Five-year tables for persons living with diagnosed HIV infection or stage 3 (AIDS) 
The next set of tables represents five-year analyses showing the annual number of persons living 
with HIV infection or stage 3 (AIDS) (also known as HIV or stage 3 [AIDS] prevalence). 
Anyone who has ever been entered into eHARS, meets the CDC surveillance case definition for 
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HIV infection, and whose vital status in eHARS is “alive” for the designated year is included in 
this set of tables. Prevalence is defined as the number of persons ever diagnosed with HIV minus 
the number of persons with a diagnosis of HIV infection that died. Again, overall counts are 
presented, stratified by sex, race/ethnicity, age group (using age at end of specified year, rather 
than age at diagnosis), and transmission category. 
For five-year period: 
1. Persons living with a diagnosis of HIV infection, by sex 
2. Persons living with a diagnosis of HIV infection, by race/ethnicity 
3. Persons living with a diagnosis of HIV infection, by age at end of specified year 
4. Persons living with a diagnosis of HIV infection, by transmission category 
Example Table Shell 
Table 3-3. Persons living with diagnosed HIV infection, by year and race/ethnicity, 2008–
2012—Jurisdiction 
 2008  2009  2010  2011  2012 
Race/ethnicity No.  No.  No.  No.  No. 
American Indian/Alaska Native          
Asian          
Black/African American          
Hispanic/Latino          
Native Hawaiian/Other Pacific Islander          
White          
Multiple race          
Unknown          
Total          
Source: 
Five-year tables for deaths of persons with diagnosed HIV infection or stage 3 (AIDS) 
The last set of tables are for five-year analyses and present the annual number of deaths of 
persons with diagnosed HIV infection or stage 3 (AIDS). Persons included in these tables are 
anyone meeting the CDC surveillance case definition for HIV infection or stage 3 (AIDS) and 
who died in the designated five-year period regardless of the cause of death. Two cumulative 
columns are also provided. Overall counts are stratified by sex, race/ethnicity, age group (by age 
at death), and transmission category. 
For five-year period: 
1. Annual number of deaths of persons with diagnosed HIV infection, by sex 
2. Annual number of deaths of persons with diagnosed HIV infection, by race/ethnicity 
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3. Annual number of deaths of persons with diagnosed HIV infection, by age at death 
4. Annual number of deaths of persons with diagnosed HIV infection, by transmission 
category 
Example Table Shell 
Table 3-4. Deaths of persons with diagnosed HIV infection, by year of death and 
race/ethnicity, 2008–2012—Jurisdiction  








American Indian/Alaska Native        
Asian        
Black/African American        
Hispanic/Latino        
Native Hawaiian/Other Pacific 
Islander 
       
White        
Multiple race        
Unknown        
Total        
Source: 
Note. See Appendix A (Sample Data Tables and Charts with Interpretation Associated with 
Chapter 3) and Appendix B (Use of Tables, Charts, and Maps to Illustrate Data). 
CDC-developed SAS programs can be used alone (unweighted data) or together with multiple 
imputation (MI) and reporting delay (RD) SAS programs (weighted data). The RD and MI 
procedures account for reporting delays and missing risk factor information, respectively. 
Section 1-B: Using Data from HIV Incidence Surveillance  
In addition to case data from HIV surveillance systems, select states and local health 
departments, funded to conduct HIV incidence surveillance, may also conduct HIV incidence 
surveillance and calculate estimates of HIV incidence. Estimates of HIV incidence provide 
information about the estimated number of persons newly infected with HIV in a population in a 
defined time period. There is an important difference between HIV incidence and a new 
diagnosis of HIV infection: HIV incidence refers to persons newly infected with HIV, whereas 
persons newly diagnosed with HIV may have been infected years before the diagnosis. 
Population-based incidence estimates include new infections that have been diagnosed as well as 
new infections that have not been diagnosed. HIV incidence data may be used to monitor 
emerging trends and guide prevention activities.  
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Program areas that collect HIV testing and treatment information and STARHS (serologic testing 
algorithm for recent HIV seroconversion) results may estimate incidence using the stratified 
extrapolation approach. The references below provide additional information about the stratified 
extrapolation approach and examples of data output: 
Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 
2008;300(5):520. 
Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI. Estimating HIV incidence in the 
United States from HIV/AIDS surveillance data and biomarker HIV test results. Statist Med 
2008;27(23):4617–4633. 
Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–
2009. PLoS One 2011;6(8):1–13. 
Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 
2007–2010. HIV Surveillance Supplemental Report 2012;17(No.4). 
http://www.cdc.gov/hiv/library/reports/surveillance/. Published December 2012.  
Other methods for estimating incidence may be available, such as statistical methods using HIV 
surveillance data and back calculation approaches. 
Recommended analyses for HIV incidence data 
HIV incidence data are expressed either as an estimated number of persons newly infected with 
HIV during a defined time period (e.g., a year) or as a rate calculated from the number of 
estimated persons with new HIV infections divided by the number of persons at risk for HIV 
infection during the specified time period. 
Sample size considerations may impact the ability to present data by select demographic 
characteristics, limiting the strata that may be reported. Program areas with sufficient sample size 
may be able to stratify by age group, race/ethnicity, sex, and transmission category. Annual 
numbers may be reported or data may be grouped over multiple years depending on the method 
used and sample size.  
You should work with local staff experienced with HIV incidence methodology (e.g., the 
incidence surveillance coordinator and a statistician) in deriving and including HIV incidence 
estimates in the epidemiologic profile. Consulting with these staff is essential for the appropriate 
interpretation of HIV incidence data and understanding the factors that may affect incidence 
estimates (e.g., increases/decreases in HIV testing, proportion of cases with stage 3 [AIDS] 
diagnosed in 6 months). 
CDC has guidance and SAS programs for program areas that are able to use the stratified 
extrapolation approach for calculating HIV incidence estimates. Check with your local HIV 
surveillance program for the availability of guidance for other methods for estimating incidence. 
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Section 1-C: HIV Program Data  
HIV testing data  
CDC collects, analyzes, and disseminates data on CDC-funded HIV testing events. Test-level 
data are reported through the National HIV Prevention Program Monitoring and Evaluation 
(NHM&E) system and represent a portion of all HIV testing done in the United States, Puerto 
Rico, and the U.S. Virgin Islands. These data can be used to provide insight into the 
demographics of persons tested, positive tests, and programmatic activities (e.g., linkage to HIV 
medical care and referral to partner and prevention services), and can be used in conjunction with 
other relevant information (e.g., progress reports, surveillance data, and census data). Because 
identifying information is not submitted with HIV testing data to CDC, it is not possible to 
deduplicate multiple HIV tests conducted with the same person. Therefore these data are 
considered to be “test-level” rather than “client-level” estimates. Calculating newly identified 
HIV cases by excluding records for which there is a current HIV-positive test result and a self-
report of a previous HIV-positive test result minimizes this limitation. Examples of such data 
output are included in the following references: 
Duran D, Usman HR, Beltrami J, Alvarez M, Valleroy L, Lyles C. HIV counseling and 
testing among Hispanics at CDC-funded sites in the United States, 2007. Am J Public Health 
2010;100(Suppl 1):S152–8.  
CDC. HIV Testing at CDC-funded Sites, United States, Puerto Rico, and the U.S. Virgin 
Islands, 2008–2009. Atlanta, GA: U.S. Department of Health and Human Services, Centers 
for Disease Control and Prevention; July 2011. 
http://www.cdc.gov/hiv/pdf/testing_report_2008_2009.pdf. Accessed June 12, 2014. 
You may increase the usefulness of the data by conducting analyses on test results of persons 
tested for the first time. Examples of such data output are included in the following reference: 
Van Handel M, Beltrami J, Margolis A, MacGowan. HIV positivity and return of HIV test 
results and posttest counseling at U.S. correctional facilities, 2007. Abstract presented at 
XVIII International AIDS Conference, Vienna, Austria. July 18–23, 2010. 
http://www.iasociety.org/Abstracts/A200735782.aspx. Accessed February 6, 2013. 
Performance indicators for HIV prevention 
Indicators are standardized measures (i.e., they are collected and reported consistently across 
agencies) that capture information related to priority questions about HIV prevention in a 
jurisdiction. They are most useful for monitoring the results of prevention efforts when viewed 
over time and in the context of surveillance data and other information about HIV (CDC 2010). 
Additionally, indicators provide useful information for documenting achievements, program 
planning and improvement, and demonstrating accountability. 
Depending on their specific purpose or use, indicators can be defined or expressed in one of 
three ways: (a) percent compliance (expressed as a ratio with a numerator and denominator); 
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(b) actual vs. expected performance (using an agency defined performance target); and 
(c) performance against a benchmark (using a national or local performance standard) (Manila 
2010, p14). However defined or expressed, a good indicator should be useful, feasible, and 
adaptable (see Table 3-5). 
Table 3-5. Criteria for a good indicator 
Useful • Provides information about key components of a program 
• Allows meaningful comparisons of data to show progress over time 
Feasible • Constitutes good use of time and resources 
• Requires reasonable efforts for data collection, and the value of the indicator 
outweighs any data collection burden 
Adaptable for 
target setting  
• Allows programs to develop performance targets that are locally relevant and that 
predict achievement in a given time period 
Source: CDC. Guidance for use of HIV prevention program performance indicators. November 2010. 
HIV prevention performance indicators generally focus on the processes or outcomes of services 
and activities being implemented in a jurisdiction (CDC 2009). Process indicators measure the 
direct outputs of program activities, populations served, and resources used. They describe what 
activities were implemented, and whether they were implemented as planned. For example, 
process indicators may focus on the extent to which an agency enrolls the planned number of 
clients in an intervention and delivers the services as intended to the target population. Outcome 
indicators measure changes that occur during or just after service delivery (e.g., knowledge of 
HIV status, linkage to medical care for HIV-positive clients) or after a period of time (e.g., 
behavior change). Both process and outcome indicator data should always be interpreted in the 
context of other relevant information about HIV in a jurisdiction. 
Impact indicators are not focused specifically on the performance of programs in a jurisdiction 
but rather are intended to assess HIV prevention efforts more broadly. They reflect both program 
performance and the overall effect of other factors related to HIV in a jurisdiction. For example, 
following the White House’s National HIV/AIDS Prevention Strategy, impact indicators may be 
used to monitor reductions in new infections (HIV incidence), improvements in HIV-related 
health outcomes, and reductions in HIV-related disparities among MSM and racial/ethnic 
groups. 
Setting realistic and thoughtful annual performance targets for indicators (i.e., projections about 
what a jurisdiction or agency expects to accomplish in a given time period) is essential for 
program planning and management. Performance targets establish clear expectations for staff, 
stakeholders, and funders (CDC 2010). In setting performance targets, agencies may consider a 
range of performance factors (e.g., funding, staffing, past experience, and local/state policies). 
Agencies can compare targets with actual data to determine whether performance expectations 
are being met and make adjustments as needed. 
HIV prevention indicators may be calculated using one or more of the data collection systems 
described in this integrated guidance document. For example, HIV surveillance provides data for 
calculating several indicators that address impact (e.g., annual number of new infections or 
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transmission rate) while HIV testing data are used to calculate several performance indicators 
that address testing-related processes and outputs/outcomes. Examples include  
1) HIV-positive tests—Percent of newly identified HIV-positive testing events among all 
testing events 
2) Return of HIV-positive test results—Percent of newly identified HIV-positive testing 
events where clients received their test results 
3) Linkage to medical care—Percent of persons newly diagnosed with HIV who were 
linked to medical care; i.e., attended first HIV medical care appointment within three 
months of diagnosis 
Grantees and providers funded by the Health Resources and Services Administration’s (HRSA) 
HIV/AIDS Bureau have a core set of data collection and reporting requirements that focus on 
outcomes, performance monitoring, and other program requirements that help to monitor service 
delivery and quality of care (HRSA 2010). The collection and use of HRSA program data are 
well-documented in the publication Using Data to Measure Public Health Performance (HRSA 
2010).  
The use of HIV prevention performance indicators is critical for demonstrating accountability 
and assessing and improving efforts toward meeting national, state, and local HIV prevention 
goals. For more information, please consult the following resources:  
• Centers for Disease Control and Prevention. Framework for Program Evaluation in 
Public Health. MMWR 1999;48(No. RR-11):[1–41]. 
• Centers for Disease Control and Prevention/Global AIDS Program and ICF Macro. 
Monitoring and Evaluation for National Program Planning and Management: Facilitator 
Guide. Atlanta, GA: Centers for Disease Control and Prevention; 2009. Available at 
http://www.globalhivmeinfo.org/Monitoring/Pages/Default.aspx. Accessed June 16, 2014.  
• DeGroff A, Schooley M, Chapel T, Poiser TH. Challenges and strategies in applying 
performance measurement to federal public health programs. Evaluation and Program 
Planning 2010;33(4):365–72. 
• Health Resources and Services Administration, HIV/AIDS Bureau. HIV/AIDS 
Performance Measures. Available at 
http://hab.hrsa.gov/deliverhivaidscare/habperformmeasures.html. Accessed June 16, 2014. 
• Horberg MA, Aberg JA, Cheever LW, Renner P, O’Brien Kaleba E, Asch SM. 
Development of national and multiagency HIV care quality measures. Clinical Infectious 
Diseases 2010;51(6):732–8. 
• National Minority AIDS Council. Organizational Effectiveness Series: Program 
Evaluation. Published 2004. Available at http://careacttarget.org/sites/default/files/file-
upload/resources/program-evalution.pdf. Accessed June 16, 2014. 
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Question 3:  What are the indicators of risk for HIV infection in the population covered by your 
service area?  
Behaviors are monitored with regard to risk taking, HIV testing, care seeking, and adhering to 
treatment for HIV in different populations. 
In this section of your profile, examine data on risk behaviors and markers from 2 perspectives:  
• Factors that affect the risk of acquiring HIV infection among HIV-negative persons  
• Factors that affect the risk of transmitting HIV infection among HIV-positive persons  
Use the data sources listed in “Types and Sources of Data for Epidemiologic Profiles” (Chapter 
2, Section 4) to examine the risk for HIV infection by transmission category, including the 
following:  
• Male-to-male sex  
• Injection drug use 
• Heterosexual contact  
Note. You may also want to examine the risk for HIV infection among populations of special 
interest, including incarcerated persons, homeless persons, migrant laborers, commercial sex 
workers, persons with mental illness, deaf and hearing-impaired persons, perinatally exposed 
persons, transgender persons, immigrant or refugee residents and any other populations in your 
local area at increased risk for HIV infection.  
Conduct stratified analyses of these exposure categories by sex, race/ethnicity, and age group.  
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Because of incomplete reporting on the variable to capture country of birth in routine 
surveillance, it is recommended that sites explore locally conducted studies involving immigrant 
or refugee residents to characterize HIV in these populations. However, where completeness on 
this variable in routine surveillance data is adequate, jurisdictions may use this variable to 
describe HIV in immigrant or refugee populations. 
The populations described in the answers to Question 2 as most affected by HIV are also the 
groups that must be included here as those at greatest risk for HIV infection.  
For each of the transmission categories as well as for local at-risk populations of special interest, 
consider not only the prevention issues for persons at risk but also the prevention and care issues 
for infected persons.  
Direct and indirect measures of risk behavior  
Direct measures of risk provide information about risk behavior that is directly associated with 
HIV transmission. Indirect measures do not directly describe HIV risk behaviors. Rather, they 
are indicators of possible HIV risk that may need further investigation. For example, an increase 
in STD or teen pregnancy rates does not directly indicate that HIV exposure is increasing but 
may indicate an increase in unprotected sex.  
Recommended analyses for data on men who have sex with men (MSM): direct measures  
• Factors that may affect the risk of acquiring or transmitting HIV, such as  
o number of sex partners  
o frequency of condom use or unprotected sex  
o whether partners are anonymous  
o substance use (including injection drug use)  
o information about discordant sex partners (i.e., one partner is HIV-positive and the 
other is HIV-negative)  
o previous or current primary or secondary syphilis infection 
Conduct stratified analyses by race/ethnicity and age group (include adolescents).  
Data sources  
In some areas, the following survey data are available:  
• At-risk populations 
o National HIV Behavioral Surveillance System (NHBS)  
o Youth Risk Behavioral Survey (YRBS). These project area surveys, along with a 
national YRBS, constitute CDC’s Youth Risk Behavioral Surveillance System 
(YRBSS).  
o In addition, seek results from locally conducted cross-sectional studies funded by the 
National Institutes of Health (NIH), CDC, and other government agencies or 
nongovernmental organizations.  
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• HIV-positive persons  
o Medical Monitoring Project (MMP) 
o National HIV Behavioral Surveillance System (NHBS) 
o In addition, seek results from locally conducted cross-sectional studies funded by 
NIH, CDC, and other government agencies or nongovernmental organizations.  
Note. See Appendix A for a description of some of the data sources mentioned above. 
Recommended analyses for MSM: Indirect measures  
• Trends in a service area in the male-to-female ratio for gonorrhea, syphilis, hepatitis A, 
and hepatitis B (an increase in this ratio may indicate increasing infections among MSM)  
• For STD data available in some areas, trends in  
o gonorrhea, chlamydia, and syphilis among MSM  
o rectal gonorrhea among men  
o proportion of Gonococcal Isolate Surveillance Project (GISP) isolates from MSM  
Conduct stratified analyses by race/ethnicity and age group (include adolescents).  
Data sources  
• STD notifiable disease surveillance data  
• Gonococcal Isolate Surveillance Project  
• HIV surveillance registry matches to STD registry to monitor trends in STD incidence 
among HIV-infected persons  
• National HIV Behavioral Surveillance System (NHBS) 
• Medical Monitoring Project (MMP) 
• Local needle exchange program data 
Recommended analyses for injection drug users (IDUs): Direct measures  
• Factors that may affect risk of acquiring or transmitting HIV, such as  
o injection drug use and other substance use  
o needle sharing  
o sharing of drug paraphernalia (cookers, cottons, water, drug solution)  
o exchanging money or drugs for sex  
o number of sex partners  
o frequency of condom use or unprotected sex  
Conduct stratified analyses by sex, race/ethnicity, and age group (include adolescents).  
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Data sources  
• Available everywhere for persons at risk  
o Behavioral Risk Factor Surveillance System (BRFSS)  
o Youth Risk Behavior Survey (YRBS). These project area surveys, along with a 
national YRBS, constitute CDC’s Youth Risk Behavioral Surveillance System 
(YRBSS) 
o HIV Testing Data 
o National Household Survey of Drug Abuse  
• Available in some areas for persons at risk  
o National HIV Behavioral Surveillance System (NHBS) 
o Medical Monitoring Project (MMP) 
o Monitoring the Future Study (National Institute on Drug Abuse—survey of drug 
abuse among youth in high school)  
o In addition, seek results from locally conducted cross-sectional studies funded by 
NIH, CDC, and other government agencies or nongovernmental organizations.  
• HIV-positive persons  
o Medical Monitoring Project (MMP) 
o In addition, seek results from locally conducted cross-sectional studies funded by 
NIH, CDC, and other government agencies or nongovernmental organizations. 
Note. See Appendix A for a description of the some of the data sources mentioned above. 
Recommended analyses for injection drug users (IDUs): Indirect measures  
• Trends in the rate of hepatitis C infection  
• Rates of mortality due to substance abuse  
• Trends in injection drug use  
• Trends in noninjection drug use (alcohol, poppers)  
• Trends in recent STD history  
Conduct stratified analyses by sex, race/ethnicity, and age group (include adolescents).  
Data sources  
• Available in every state  
o National Notifiable Diseases Surveillance System  
• Available in some areas  
o Drug Abuse Warning Network  
o National Household Survey on Drug Abuse (NHSDA)  
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o Treatment episode data set  
o Community epidemiology work group reports  
Note. Use these sources to glean data on which drugs are prevalent in your service area, among 
which groups, and whether the pattern is changing. All of these factors can affect HIV risk. See 
Appendix A for a description of some of the data sources mentioned above. 
Recommended analyses for data on heterosexual populations: Direct measures  
• Number of sex partners  
• Frequency of condom use or unprotected sex  
• Substance use (including injection drug use)  
• Exchanging money or drugs for sex  
• Information about discordant sex partners (i.e., one partner is HIV-positive and the other 
is HIV-negative)  
Conduct stratified analyses of by sex, race/ethnicity, and age group (include adolescents).  
Data sources  
• Available in all areas for persons at risk  
o Behavioral Risk Factor Surveillance System (BRFSS)  
o Kaiser Family Foundation – State Health Facts  
o HIV testing data 
• Available in some areas for persons at risk  
o Youth Risk Behavior Survey (YRBS). These project area surveys, along with a 
national YRBS, constitute CDC’s Youth Risk Behavioral Surveillance System 
(YRBSS). 
o National HIV Behavioral Surveillance System (NHBS) 
o National Health Interview Survey  
o National Survey of Family Growth  
• Available in some areas for persons who are HIV-positive  
o Medical Monitoring Project (MMP) 
o In addition to routine surveillance data, seek results from locally conducted cross-
sectional studies funded by NIH, CDC, other government agencies, or 
nongovernmental organizations. 
Note. See Appendix A for a description of some of the data sources mentioned above. 
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Recommended analyses for heterosexual populations: Indirect measures  
• Trends in  
o teen pregnancy rates 
o gonorrhea rates 
o primary and secondary syphilis*  
o recent STD history  
Conduct stratified analyses by sex, race/ethnicity, and age group (include adolescents).  
*Note. This analysis might be appropriate in an area that has a large number of syphilis cases. If 
your area has a small number of syphilis cases (<20), use this analysis with caution: sporadic 
outbreaks do not necessarily indicate changes in risk behavior in the community.  
Data sources  
• Available in every state  
o Vital statistics  
• Available in some areas for persons who are HIV-positive  
o HIV surveillance registry matches to STD registry to monitor trends in STD 
incidence among HIV-infected persons  
o STD programs  
Note. See Appendix A for a description of some of the data sources mentioned above. 
Recommended analyses for data on other populations of special interest  
You may wish to include other populations in your profile because their members may belong to 
the groups already listed or because of unique factors that influence their risk. Evaluate the effect 
that these groups have on HIV in your service area. Data may be available from a variety of 
sources, including some of those already listed and others that are local. Analyses of case data 
may also suggest the need for additional studies of these populations. Take note of cases in 
persons reported in one state but in care in another state (common in areas of low morbidity). 
When routine surveillance data are not available, seek results from locally conducted cross-
sectional studies funded by NIH, CDC, other government agencies, or nongovernmental 
organizations.  
Optional analyses for HIV testing  
Planning groups may find it useful to analyze testing data in their communities to help focus 
testing campaigns and other efforts.  
Data sources  
• Available everywhere  
o HIV testing data  
Describing the Burden of HIV 
Page 53 of 132—8/25/2014 
o Behavioral Risk Factor Surveillance System (BRFSS)  
o School health profiles  
• Available in some areas  
o National Health Interview Survey  
o Youth Risk Behavior Survey (YRBS). These project area surveys, along with a 
national YRBS, constitute CDC’s Youth Risk Behavioral Surveillance System 
(YRBSS) (may not include testing questions).  
o National HIV Behavioral Surveillance System (NHBS) 
o Pregnancy Risk Assessment Monitoring System (PRAMS) 
• Available in some areas for persons who are HIV-positive  
o Medical Monitoring Project (MMP)  
Note. See Appendix A for a description of some of the data sources mentioned above. 
Summary of recommended analyses for question 3  
• Examine direct and indirect measures of risk for HIV infection by transmission category:  
o Male-to-male sex  
o Injection drug use  
o Heterosexual contact  
• If desired, examine risk for HIV among populations of special interest, including 
incarcerated persons, homeless persons, migrant laborers, commercial sex workers, 
persons with mental illness, deaf and hearing-impaired persons, perinatally exposed 
persons, transgender persons, and any other populations in the local area at increased risk 
for HIV infection  
• Conduct stratified analyses of these transmission categories by sex, race/ethnicity, and 
age group (including adolescents).  
• Analyze HIV testing data to determine HIV testing-related characteristics among specific 
groups. 
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Section 2: Special Questions and Considerations for Ryan 
White HIV/AIDS Program Grantees  
Programmatic activities and funding allocations should be based on local public health data and 
information, with appropriate consideration of state and regional level public health data, when 
monitoring the impact of care and treatment services on people living with HIV who are served 
by the Ryan White HIV/AIDS Program. This section contains two questions that pertain to 
Health Resources and Services Administration’s (HRSA) Ryan White HIV/AIDS Program 
planning groups (including Part A planning councils and Part B consortia) and grantees. In 
addition to the core epidemiologic questions in Section 1, Ryan White HIV/AIDS Program 
grantees should make an effort to address the following questions. 
Question 1:  Using epidemiologic and related public health data, what is the impact of the care 
and treatment services of the Ryan White HIV/AIDS Programs on people living 
with HIV?  
Ryan White HIV/AIDS Program planning groups and grantees base program planning and 
funding prioritization and distribution on pertinent public health and epidemiologic data for 
people living with HIV and AIDS in the local area and region or state. Ryan White grantees have 
access to a variety of data and information that can assist them in program planning and funding 
allocation decisions. In the HRSA HIV/AIDS Bureau monograph entitled “Using Data to 
Measure Public Health Performance—A Guide for Ryan White HIV/AIDS Program Grantees” 
(http://hab.hrsa.gov/manageyourgrant/files/datatomeasure2010.pdf), a section is included to help 
grantees use various sources of data to monitor and measure the performance of their programs; 
the Ryan White HIV/AIDS Program grantee is encouraged to review this monograph. The above 
question can be considered in terms of the local measurement of public health outcomes and 
assessing the need for HIV services.  
Measuring public health outcomes 
A grantee can measure outcomes from various perspectives—perhaps assessing health outcomes 
through the provision of Ryan White core medical and support services or assessing provider 
adherence to established clinical practice standards, protocol, or HHS guidelines. Regardless of 
the way in which the grantee decides to measure outcomes for the program, the grantee must 
consider the topic in terms of race/ethnicity, sex, age, risk, insurance status, and poverty level 
along with other variables of interest to the local area. 
Part A and Part B grantees are required to evaluate program “effectiveness.” Although legislative 
language on evaluation is more limited for Parts C and D, program guidance requires evaluation. 
Specific evaluation requirements include the following:  
• Each Part A planning council shall establish priorities for the allocation of funds on the 
basis of factors including the “demonstrated (or probable) cost effectiveness and outcome 
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effectiveness of proposed strategies and interventions, to the extent that data are 
reasonably available.” Each council may, at its discretion, “assess the effectiveness, 
either directly or through contractual arrangements, of the services offered in meeting the 
identified needs.”  
• Each Part B consortium is required to submit to the state an application that 
“(D) demonstrates that the consortium has created a mechanism to evaluate 
periodically—(i) the success of the consortium in responding to identified needs; (ii) the 
cost-effectiveness of the mechanisms employed by the consortium to deliver 
comprehensive care; and (E) demonstrates that the consortium will report to the state the 
results of the evaluations described in subparagraph (D) and shall make available to the 
state or the Secretary, on request, such data and information on the program methodology 
that may be required to perform an independent evaluation.”  
• Part C programs may spend no more than “10 percent, including planning and evaluation 
of the grant for administrative expenses with respect to the grant” (§ 2664(g)(3)). 
• Each Part D program is required by the Secretary to “directly or through contracts with 
public and private entities, provide for evaluations of programs carried out pursuant to 
subsection (a)” (§ 2671(e)(2)).  
Many factors contribute to the need for outcomes evaluation among Ryan White HIV/AIDS 
Program grantees and their providers. Client-level outcomes data are available through the Ryan 
White HIV/AIDS Program Services Report (RSR). Grantees and planning bodies need outcomes 
evaluation data to support their work at the state and local levels. Both grantees and lead 
agencies need outcome measures to include in their Requests for Proposals (RFPs) and in 
provider contracts so they can document results. Planning bodies need outcomes data as input to 
their planning and priority setting. States and municipalities often require documentation that 
programs are making a difference, whether they are supported solely through the resources of the 
Ryan White HIV/AIDS Treatment Extension Act of 2009 or by a combination of public and 
other funding sources. Providers must document program outcomes as they seek public and 
private funds and as they work to improve and coordinate services.  
HIV care is now based largely on a medical service delivery model designed to reduce morbidity 
and mortality. Determining the effectiveness of Ryan White HIV/AIDS Program services 
therefore requires understanding whether such services help clients to access care and achieve 
improved health status. As a result, outcomes evaluation for almost any Ryan White HIV/AIDS 
Program–supported service category, from case management to transportation, needs to include 
an indication of whether program participation can demonstrate linkages to primary care—
which, in turn, contributes to improved clinical outcomes. Most providers lack access to data on 
client health status, but they can document their ability to link clients to outpatient or ambulatory 
medical care (e.g., helping them engage in care, keep appointments, and adhere to medications). 
Ryan White HIV/AIDS Program grantees, especially Part A and Part B grantees typically help 
support a system of HIV services. Grantees and planning bodies want evaluation data that can 
guide decision making about program priorities and resource allocation. Ideally, that means 
understanding the outcomes associated with not just one category of services (e.g., primary 
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medical care or medical case management) but rather a combination of core medical and support 
services—or an entire system of care. 
Assessing the need for HIV services 
A grantee can assess need from various perspectives—perhaps HIV seroprevalence and 
surrogate markers, target populations and their unique needs, or barriers to care. Regardless of 
the way in which the grantee decides to assess need, the Ryan White grantee must consider the 
topic in terms of race/ethnicity, gender, age, risk, insurance status, and poverty level along with 
other variables of interest to the local area. 
Parts A, B, C, and D grantees are responsible for assessing the need for services for their service 
population, so that they can address those needs through Ryan White HIV/AIDS Program and 
other funds. Needs assessment responsibilities are summarized in the Ryan White HIV/AIDS 
Treatment Extension Act of 2009 and grant guidance, which identify several components of 
needs assessment, including use of HIV seroprevalence and surrogate markers to estimate 
current and future demand for HIV services; the social context of HIV, such as HIV risk 
behaviors, that help describe populations needing services and their unique requirements; the 
current HIV service delivery and financing system; barriers to care; demand for care on the basis 
of the number of people living with HIV who do not have health insurance or other resources to 
pay for care; and estimated unmet need on the basis of the size of the population aware that they 
are living with HIV but are not in care. 
Ryan White HIV/AIDS Program grantees use many data sources to conduct needs assessment. 
Table 5.3 of the HRSA HIV/AIDS Bureau monograph “Using Data to Measure Public Health 
Performance—A Guide for Ryan White HIV/AIDS Program Grantees” 
(http://hab.hrsa.gov/manageyourgrant/files/datatomeasure2010.pdf) summarizes the types of data 
and their sources. Factors to consider when using the data include:  
• HIV epidemiologic profiles address the scope of HIV in the service area, document 
unmet need, and demonstrate the disproportionate impact of HIV on vulnerable 
populations. Availability of timely, detailed epidemiologic data is vital. 
• In some jurisdictions, HIV name-based reporting is relatively recent, therefore, data to 
calculate long-term trends in HIV diagnosis and prevalence may not be available. 
Information regarding the various components of the HIV service delivery and financing 
systems may vary. Data regarding HIV-related hospitalization rates, emergency 
department admissions, and public or commercial insurance expenditures may be 
unavailable or untimely because of the time required to gather and report data.  
• Detailed survey or other data that can be used to describe the demographic, economic, 
health insurance coverage, and geographic characteristics of persons living HIV. In some 
jurisdictions, government or other sponsors have supported the cost of those surveys. In 
other jurisdictions, Ryan White HIV/AIDS Program grantees have sponsored surveys.  
The type of the service area to be addressed by the needs assessment contributes to the approach 
taken. For example, urban areas in a state may have detailed data available for needs assessment, 
but rural areas may have minimal data. 
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Table 3-6.  Types and sources of HRSA/HAB* data sources used in HIV needs 
assessments 
Responsibilities Examples of data HAB/Grantee data sources 
HIV seroprevalence and 
surrogate markers 
HIV incidence and prevalence, CD4 and viral load, resistance, 
geographic distribution of HIV, demographic characteristics of 
persons with HIV, year of HIV and AIDS diagnosis, and HIV risk 
behaviors 
RSR Client Report, 
MAI Report 
Social context of HIV Demographic characteristics of persons with HIV , social and 
economic characteristics, health insurance coverage 
RSR Client Report, 
MAI Report 
Target populations and 
their unique needs 
Rates of homelessness, unstable housing, addiction, mental 
illness, and other social characteristics; income and other economic 
characteristics; type of health insurance coverage and scope of 
benefits; family characteristics 
RSR Client Report, 
MAI Report 
HIV service delivery and 
financing system 
Inventory of providers delivering HIV services, types and amounts 
of Ryan White HIV/AIDS Program and other funds, eligibility criteria 
for health insurance, eligibility criteria for disability income 
programs, mix of services available, HIV-related inpatient 
admissions and emergency room visits 
RSR Provider Report, 
ADAP Quarterly and 
Annual Reports 
Barriers or facilitators to 
care 
Eligibility determination process, capacity to serve more clients, 
travel time to HIV providers, parking, transportation, hours of 
operation, wait time for appointments, wait time at provider site, 
culturally or linguistically competent clinicians and other workers, 
availability of services, use of personnel to facilitate navigation of 
the care continuum 
RSR Client Report 
Documenting demand 
for care 
Service utilization rates, frequency of visits or other units of service, 
mix of services usedRDR, RSR Client Report, MAI Report, ADAP 
Quarterly and Annual Report, CBDPP and DRP 
Dental Services Report 
Unmet need for care HIV seroprevalence rates, AIDS rates, enrollment in health 
insurance or other insurance coverage, incarceration rates of 
persons with HIV  
RSR Client Report 
*HRSA/HAB: Health Resources and Services Administration/HIV/AIDS Bureau 
The Ryan White HIV/AIDS Program encourages grantees to use epidemiological and related 
public health data to understand the impact of HIV in a service area. For the Ryan White 
HIV/AIDS Program, the use of epidemiology and related public health data must be used to 
improve decisions about the management of health services for people living with HIV and 
clients of the Ryan White HIV/AIDS Program. Ryan White HIV/AIDS Program grantees must 
clearly illustrate how epidemiology and related public health data have been incorporated in 
public health planning and evaluation activities along with the implementation and management 
of Ryan White public health care and treatment services for people living with HIV in a service 
area. The Ryan White HIV/AIDS Program expects that many of the suggestions contained in this 
document would be included in reports and documents submitted to HRSA’s HIV/AIDS Bureau. 
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Question 2:  What are some things to keep in mind as a Ryan White HIV/AIDS Program 
grantee prepares the epidemiologic profile document for HRSA’s HIV/AIDS 
Bureau? 
For the Ryan White HIV/AIDS Program, the epidemiologic profile provides important 
information about the HIV experience in a state or local area. As such, it is essential for HIV 
services planning, priority-setting and service delivery, as well as coordination with HIV 
prevention and related public health activities. HRSA’s HIV/AIDS Bureau expects that Ryan 
White HIV/AIDS program grantees will demonstrate and apply knowledge of the local 
epidemiologic experience when proposing public health activities in grant applications.  
Parts A and B 
The HIV/AIDS Bureau requires new and existing Ryan White grantees to demonstrate the 
following in the epidemiologic profile submitted to HRSA: 
1. Determine the size and demographics of the population with HIV infection. 
2. Determine the service needs of these populations, with particular attention to those who 
know they have HIV but are not receiving HIV-related services and to historically 
underserved persons and communities that are experiencing difficulties in obtaining 
services. 
3. Identify populations with severe needs and comorbidities. 
4. If applying for funds from multiple Ryan White funding streams, use the epidemiologic 
profile information consistently to inform each grant application/service plan. 
Parts C and D 
The epidemiologic profile or needs assessment section of your grant application or grant reports 
should outline (or update) the needs of your community and provide information on the impact 
of HIV in your community. (If this section contains an “update,” please make note of this fact in 
the narrative.) The epidemiologic profile should define your service area, provide information on 
the rate of HIV in your service area, describe the target populations to be served, the medical and 
social support needs of the people you serve or propose to serve, and any unmet health needs. 
Describe gaps in HIV primary care services for the targeted populations within the proposed 
service area and the impact these gaps have on clients.  
Please pay particular attention to these four (4) components in your epidemiologic profile 
discussion: 
1. HIV seroprevalence and surrogate markers 
2. Social context of HIV 
3. Target populations 
4. Local HIV service delivery system 
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The Funding Opportunity Announcement (aka, grant announcement) describes what should be 
included within each component. 
HRSA/HAB grantees use data to address responsibilities including achieving health outcomes; 
clinical quality management QM and performance assessment; resource allocation; financing, 
organizing, and delivering services; training; and needs assessment.  
The types of data needed by grantees vary by Part, size of the service area, size and scope of the 
burden of HIV addressed by the grantee, amount of funds allocated to the grantee, number of 
clients served, number of providers, service mix, and interventions undertaken. 
Reports required by HRSA/HAB can be used to address many grantee responsibilities. The 
availability of Ryan White HIV/AIDS Program Services Report (RSR) client-level data 
submitted to HAB, if also used by grantee, may greatly improve the ability to meet various 
administrative, programmatic, QM, planning, resource allocation, and other responsibilities. The 
grantee is encouraged to examine the RSR data submitted to HRSA/HAB for possible utilization 
in this section. 
The HRSA/HAB HIV/AIDS Core Clinical Performance Measures for Adults and Adolescents 
can be used in monitoring the quality of care provided by their programs or their contracted 
providers. Several of the measures are incorporated into the RSR Client Report. Grantees should 
select measures that are most important to their agencies and the populations they serve. Some 
HRSA/HAB Group 1 performance measures are included in the RSR. 
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Chapter 4. 
Completing the Epidemiologic Profile  
Section 1  Making Your Profile User-Friendly  
Section 2  Writing Your Narrative  
Section 3 Disseminating Your Profile  
Once you have gathered and analyzed all your data, making your profile user-friendly will help 
ensure that prevention and care planning groups appropriately use the information to make 
decisions about prevention and care programs and resources.  
This chapter provides suggestions for ensuring that your profile is accessible and useful. It 
focuses first on ways to ensure that the body of your epidemiologic profile—your data and 
accompanying narrative—is clear and effective. It then provides guidance on preparing the 
remaining sections. The chapter concludes with some suggestions for preparing oral 
presentations of your data and analyses and for disseminating your profile.  
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Section 1: Making Your Profile User-Friendly  
• Organize the profile in a logical sequence, using the sections described in Chapter 2, 
section 2  
• Present your data in clear, easy-to-understand tables and figures (graphs, charts, maps).  
• Explain your data in a well-organized narrative, using straightforward and easy-to-
understand language.  
Presenting your data 
Summarizing your data and presenting them in tables or figures are critical to an effective profile 
because raw data are difficult to  
• understand  
• visualize  
• aggregate  
• use in detecting trends  
When used appropriately, tables and figures can be used to summarize and display complex data 
clearly and effectively and can emphasize specific points. These tools let you identify and 
present distributions, trends, and relationships among the data. They help make sense of the data 
in the profile and communicate findings to planning groups.  
However, poorly designed or executed tables and figures can mislead users or distract them from 
your message.  
Tables may be the only presentation format needed when the data are few and relationships are 
straightforward (tables are the best choice when the display of exact values is important). Figures 
(e.g., line and bar graphs, pie charts) make more sense for trends and for comparing populations, 
especially when you wish to show populations broken into subsets, such as males and females or 
age groups. The key points of tables and figures should always be explained in the 
accompanying narrative.  
As you develop the profile and determine which kind of display to use, ask yourself these 
questions:  
• Can the planning group determine what I want to convey by looking at this type of 
display, or would another type be better?  
• Given the needs of the planning group, is this presentation of the data logical?  
• Will the data set displayed provide the planning group with the accurate information 
needed to make an informed decision? 
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Important considerations for presenting data  
The following guidelines apply to all graphic aids:  
• The table or figure should be an integral part of the text but should also be able to stand 
alone (i.e., the reader should understand the table or figure without reference to the text). 
Ideally, a table or figure should convey one main point.  
• The table or figure should explain the who, what, when, and where of your data. For 
example, a figure (perhaps a line or bar graph) is useful for showing gender or 
racial/ethnic differences, geographic differences, or trends.  
• Consider the number of tables and figures in the profile. You should have enough to 
clearly summarize and display your data, but not so many that they are confusing and 
difficult to understand in terms of the text, regardless of the user’s technical background.  
• For figures, write clear and consistent labels, and label all elements to avoid 
misunderstanding. For tables, write clear and consistent column headings and row entries 
(use consistent terms).  
• Avoid clutter. Include only what you need to communicate the point. Eliminate 
unnecessary words and avoid unnecessarily large words that can detract from the 
message (e.g., footnotes to tables and notes to figures need not be expressed in complete 
sentences).  
• Maintain scale and balance by keeping the width and height of the table or figure in 
proportion (i.e., for a figure, the length of the vertical [y] axis should be approximately 
two-thirds the length of the horizontal [x] axis; in general, tables are longer than they are 
wide).  
• Write a clear, concise title.  
• Name the source of your data.  
• Discuss the key points of the table or figure in your text.  
• Consider how copies of the profile will be produced. Often, epidemiologic profiles are 
photocopied rather than professionally printed. If a color document is photocopied in 
black and white, the data elements (e.g., bars in a chart of slices of a pie chart) will 
probably be difficult to distinguish. Consider using patterns (e.g., dots, wavy lines, solid 
black). Shades of gray must differ at least 30%, or the gray elements will not be clearly 
distinguished in the original or in the copies (even if the document is professionally 
printed).  
• Consider the preferences of your planning group. If you have an opportunity, find out 
how they would like to see the data presented. That will help you determine the types of 
presentation that are easiest for them to understand and use.  
• Consider the best way to present your data:  
o Ensure that your presentation of epidemiologic data does not inadvertently stigmatize 
the demographic groups to which the data refer. Work with your HPG to avoid this 
problem.  
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o In situations in which the presentation of data on larger groups would overwhelm the 
presentation of data on smaller groups, you can present the data on the smaller groups 
separately. In the explanation below the figure, point out the differences between the 
larger and smaller groups. For additional information on how to present data, see: 
Edward R. Tufte. The Visual Display of Quantitative Information. Cheshire, CT: 
Graphics Press; 2nd edition, 2009. 
o When the numbers for a group are small, observe restrictions on cell size to protect 
confidentiality.  
See Appendix B (Use of Tables, Charts, and Maps to Illustrate Data) for examples of table and 
figure presentations suitable for your epidemiologic profile.  
Mapping using geographic information system (GIS) 
Geocoding of addresses of persons with a diagnosis of HIV infection allows for geographic 
analyses of the burden of disease. In addition, linkage of HIV surveillance data to U.S. Census or 
other data, based on geographic area (e.g., census tract), allows assessments of social 
determinants of health (e.g., socioeconomic status, poverty, and education) to identify 
populations that are disproportionately affected by HIV and related diseases and conditions in 
order to help eliminate health disparities.  
GIS technology can be used to display epidemiologic data by a geographic reference (e.g., a city 
or a neighborhood census block). From the geocoded data, users can create thematic maps (e.g., 
choropleth map, dot density map, or graduated symbol map), which illustrate the distribution of 
HIV infection without disclosing the locations of individuals. This information can be used to 
inform planning for prevention and care and treatment services, and to identify areas to target for 
counseling and testing and/or care and treatment services or facilities. This method of 
representation of data illustrates an enhancement of the epidemiologic, analytic, and 
technological capacity at the local and state level. For more details on geocoding, GIS, and 
guidance for creating maps, please refer to Technical Guidance for HIV Surveillance 
Programs—Policies and Procedures for Geocoding and Linking Activities with HIV Data 
(available at https://partner.cdc.gov/sites/NCHHSTP/HICSB/default.aspx). 
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Section 2: Writing Your Narrative 
Presenting data without effective explanation and interpretation often limits the clarity and user-
friendliness of an epidemiologic profile. Your narrative is crucial in helping users understand and 
interpret the data you present about HIV in your service area and in helping them use the data 
appropriately to plan prevention and care programs.  
Effective writing has many elements. This section concentrates on 3 elements that can 
significantly affect your profile:  
• Know your audience—who they are, their level of familiarity with epidemiologic issues 
and terminology, and their perspectives as end users of your profile.  
• Focus your narrative on findings so that its purpose is clear and it addresses specific 
questions and the needs of specific end users.  
• Write clearly, using concrete, familiar words and strong, active language.  
See Appendix A (Sample Data Tables and Charts with Interpretation Associated with Chapter 3) 
for examples of narrative interpretations of epidemiologic data. 
Know your audience  
Good writing is reader-centered, not writer-centered. Start by assessing your audience—the end 
users of the profile. Remember, your profile should be a document that planning group members 
can use to make decisions about prevention and care programs and resources. To help you bring 
your users into focus, ask yourself:  
• Who will read the profile?  
• How would I describe their professions, their viewpoints on HIV disease, and their 
familiarity with epidemiology?  
• How much do they already know about HIV?  
• What are the most important things they will be looking for in the profile?  
• How will they use the information in the profile?  
Knowing the backgrounds of planning group members, their experience and expertise with 
epidemiology, and the uses to which they will put the information can help you ensure that the 
profile meets their needs and capabilities. Planning groups may be diverse (e.g., community 
advocates; paraprofessionals, such as outreach workers; health care professionals, such as nurses, 
social workers, counselors, physicians, or psychologists; and program managers with differing 
educational backgrounds). Some members will have had formal training in epidemiology or 
statistics. Others may have had no formal training but may be able to easily assimilate 
epidemiologic concepts and the implications of those concepts for prevention and care programs. 
Still others will know their communities well but have little or no experience working with data.  
Members will also have diverse experience and expertise with HIV, and that diversity will 
influence what you include in your profile and how you frame the information. For example, 
consider questions such as changing demographics or clinical patterns that service providers and 
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advocates in the planning group may have observed. Think about how your data may or may not 
be able to address these kinds of changes.  
In addition, members of HPGs will differ in their ability to read and comprehend English. When 
you prepare slides for oral presentations, remember that persons who are color-blind cannot 
distinguish red and green when they are close together and that persons with vision defects may 
have difficulty with graduated colors (sometimes called color sweeps).  
Work closely with members of the HPG in developing the profile. In doing so, keep the 
following in mind:  
• Understand the perspectives of the HPG; the members are the primary end users. This 
will help you  
o address populations that group members serve and will also help you address those 
populations specifically, in terms of risk, reported cases, and testing or other service 
patterns  
o address policies that affect the data and also may affect service delivery (e.g., changes 
in case reporting resulting from named reporting)  
• Recognize and respect different world views among end users. For example, service 
providers and advocates tend to think in terms of individuals and trends among the 
individuals they see rather than in terms of grouped data (e.g., population-level 
measurements, such as mean and median).  
Focus your narrative on the needs of users  
Although the profile is not the only resource that HPGs use, it is a principal contributor to the 
planning process. Therefore, your profile needs to be focused on the uses of the data spelled out 
in CDC and HRSA guidance. You also need to explain your conclusions carefully and clearly to 
minimize the possibility that users will misinterpret them. Here are some suggestions for how to 
respond to these uses. Craft your profile so that it allows planning groups to  
• set priorities among populations by  
o describing differences in HIV risk (geographic and by population)  
o describing differences in the burden of HIV (geographic and by population)  
o presenting trends in risk and effect  
o detailing changes in policy, diagnostics, and treatment strategies that may affect risk, 
effect, or care and prevention needs  
• prepare for needs assessments and for analysis of gaps in prevention and care by  
o describing differences in HIV risk (geographic and by population)  
o describing differences in the effect of HIV (geographic and by population)  
o presenting trends in risk and burden of HIV  
o detailing changes in policy, diagnostics, and treatment strategies that may affect risk, 
burden of HIV or care and prevention needs  
o identifying questions that cannot be answered from the epidemiologic data  
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• set priorities among interventions by  
o defining populations who need prevention or care services  
o identifying and describing areas that need prevention or care services  
o describing whether services match the population and geographic distribution of HIV 
and relevant risk behaviors  
Write clearly  
Good writing is straightforward and easy to follow. The ideas flow logically from one to another. 
Readers should not have to stop and ask, “Now, what did that mean?” They should come to the 
end of a document with a clear sense of the author’s main points and the conclusions they should 
draw from the information presented.  
These concepts are vital in an epidemiologic profile because HPG members have to understand 
the narrative and the data presentations if they are to make sound decisions about prevention and 
care services.  
Here are suggestions for avoiding several common pitfalls in scientific or technical documents. 
Skirting these pitfalls will make your profile clearer, more explicit, and more accessible to your 
users, and therefore more useful.  
Avoid jargon and overly technical terms  
Jargon is the specialized vocabulary and idioms of a particular field or profession. Jargon works 
against clarity because it is often composed of long or unfamiliar words or phrases.  
Many people view jargon and overly technical terms as pretentious. The use of jargon and 
technical terms is also seen as a way of talking above a group or avoiding direct discussion of 
controversial issues.  
Avoiding jargon and overly technical terms does not mean that you write down to the audience 
or that you eliminate all technical terms related to epidemiology. In fact, many terms are 
necessary to describe HIV in the service area (e.g., prevalence, incidence, rates). Avoiding 
jargon does mean that you explain the technical term and how it relates to the data. The 
following example demonstrates how to translate epidemiologic jargon into useful information.  
Example  
Jargon: The data show an increase in the prevalence of persons living with HIV in 2011. 
Data show an increase in adolescent drinking and unprotected sex; thus, there is an increased 
risk of exposure for adolescents.  
Useful information: In 2011, compared with earlier years, adolescents in County X were at 
increased risk for exposure to HIV. Data show an increased prevalence (the total number of 
persons with HIV who were alive) of HIV in 2011. At the same time, the frequency of high-
risk behavior among adolescents—drinking and unprotected sex—also increased. When the 
prevalence of HIV infection in the community and the frequency with which adolescents 
practice high-risk behavior increase, the risk for exposure may also increase.  
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Spell out abbreviations  
Abbreviations (used here to include acronyms and initialisms) can be especially confusing to 
those who are not familiar with them. Be sure to write out the term or proper name at first use. 
Include in your profile a list of abbreviations and the written-out forms for which they stand.  
Use active, not passive, voice  
Voice is the relation of a subject to its verb; that is, whether the subject acts or is acted upon. In 
the passive voice, the subject receives the action (is acted upon). It is formed by adding the past 
participle of a verb to the proper form of the verb to be.  
Many authors use the passive voice in scientific documents because they believe that it 
contributes to an impersonal, more formal style. However, it requires more words and forces the 
reader to work harder. Active voice, in which the subject acts, is usually better than passive voice 
because it  
• is easier to understand and sentences are often shorter  
• gives more information  
• is often more direct  
• is closer to spoken language and therefore is more natural  
• names the doer of the action  
Examples  
Here are two examples of the passive voice:  
An additional seroprevalence study was conducted by the HIV Epidemiology Program. 
The plan of the XYZ Prevention Planning Group was submitted to the committee.  
Here are the same two sentences in the active voice:  
The HIV Epidemiology Program conducted an additional seroprevalence study. 
The XYZ Prevention Planning Group submitted its plan to the committee.  
Uncover smothered verbs  
Verbs are action words. Burying them in a group of other words robs them of their power. 
Smothered verbs often end in ion—as in collection of—and may accompany the passive voice. 
Getting rid of one sometimes helps you get rid of the other.  
Example  
Smothered: Collection of data occurs throughout the year.  
Uncovered: The health department collects data throughout the year.  
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Avoid “there is” and “there are” constructions  
Beginning a sentence with these phrases often leads to a wordy, weak sentence. You can almost 
always rework your sentence to avoid this construction by beginning with the word that is the 
subject of the sentence. Your writing will be shorter and more direct as a result.  
Examples  
Before: There is very limited information available on the risk behaviors among transgender 
persons.  
After: Information on the risk behaviors of transgender persons is very limited.  
Before: There are hundreds of Native American tribes in the United States.  
After: Hundreds of Native American tribes live in the United States.  
Be explicit  
As the writer of the profile, you cannot assume that your readers know everything about the 
subject or can intuit your meaning. When you write explicitly, you anticipate readers’ questions. 
For example,  
• Have you raised a question or issue but not answered it?  
• Have you come to a conclusion in your paragraph but not stated it?  
• Have you assumed important information in coming to a conclusion but not stated it?  
• Are 2 points related in some way that is not evident to a reader who is not very familiar 
with the subject matter?  
If you can answer yes to any of these questions, you should revise your text.  
Additional suggestions and reminders for clear writing and user-friendly formats  
• The word data is plural, not singular. For example, “Data show that injection drug use 
increases a person’s risk for HIV.”  
• Consider using the reading-level feature built into word processing software to determine 
readability.  
• Ask another person to read your draft profile. If he or she has trouble understanding what 
you have written or stumbles into the pitfalls already described, you should revise. 
Having another person read your draft is particularly helpful for catching writing that 
assumes knowledge that a reader may not have or writing that is not explicit.  
• Use consistent formats for headings in the overall profile and within sections and for 
tables and figures.  
• Use bullets to highlight key information and to break up a long series of items listed in a 
single sentence.  
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Section 3: Disseminating Your Profile  
Writers of epidemiologic profiles should ensure that the completed profile is disseminated by the 
state health department to members of HIV prevention planning groups. The epidemiologic 
profiles should also be disseminated to Ryan White HIV/AIDS Program grantees and planning 
councils and consortia as part of the comprehensive needs assessment.  
The epidemiologic profile is the first step in the planning process for both prevention and care 
groups, and each process includes other key elements. Prevention planning groups use the 
community services assessment to build on the epidemiologic profile and thus examine resource 
needs of the populations described in the profile. The comprehensive needs assessment 
conducted by care planning groups consists of 5 components:  
• Epidemiologic profile  
• Description of service needs of the affected population  
• Resource inventory  
• Profile of provider capacity and capability  
• Description of unmet needs for primary health care and of other gaps in services  
Both types of groups use these elements to identify gaps in the coverage of prevention services, 
set priorities among infected populations, and conduct interventions for high-risk populations. In 
addition, care planning groups use these elements to identify gaps in the coverage of Ryan White 
HIV/AIDS Program services and to set priorities that address the care needs of HIV-infected and 
affected populations.  
Disseminating your profile for other purposes 
You may wish to distribute your profile to other key stakeholders. Here are some suggestions for 
doing this successfully:  
• Develop a dissemination plan well in advance of the final publication.  
• Distribute the profile widely, under the name of, or with a cover letter from a well-known 
official at the top of the health department.  
• Post the profile on the health department Web site. This is recommended as the primary 
method of distribution. 
• Draw the attention of relevant individuals and agencies to the availability of the profile 
online: executive directors of local CBOs; the major providers of HIV care, including 
physicians, nurses, and physician assistants; sister government agencies or departments 
(e.g., STD and TB program directors); community activists; local academic HIV 
researchers; and local government officials. 
• Mail hard copies when it is necessary to do so.  
• Make presentations to HPGs, Ryan White planning councils, CBOs, provider groups, 
university audiences, and others.  
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• Put copies in the reception areas of your offices for visitors.  
• When inquiries are made about data on a specific risk group, refer the caller to 
the profile.  
See Appendix E (Preparing Oral Presentations of Your Profile). 
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Chapter 5. 
Special Considerations  
Section 1  Confidentiality  
Section 2  Special-Needs Populations  
Section 3  Comorbidity  
Section 4  Areas with Low Morbidity and Minimal Data 
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Section 1: Confidentiality 
Confidentiality is defined as the protection of information that an individual or institution has 
disclosed in a relationship of trust, with the expectation that it will not be divulged to others in 
ways that are inconsistent with the individual’s or the institution’s understanding of the 
original disclosure.  
Why is it important for health departments and service providers to maintain the confidentiality 
of HIV surveillance data and information about clients and services? Because people at risk for, 
and living with, HIV infection have the right to know that information about them is kept 
confidential by everyone involved, including prevention and care program planners, service 
providers, and funders. Ensuring the confidentiality of information on individuals is a 
fundamental requirement.  
What is confidential information?  
Confidential information is any information about an identifiable person or establishment, when 
the person or establishment providing the data or described in it has not given consent to make 
that information public and was assured of confidentiality when the information was provided.  
A breach in confidentiality 
A breach in confidentiality is a security infraction that results in the release of private 
information with or without harm to 1 or more persons. A breach in confidentiality may cause a 
person to be subject to harassment and discrimination because his or her HIV status or other 
confidential information became publicly linked to that person. Even the erroneous appearance 
of a link (e.g., someone believed to be HIV-positive because of the release of personal 
identifying information) can lead to these problems. Therefore, protection of confidentiality is 
essential to surveillance and the use of data from surveillance and other public health programs.  
The relationship of the community, the health department, and care services providers hinges on 
trust. One way that officials and providers maintain trust is through ensuring the confidentiality 
of surveillance information. A breach can erode the community’s confidence in public health and 
care systems.  
Confidentiality and the use of data  
Most states have laws to protect the confidentiality of HIV surveillance data and other 
information and to protect the privacy of HIV-infected persons. These laws are supported by 
several federal statutes. HIV surveillance data reported to CDC are protected by federal 
assurance of confidentiality. HIV surveillance programs should remind providers that the Health 
Insurance Portability and Accountability Act (HIPAA) permits public health reporting 
requirements and that providers are still subject to relevant laws, regulations, and public health 
practices, as described in “HIPPAA Privacy Rule and Public Health: Guidance from CDC and 
the U.S. Department of Health and Human Services” 
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(http://www.cdc.gov/mmwr/PDF/wk/mm52SU01.pdf). Surveillance staff can also find answers 
to many frequently asked questions regarding HIPAA and public health at the Office of Civil 
Rights Web site (http://www.hhs.gov/ocr/hipaa). In addition, CDC requires, as a condition of 
funding, that states follow CDC’s Data Security and Confidentiality Guidelines for HIV, Viral 
Hepatitis, STD, and TB Programs: Standards to Facilitate Sharing and Use of Surveillance Data 
for Public Health Action.* These standards cover health department responsibilities for the ways 
in which HIV data are collected, analyzed, maintained, transmitted to CDC or other state 
agencies, released, and disposed of.  
Confidentiality and epidemiologic profiles  
When developing your epidemiologic profile, keep confidentiality concerns regarding the data in 
mind. Use aggregate—rather than individual—data throughout, including tables and figures. 
Aggregate data include summary statistics compiled from personal information that have been 
grouped to preclude the identification of individuals.  
For your epidemiologic profile, observe local data release policies and restrictions on small cell 
size. Many areas suppress data with small cells (e.g., <3 or <5) to prevent the inadvertent 
disclosure of confidential information. These rules may be applicable to certain geographic areas 
and cross tabulations of data. In addition, some areas may suppress data when populations 
denominators are small (e.g., population subgroups <100). Areas may also have rules that 
caution regarding stability of rates based on small numbers of cases. For example, a rule that will 
be applied when rates are calculated where any numerator in a series is fewer than XX cases 
(e.g., <12 cases or <20 cases). Under these circumstances, a cautionary note should be included 
when the data are provided; in some instances, the data should not be released. The following is 
an example of a cautionary note: “Note. Reported numbers less than 12, as well as estimated 
numbers (and accompanying rates and trends) based on these numbers, should be interpreted 
with caution because the numbers have underlying relative standard errors greater than 30% and 
are considered unreliable.” Contractors should become familiar with the local data release 
policies. When preparing the profile, writers should indicate when data were suppressed because 
of small cell size.  
Analyze cases by geographic area within strict guidelines for the confidentiality and release of 
HIV surveillance data as specified by the health department.  
Do not include in the profile or in summary data or provide to the planning group any 
information (e.g., name, address, month and day of birth, or Social Security number) that could 
identify an individual.  
                                                            
*  CDC. Data Security and Confidentiality Guidelines for HIV, Viral Hepatitis, Sexually Transmitted Disease, and 
Tuberculosis Programs: Standards to Facilitate Sharing and Use of Surveillance Data for Public Health Action. Published 
2011. Available at http://www.cdc.gov/nchhstp/programintegration/docs/PCSIDataSecurityGuidelines.pdf.  
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Section 2: Special-Needs Populations  
The Ryan White HIV/AIDS Treatment Extension Act of 2009 (Public Law 111-87, October 30, 
2009; aka the Ryan White HIV/AIDS Program law) requires that applicants for program funds 
demonstrate the need for Ryan White program funds. Furthermore, the law requires that needs 
assessments and comprehensive plans used by Ryan White planning councils or consortia in 
setting priorities and allocating funds identify and address the unmet service needs of special 
populations. (Section 2 of the HRSA HIV/AIDS Bureau data monograph entitled “Using Data to 
Measure Public Health Performance: A Guide for Ryan White HIV/AIDS Program Grantees” 
[http://hab.hrsa.gov/manageyourgrant/files/datatomeasure2010.pdf] describes the conditions that 
unpin the collection and submission of Ryan White program data. The Ryan White grantee 
should be familiar with this data monograph.) 
In planning for special populations, unmet needs may refer to the service needs of persons not 
currently in the system of HIV care. It may also refer to persons in the system of HIV care whose 
needs are being only partially met. Determining unmet needs among special or targeted 
populations, which should be carried out during needs assessment, is important in determining 
how to direct resources to people living with HIV (PLWH) who may be disenfranchised from 
HIV care services.  
HRSA’s HIV/AIDS Bureau identified the following populations as requiring special attention 
during the planning and resource allocations processes conducted in a particular Ryan White 
service area:  
• Youth 13–24 years of age  
• Injection drug users  
• Substance users other than injection drug users  
• Men of color who have sex with men  
• White, or Anglo, men who have sex with men  
• Women of childbearing age (13 years of age and older)  
In addition, Ryan White HIV/AIDS Program applicants are encouraged to identify other 
populations that have been significantly or disproportionately affected by HIV. Evidence 
indicating that a population has been significantly affected should be provided by the data 
included for underserved populations. These data should come from epidemiologic profiles and 
needs assessments and may also include other national and local data.  
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Section 3: Comorbidity  
The Ryan White HIV/AIDS Program law provides additional guidance on how HRSA’s 
HIV/AIDS Bureau is to consider the severe-need factor in distributing Part A supplemental grant 
funds among Part A EMAs/TGAs (transitional grant areas). The Manager’s Statement, which 
accompanies the Ryan White HIV/AIDS Program law, defines areas most in need of Part A 
funding as having “the greatest or expanding public health challenges in confronting the burden 
of HIV.”  
In setting service priorities and allocating Ryan White program funding, Part A planning 
councils/planning groups are required to consider epidemiologic data on comorbid conditions. 
They must especially consider how these conditions may increase the cost and complexity of 
delivering HIV primary medical care and support services to PLWH in the EMA.  
A useful epidemiologic profile provides information on HIV prevalence among populations 
identified by a comorbid condition, such as STDs, hepatitis B or C, TB, substance use, or severe 
mental illness. It will also be important to provide information on increases or decreases in 
comorbid conditions among PLWH in the HIV care system. When possible, match the cost of 
comorbidities with the HIV population data to document the additional treatment costs.  
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Section 4: Areas with Low Morbidity and Minimal Data 
For areas with a small number of cases, data may need to be aggregated to protect confidentiality. 
The epidemiologists providing data for the profile should determine when aggregating data is 
appropriate and which aggregates are most useful. For data re-release, CDC suppresses cells <5 for 
tabulations in areas with less than 500,000 population. A suppression rule is also applied for 
analyses when population denominators are <100. See “Data Analysis and Dissemination” in 
Technical Guidance for HIV Surveillance Programs: Policies and Procedures (available at 
https://partner.cdc.gov/Sites/NCHHSTP/HICSB/Technical%20Guidance/). 
For areas with low morbidity, geographic analysis may be particularly difficult and, in some 
instances, inappropriate. For example, analysis at the county level may be inappropriate because 
of the small number of cases. EMAs/TGAs often consist of multiple counties or other 
jurisdictions of which one (the “dominant” county) typically has most of the cases, and the 
boundaries of the EMA/TGA may cross state lines (e.g., Washington D.C., Kansas City). The 
numbers of cases in the nondominant or less populous counties may be too small for comparison 
with those in the dominant county or for analysis of other variables within individual 
nondominant counties. Consequently, the suggested analyses by “geographic area” should 
generally pertain only to EMAs/TGAs within states, not to counties or other smaller areas within 
an EMA or TGA. Apply the same rationale when examining rural and urban data.  
If the distribution of HIV has remained stable in your service area, explain the data and possible 
reasons for this stability in your epidemiologic profile and in presentations to your community 
planning group. If data are available from supplemental data sources or local studies that may 
help explain the distribution of HIV in your service area, be sure to include those results in your 
epidemiologic profile. For service areas in which data are not available, note this lack of data in 
the profile. 
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Appendix A. 
Sample Data Tables and Charts with Interpretation 
Associated with Chapter 3 
Table A-1. HIV diagnoses and rates among persons in State X, by race/ethnicity and sex, 
2010 
 Males  Females  Total 
Race/ethnicity No. % Ratea  No. % Ratea  No. % Ratea 
American Indian/Alaska Native 16 <1 18.9  10 <1 11.9  26 <1 15.4 
Asian 42 1 9.4  16 1 3.3  58 1 6.2 
Black/African American 2,107 52 106.1  1,179 69 53.9  3,286 56 78.9 
Hispanic/Latino 597 14 54.9  195 11 17.9  792 14 36.4 
Native Hawaiian/Other Pacific Islander 3 <1 48.9  1 <1 22.3  4 <1 32.1 
White 1,300 32 10.2  305 18 2.3  1,605 28 6.1 
Total 4,065 100 25.1  1,706 100 10.1  5,771 100 17.0 
Source: X 
a  Rates are per 100,000 population. 
Interpretation: In 2010, HIV was diagnosed for 5,771 persons of whom 4,065 (70%) were male 
and 1,706 (30%) were female. By race/ethnicity, 3,286 (56%) were black, 1,605 (28%) were 
white, 792 (14%) were Hispanic/Latino, 58 (1%) were Asian. American Indians/Alaska Natives 
(26) and Native Hawaiians/Other Pacific Islanders constituted less than 1% each. 
The rate of diagnosed cases of HIV was 17 per 100,000 in State X. The rate for males was 2 
times that for females (25/100,000 compared with 10/100,000). By race/ethnicity, the rate was 
highest for blacks (79/100 000) compared with Hispanics (36/100,000), American 
Indians/Alaska Natives (15/100 000), Native Hawaiian/Other Pacific Islander (32/100,000), and 
Asians and whites (6/100,000). The rates for black and Hispanic males were higher than those 
for all other groups (106/100,000 and 55/100,000, respectively). The third highest rate was that 
for black females (54/100,000). Note that reported numbers less than 12, as well as estimated 
numbers (and accompanying rates and trends) based on these numbers, should be interpreted 
with caution because the numbers have underlying relative standard errors greater than 30% and 
are considered unreliable (refer to Chapter 6, Section 1, Confidentiality). 
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Table A-2. HIV diagnoses among persons in State X, by age group and sex, 2010 
 Males  Females  Total 
Age (yrs) No. %  No. %  No. % 
0–1 7 <1  7 <1  14 <1 
2–12 7 <1  12 <1  19 <1 
13–24 320 8  216 12  536 10 
25–44 2,725 64  1,111 64  3,836 63 
45–64 984 24  363 21  1,347 23 
≥65 64 1  22 1  86 1 
Total 4,107 100  1,731 100  5,838 100 
Source: X 
Interpretation: In 2010, a diagnosis of HIV was made for 5,838 persons in State X. Most of the 
diagnoses (66%) were for males aged 25–44 years. 
Table A-3. HIV diagnoses among persons in State X, by transmission category and 
sex, 2010 
 Males  Females  Total 
Transmission category No. %  No. %  No. % 
Male-to-male sexual contact 2,095 51  N/A   2,095 36 
Injection drug use 1,016 25  476 28  1,492 26 
Male-to-male sexual contact 
and injection drug use 
188 5  NA   188 3 
Heterosexual contact 751 18  1,204 70  1,955 34 
Other/unknown 44 1  33 2  77 1 
Total 4,094 100  1,713 100  5,807 100 
Source: X 
N/A, not applicable 
Interpretation: By transmission category, 2,095 (36%) persons were classified as infected 
through male-to-male sexual contact, 1,955 (34%) through heterosexual contact, and 1,492 
(26%) through injection drug use. Among the 4,094 males diagnosed with HIV infection, the 
predominant transmission category was male-to-male sexual contact (51%), followed by 
injection drug use (25%) and heterosexual contact (18%). Among the 1,713 females diagnosed 
with HIV infection, the primary transmission category was heterosexual contact (70%), followed 
by injection drug use (28%).  
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Islander White Total 
 No. % No. % No. % No. % No. % No. % No. % 
Male-to-male sexual 
contact 
7 27 21 34 874 27 261 33 —  921 57 2,084 36 
Injection drug use 5 19 13 21 924 28 243 31 —  284 18 1,469 26 
Male-to-male sexual 
contact and 
injection drug use 
—  —  86 3 28 4 —  69 4 183 3 
Heterosexual contact 14 54 27 45 1,349 41 241 31 —  299 19 1,930 34 
Other/unknown —  —  33 1 9 1 —  28 2 70 1 
Total 26 100 61 100 3,253 100 782 100 —  1,601 100 5,736 100 
Source: X 
Dash indicates cell size of ≤3. 
Interpretation: The percentage of persons with HIV infection attributed to male-to-male sexual 
contact was higher among whites than other racial/ethnic groups; injection drug use was higher 
for blacks/African Americans and Hispanics/Latinos. The percentage of blacks/African 
Americans, Asians, and American Indians/Alaska Natives with infection attributed to 
heterosexual contact was more than twice the percentage for whites and 1.5 times the percentage 
for Hispanics/Latinos.  
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Table A-5. Number of deaths of persons diagnosed with HIV infection and death rates per 
100,000 population in State X, by race/ethnicity, 2010 
 Males  Female  Total 
Race/ethnicity No. % Ratea  No. % Ratea  No. % Ratea 
American Indian/Alaska Native 7 1 8.3  0 — —  7 1 5.9 
Asian 6 1 1.2  0 — —  6 <1 0.9 
Black/African American 738 61 37.3  338 71 15.4  1,076 64 25.8 
Hispanic/Latino 135    43 9 4.0  178 11 8.2 
Native Hawaiian/Other Pacific Islander 1 <1 —  —     1 <1 
White 323 26 2.5  88 19 0.7  411 24 1.6 
Total 1,210 100 7.4  469 100 2.8  1,679 100 5.0 
Source: X 
Note. Deaths may be due to any cause. 
Dash indicates cell size of ≤3. 
a  Rates are per 100,000 population. 
Interpretation: The rate of death of persons diagnosed with HIV infection was much greater 
among males than among females and greater among blacks than among whites. The rate for 
Hispanics was intermediate between the rate for whites and the rate for blacks.  
Note. The denominator used in calculating death rates is the population of interest in a service 
area. For example, in Table A-5, since the numbers and rates of deaths are being calculated for 
persons with a diagnosis of HIV infection, the denominator is the entire population in the service 
area. If you wanted to calculate the rate of deaths among HIV-infected persons aged 25–44, the 
denominator would be limited to the population in this age group.  
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Table A-6. Ranking of 10 leading underlying causes of death among persons 25–44 years 




 Total deaths, % 
(N=934) 
Unintentional injury 1  238  25.5 
Malignant neoplasms 2  139  14.9 
HIV disease 3  115  12.3 
Homicide 4  86  9.2 
Heart disease 5  80  8.6 
Suicide 6  65  7.0 
Cerebrovascular disease 7  16  1.7 
Chronic liver disease 8  15  1.6 
Diabetes mellitus 9  7  0.7 
Pneumonia and influenza 10  6  0.6 
Source: X 
Note. Restricted to groups with at least 50 deaths from all causes and excluding causes of death that resulted in 3 or fewer deaths 
per group. HIV disease not listed if it either was not among the top 10 causes or caused 3 or fewer deaths per group.  
Interpretation: HIV disease was the third leading cause of death in 2010 among persons 25–44 
years old in State X, accounting for 12% of all deaths in this age group. 
Figure A-1. Annual number of HIV diagnoses among persons in State X, 2006–2010 
 
Source: X 
Interpretation: From 2006 through 2010, the number of HIV diagnoses steadily declined. In 
2006, the number of cases diagnosed was 17,500; in 2010, the number was 9,500.  
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Appendix B.  
Use of Tables, Charts, and Maps to Illustrate Data 
TABLES  
A table is a set of data arranged in rows and columns. Almost any quantitative (i.e., numeric) 
data can be organized into a table. Tables provide a reference for all the descriptive data on a 
topic and are also a basis for preparing figures, which reflect relationships, trends, or patterns, 
not details. See Tables B-1 and B-2, which are examples of presentations with differing numbers 
of variables.  
Table B-1. Example of table with 1 variable  
Diagnoses of HIV infection, by metropolitan statistical area of residence, 2009 
 No. 
New York, NY-NJ-PA  4,973 
Los Angeles, CA  2,101 
San Francisco, CA  886 
Miami, FL  2,741 
Washington, DC-VA-MD-WV  1,551 
Chicago, IL-IN-WI  1,516 
Houston-Baytown-Sugar Land, TX  1,463 
Source: CDC. 
Table B-2. Example of table with 2 variables  
Diagnoses of HIV infection, by geographic unit and race/ethnicity, January–
December, 2009 
 USA  State X  County X 
 %  %  % 
Black/African American 51  34  52 
Hispanic/Latino 17  20  18 
White 28  40  26 
Other races  4  6  4 
Source: X 
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PIE CHARTS  
In the pie chart, the size of a “slice” is proportional to its percentage contribution to the whole. 
That is, each slice shows how much of the pie each group represents. Pie charts are useful for 
showing differences in proportions. For example, a pie chart can be used to show diagnosis of 
HIV among female adults and adolescents, by transmission category (see Figure B-1).  
Figure B-1. Example of pie chart  
Estimated HIV diagnoses* among female adults and adolescents, by transmission 
category, County X, 2010  
 
Source: X 
Tip: More than 8 slices can be ineffective because slices become too small for clear labels or 
visibility. 
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LINE GRAPHS  
Line graphs display relationships between 2 variables on 2 dimensions, or axes. The dependent 
variable (the variable you wish to predict or explain) is usually shown on the vertical axis, and 
the independent variable (the variable you think will influence the dependent variable) is shown 
on the horizontal axis. Values are recorded as points on a graph and then connected (as a line) to 
show trends.  
Line graphs are useful for showing patterns, trends, aberrations, similarities, and differences in 
the data, especially trends in data from multiple periods of equal length (e.g., years).  
In Figure B-2, the dependent variable (the number of persons living with diagnosed HIV) is 
shown on the vertical axis, and the independent variable (the range of years) is shown on the 
horizontal axis. This line graph shows that the number of adult and adolescent males and females 
living with diagnosed HIV in the United States has been increasing.  
Figure B-2. Example of line graph  
  
Source: http://www.cdc.gov/hiv/library/slideSets/index.html. 
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EPIDEMIC CURVES  
The epidemic curve (Figure B-3) is a line graph that shows stage 3 (AIDS classifications) and 
deaths of persons ever classified as stage 3 (AIDS) by year of diagnosis or death.  
Figure B-3. Example of epidemic curve  
 
Source: http://www.cdc.gov/hiv/library/slideSets/index.html. 
The epidemic curve is important because it tells what is happening with the disease in the 
population. Notice the sudden rise in stage 3 (AIDS) classifications in 1993. This is due to an 
expansion of the HIV surveillance case definition implemented in 1993. Figure B-3 also shows a 
downward trend from 1966 in stage 3 (AIDS) classifications and deaths of persons ever 
classified as stage 3 (AIDS). This is due in part to the effectiveness of new treatments, such as 
highly active antiretroviral therapy (HAART), which inhibits the progression from HIV infection 
to stage 3 (AIDS) and allows persons with HIV to live longer.  
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BAR, OR COLUMN, GRAPHS  
In a bar, or column, graph, data are organized so that each observation can fall into 1category of 
the variable.  
Bar graphs are useful for showing how data change during a time period or for comparing 
categories. In a vertical bar graph, the measurable feature (e.g., percentage or rate) is shown on 
the vertical axis, sometimes called the measuring axis. Categories of a variable (e.g., locations, 
groups) are represented by bars on the horizontal baseline. The length of each bar corresponds to 
a value on the measuring axis.  
For example, Figure B-4 shows the measurable feature—rates per 100 tested—along the vertical 
(measuring) axis and the categories of the variable—race/ethnicity—along the horizontal 
baseline. In this example, you can see that among IDUs, the rate of testing positive for HIV 
infection is higher for blacks than for whites or Hispanics/Latinos.  
Figure B-4. Example of bar, or column, graph  
HIV-positive injection drug users, by race/ethnicity, County X, STD Clinics, 2000–2010 
 
Source: X  
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HISTOGRAMS  
The histogram, which resembles a bar graph because of the use of series of contiguous 
rectangles, represents the frequency distribution of an ordinal variable with interval properties 
(i.e., a variable, such as age, which has an infinite number of values). The contiguous, or 
adjoining, rectangles represent the number of observations for each class of interval in the 
distribution. The height of each rectangle is proportional to the number of observations (values) 
in that range.  
Figure B-5. Example of Histogram 
AIDS Cases by Age and Sex, reported 1981–2000, United States 
 
Source: X  
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MAPS  
Maps are useful for showing the geographic location of events or attributes. Spot maps show 
where a disease or an event occurred, area maps (see Figure B-6) show either the incidence of an 
event in an area or the distribution of some condition throughout a geographic area, and maps 
produced by the use of Geographic Information Systems, or GIS, (see Chapter 4) display data 
based on geographic mapping coordinates.  
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Appendix C. 
Data Sources  
CORE DATA SOURCES  
HIV Surveillance  
Overview: HIV surveillance data include all persons with confirmed diagnosis of HIV infection 
(including stage 3 [AIDS]) and who have been reported to a state or local health department. 
State and local health departments solicit disease reports from health care providers and 
laboratories. Standardized case report forms are used to collect sociodemographic information, 
mode of exposure, laboratory and clinical information, vital status, and referrals for treatment or 
services. HIV surveillance monitors the diagnosis of HIV infection, the demographic profile of 
HIV infected persons, and the mode of transmission. HIV surveillance data are also used to 
allocate resources for Ryan White HIV/AIDS Programs. 
Population: All persons who test positive for HIV  
Strengths: According to state evaluations, HIV infection reporting is estimated to be 80%–90% 
complete for persons who have tested positive for HIV. HIV surveillance provides information 
on persons known to be HIV infected and reported to the health department, emerging patterns of 
transmission, and trends in HIV infections among populations of particular interest (e.g., 
children, adolescents, women). HIV data also provide a basis for establishing and evaluating 
linkage to care, retention in care, and viral suppression. They can be used to anticipate unmet 
needs for HIV care.  
Limitations: All areas now have confidential name-based HIV reporting laws or regulations. 
However, HIV surveillance data may underestimate the number of infected persons because 
some infected persons have not been diagnosed. Persons who have tested positive at an 
anonymous test site and have not sought medical care, during which they would be 
confidentially tested, are not reported to the surveillance system. Furthermore, reporting of 
behavioral risk information may not be complete.  
Where available: All 50 states; U.S. territories; District of Columbia. 
Contact: State or local health department, HIV surveillance coordinator  
Reference 
CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and 
children <18 months and for HIV infection and AIDS among children aged 18 months to <13 
years—United States, 2008. MMWR 2008;57(RR-10);1–8. 
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SUPPLEMENTAL DATA SOURCES  
Behavioral Risk Factor Surveillance System (BRFSS)  
Overview: BRFSS is a state-based, random-digit–dialed telephone survey that monitors state-
level prevalence of the major behavioral risks associated with premature morbidity and mortality 
among adults. Each month, a sample of households is contacted, and 1 person in the household 
who is 18 years or older is randomly selected for an interview. Multiple attempts are made to 
contact the sampled household. A Spanish translation of the interview is available. Respondents 
are asked a variety of questions about their personal health behaviors and health experiences. 
Since 1994, the BRFSS questionnaire has included questions related to HIV for respondents aged 
18 to 49 years. These questions include perceived risk of getting an HIV infection; use of HIV 
testing; reasons for testing; if tested, the type of place where tested and receipt of posttest HIV 
counseling; attitudes about condoms; and attitudes about when to initiate HIV education in 
schools. As of 2001, respondents have been asked about their perception of the importance of 
HIV testing.  
Population: All noninstitutionalized adults, 18 years and older, who reside in a household with a 
telephone  
Strengths: Data are population-based; thus, estimates about testing attitudes and practices can be 
generalized to the adult population of a state. Information collected from the BRFSS survey may 
be useful for planning community-wide education programs.  
Limitations: BRFSS data are self-reported; thus, the information may be subject to recall bias. 
Respondents are contacted by telephone survey; thus, the data are not representative of 
households without a telephone. In addition, BRFSS data are representative of the general, 
noninstitutionalized adult population in an area, not just persons at highest risk for HIV.  
Where available: Since 1994, all 50 states and the District of Columbia have conducted BRFSS. 
As of 2011, American Samoa, Guam, Palau, Puerto Rico, and the U.S. Virgin Islands have 
participated in BRFSS.  
Contact: BRFSS coordinator for your state or territory. Additional background and information 
on whom to contact in your area is available at http://www.cdc.gov/brfss (accessed June 12, 
2014). 
CDC Medical Monitoring Project (MMP)  
Overview: MMP is a supplemental surveillance project designed to produce nationally 
representative data on people living with HIV who are receiving care in the United States. MMP 
has a 3-stage sampling design. During the first stage of sampling, geographic areas were sampled 
with probability proportional to size based on stage 3 (AIDS) prevalence at the end of 2002. 
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During the second stage of sampling, a representative sample of HIV care providers is chosen 
from each area. During the third stage of sampling HIV-infected patients are selected from 
sampled providers. MMP’s data collection has two primary components: an interview and 
medical record abstraction. Collection of data from interviews with HIV-infected patients will 
provide information on the current behaviors that may facilitate HIV transmission; patients’ 
seeking access to and use of HIV-related prevention services; utilization of HIV-related medical 
services; and adherence to medication regimens. Through abstraction of medical records, MMP 
provides information on clinical conditions that result from HIV-infected persons’ disease or the 
medications they take, as well as the HIV care and support services they receive and the quality 
of these services. 
Populations: Patients receiving outpatient medical care for HIV infection. 
Strengths: The design allows for national and state or local estimates of certain characteristics 
and behaviors that will be generalizable to adults in care for HIV infection in the United States. 
Data will be available in the same jurisdictions over time, allowing analysis for trends.  
Limitations: HIV-infected individuals not receiving HIV medical care are not sampled. 
Additionally, HIV-infected individuals receiving HIV care in federal, state and local correctional 
and work-release facilities; tribal facilities; health facilities located on military installations; and 
facilities that have provided HIV care only to patients under the age of 18 are not included.  
Where available: As of 2013, a total of 23 project areas (17 states and 6 separately funded 
metropolitan statistical areas within funded states) are conducting MMP activities: California; 
Chicago, IL; Delaware; Florida; Georgia; Houston, Texas; Illinois; Indiana; Los Angeles, CA; 
Michigan; Mississippi; New Jersey; New York; New York City, NY; North Carolina; Oregon; 
Pennsylvania; Philadelphia, PA; Puerto Rico; San Francisco, CA; Texas; Virginia; and 
Washington.  
Contact: State or local health department MMP Coordinator, Principal Investigator, or Project 
Coordinator (available at http://www.cdc.gov/hiv/statistics/systems/mmp/projectareas.html); for 
MMP at CDC, see http://www.cdc.gov/hiv/statistics/systems/mmp/contact.html for detailed 
contact information.  
CDC National HIV Behavioral Surveillance System (NHBS) 
Overview: NHBS is CDC’s comprehensive system for conducting behavioral surveillance 
among persons at highest risk for HIV infection in the US. The overall strategy for NHBS 
involves conducting rotating 12-month cycles of surveillance in 3 different populations at high 
risk for HIV: men who have sex with men (MSM), injection drug users (IDU) and heterosexuals 
at increased risk of HIV infection (HET). The behavioral survey assesses risk behaviors 
(including sex and drugs) and use of and access to prevention services among persons older than 
18 years of age who are at increased risk for HIV infection. Anonymous HIV testing is offered to 
all participants, which can then be used to estimate HIV prevalence in these populations.  
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Populations: Men who have sex with men, injection drug users, and heterosexuals at increased 
risk.  
Strengths: Among MSM, venue-based time-space sampling is used to obtain a sample of men 
attending venues. Among IDU and HET, respondent-driven sampling is used. Behavioral data 
will be available in the same metropolitan statistical areas over time, allowing analysis for trends.  
Limitations: At-risk persons who do not attend venues, or who are not recruited by their peers, 
are not sampled.  
Where available: 20 state and local health departments and their grantees in metropolitan 
statistical areas (from 2011–2015) where HIV prevalence is highest: Atlanta, GA; Baltimore, 
MD; Boston, MA; Chicago, IL; Dallas, TX; Denver, CO; Detroit, MI; Houston, TX; Los 
Angeles, CA; Miami, FL; Nassau-Suffolk, NY; New Orleans, LA; New York City, NY; Newark, 
NJ; Philadelphia, PA, San Diego, CA; San Francisco, CA; San Juan, PR; Seattle, WA; and 
Washington, DC. 
Contact: State or local health department NHBS Coordinator (available at 
http://www.cdc.gov/hiv/statistics/systems/nhbs/contacts.html); for NHBS at CDC, see 
http://www.cdc.gov/hiv/statistics/systems/nhbs/contacts.html for detailed contact information. 
CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention ATLAS 
Overview: The Atlas provides an interactive platform for accessing state and county-level HIV 
surveillance data collected by CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention (NCHHSTP). This interactive tool allows users to observe trends and patterns by 
creating detailed reports, maps, and other graphics.  
Surveillance data available through the NCHHSTP Atlas:  
• HIV 
• Sexually transmitted disease  
• Tuberculosis 
• Viral Hepatitis 
Where available: http://gis.cdc.gov/GRASP/NCHHSTPAtlas/main.html. Accessed June 12, 
2014.  
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CDC Wide Ranging Online Data for Epidemiologic Reporting 
(WONDER)  
Overview: The WONDER Web site may be useful for obtaining population estimates from the 
Bureau of the Census at the county level, by age and sex for a given race or by age and sex for 
Hispanics (all races combined).  
Other data available through WONDER:  
• Vital statistics mortality data from the National Center for Health Statistics at the county 
level, by age, sex, and race  
• Census state population projections  
Strengths: The tabulations from CDC WONDER can be printed, and some of the data sets can 
be downloaded in an Excel-compatible format. They provide numbers and rates, but not 
percentage distributions (which you would have to calculate yourself). WONDER allows users 
to quickly query large data sets across several years in order to identify trends. The Compressed 
Mortality application allows users the option of customizing the calculation of age-adjusted 
rates, selecting the demographic attributes for the standard population.  
Where available: http://wonder.cdc.gov. Accessed February 7, 2013.  
Coinfection with Human Immunodeficiency Virus (HIV) among 
Reported Cases of Primary and Secondary Syphilis 
Overview: Since 2008, HIV status has been a required data element of case report data for 
syphilis, including reports of primary and secondary (P&S) syphilis. These data, in addition to 
other required data elements like sex of sex partner, information source, and stage of diagnosis, 
are used to describe the current epidemiology of P&S syphilis, including affected populations.  
Population: Patients with reported cases of P&S syphilis in the United States. 
Strengths: Provides national level data on populations at risk for both P&S syphilis and HIV 
infection (e.g., men who have sex with men, or MSM). Such surveillance allows comparisons of 
different populations (e.g., MSM of different races/ethnicities and age groups) among different 
regions (e.g., the South, the West, as defined by the U.S. Census Bureau). These data assist the 
Centers for Disease Control and Prevention (CDC) to identify existing and emerging risk 
populations and focus efforts to prevent and reduce disease in these populations.  
Limitations: Some public health jurisdictions do not report HIV status. Therefore, these data 
might not reflect the epidemiology of HIV coinfection across all areas of the United States. Some 
populations in the United States can only be estimated (e.g., MSM), limiting the ability to 
calculate rates of HIV coinfection. Because of different social factors (e.g., reluctance of patients 
to disclose sexual behaviors to their care providers), these data might reflect underreporting of 
true case counts of HIV coinfection.  
Data Sources 
Page 95 of 132—8/25/2014 
Where available: Multiple states in the United States.  
Contact: State and local health department STD Programs, CDC, Division of STD Prevention, 
Epidemiology and Surveillance Branch, Surveillance and Special Studies Team 
Drug Abuse Warning Network (DAWN)  
Overview: DAWN is a national data system that collects information on drug-related deaths 
from participating medical examiner offices and information on drug-related visits to hospital 
emergency departments from a nationally representative sample of short-stay general hospitals 
throughout the contiguous United States. Emergency department estimates are produced for 21 
large metropolitan areas and for the nation. Drug-related death data are produced for more than 
40 metropolitan areas.  
DAWN was established to provide national, state, and local areas with data for program planning 
and policy; to identify substances associated with drug abuse deaths; to monitor drug abuse 
patterns and trends and detect new drugs of abuse; and assess adverse health outcomes associated 
with drug abuse.  
Population: Persons who died at 6–97 years of age, whose death was drug induced or drug 
related, and who had used the substance because of dependence, to commit suicide, for 
recreational purposes, or to achieve other psychic effects.  
Strengths: DAWN provides ongoing data on the patterns of drug-induced and drug-related 
deaths from many areas of the United States. Standardized data collection and data management 
procedures are used to ensure the accuracy of DAWN data. Because of concerns about the 
accuracy of DAWN data, the methods were revised, and the protocol modifications were 
delivered in 2001.  
Limitations: Participation in DAWN is voluntary; thus, counts of deaths do not represent the 
entire service area if participation is not universal. DAWN collects information only about drug 
abuse episodes that have resulted in a death and deaths that have been identified as drug induced 
or drug related. Finally, because DAWN relies on death investigation case files for reporting, the 
drugs may be underreported (if not reported), or the drug information may not be specific (if 
drug name is recorded differently).  
Where available: Atlanta, Baltimore, Boston, Buffalo, Chicago, Dallas, Denver, Detroit, District 
of Columbia, Los Angeles, Miami, Minneapolis, Newark, New Orleans, New York City, 
Philadelphia, Phoenix, San Diego, San Francisco, Seattle, St. Louis.  
Source: http://www.samhsa.gov. Accessed June 12, 2014. 
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Enhanced Perinatal Surveillance (EPS) 1999–2011 
Overview: The project was established to monitor the implementation and effect of the Public 
Health Service recommendations for preventing perinatal HIV transmission on pediatric HIV 
trends, provide a data collection system that enables states to respond to selected requirements of 
the Ryan White HIV/AIDS Program, and assist with timely evaluation of perinatal prevention 
efforts. The project collects data by the use of the HIV case report form and collects additional 
information from supplemental records by the use of a medical record abstraction form. The 
enhanced surveillance methods used to identify HIV-infected mothers and their perinatally 
exposed children include matching the birth registry to the HIV surveillance registry and the 
linking of mother-infant pairs. Information on HIV-infected mothers and their perinatally 
exposed children is abstracted from multiple sources: the maternal HIV record, prenatal care 
records, labor and delivery records, birth records, pediatric HIV records, birth and death 
certificates, and laboratory reports. The data that are collected include maternal and prenatal 
care, mother’s HIV test history, prenatal and neonatal antiretroviral therapy, other interventions 
to prevent transmission, receipt of prophylaxis and treatment of the infant, appropriate follow-up 
care of the mother and child, and other interventions relevant to the evaluation of recommended 
public health actions to prevent perinatal HIV transmission. Infants identified through enhanced 
surveillance are followed up every 6 months until their HIV infection status is determined; if 
they meet the case definition, they are followed up to determine their vital status.  
Population: All HIV-exposed infants born during 2005–2010 and their HIV-positive mothers  
Strengths: The project is population-based in most areas. In the facility-based project areas, the 
selected facilities were those where most of the births to HIV-positive women take place. The 
project collects information on HIV-exposed infants every 6 months until HIV infection is 
diagnosed. Study sites are able to characterize trends in perinatal HIV, monitor the 
implementation and effect of perinatal prevention guidelines, assess resource needs, assess 
missed prevention opportunities, and monitor the effect of prevention programs.  
Limitations: Data for the project rely upon the ability to identify an HIV-exposed infant and 
locate the supplemental medical charts needed to complete the abstraction form. The 
completeness of data elements relies upon the level of documentation in each of these medical 
records. Because the Survey of Childbearing Women was discontinued in 1994, no population-
based seroprevalence data are available to estimate the completeness of ascertainment of infants 
born to HIV-infected mothers for birth cohort years 2005 and later.  
Where available: Chicago, Connecticut, Delaware, Georgia, Houston, Los Angeles, Louisiana, 
Maryland, New Jersey, New York City, New York State, Philadelphia, Puerto Rico, South 
Carolina, and Texas. 
Contact: State or local health department, HIV surveillance coordinator; CDC, Division of 
HIV/AIDS Prevention, HIV Incidence and Case Surveillance Branch  
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Perinatal HIV Exposure Reporting (PHER) 2013–Current 
Overview: PHER differs from EPS in that information collected focuses on fewer key data 
elements to be collected on the standard pediatric case report form. In PHER, infants known to 
be HIV-exposed are monitored after birth up to 18 months of age to determine HIV infection 
status of the child and progression to HIV, stage 3 (AIDS). PHER attempts to get women 
reported as early as possible in their pregnancy by working with providers (HIV care providers, 
prenatal and obstetric care providers) to identify and report HIV-infected women who are 
pregnant and obtain information on their children.  
Population: All HIV-exposed infants born during 2013–current and their HIV-positive mothers.  
Strengths: The project is population based. The project collects information on HIV-exposed 
infants every 6 months until HIV infection is diagnosed. Study sites are able to characterize 
trends in perinatal HIV, monitor the implementation and effect of perinatal prevention 
guidelines, assess resource needs, assess missed prevention opportunities, and monitor the effect 
of prevention programs.  
Limitations: Data for the project rely upon the ability to identify an HIV-exposed infant and 
locate the supplemental medical charts needed to complete the abstraction form. The 
completeness of data elements relies upon the level of documentation in each of these medical 
records.  
Where available: Authority to establish notifiable disease reporting systems lies with state and 
local jurisdictions. Thus, jurisdictions must have appropriate legal authority in place to be 
eligible for PHER funding. Although all jurisdictions currently have authority to require 
reporting of persons diagnosed with HIV infection, they all do not have the authority to require 
the reporting of infants exposed to HIV but of undetermined HIV status.  
Contact person(s): State or local health department, HIV surveillance coordinator or PHER 
coordinator; CDC, Division of HIV/AIDS Prevention, HIV Incidence and Case Surveillance 
Branch. 
Gonococcal Isolate Surveillance Project (GISP)  
Overview: Established in 1986 to monitor trends in antimicrobial susceptibilities of strains of N. 
gonorrhea in the United States in order to establish a rational basis for the selection of 
gonococcal therapies. GISP is a collaborative project among selected sexually transmitted 
disease (STD) clinics, 5 regional laboratories, and CDC.  
In GISP, N. gonorrhoeae isolates are collected from the first 25 men with urethral gonorrhea 
attending STD clinics each month in approximately 28 cities in the United States. At regional 
laboratories, the susceptibilities of these isolates to penicillin, tetracycline, spectinomycin, 
ciprofloxacin, ceftriaxone, cefixime, and azithromycin are determined by agar dilution. 
Minimum inhibitory concentrations (MICs) are measured, and values are interpreted according 
to criteria recommended by the National Committee for Clinical Laboratory Standards (NCCLS).  
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Population: The first 25 men with urethral gonorrhea each month at participating STD clinics  
Strengths: GISP offers ongoing data on the level of antimicrobial susceptibilities among men 
who seek care at public STD clinics and who have urethral discharge. Despite the convenience 
sampling used by GISP, the data are useful for assessing trends in gonorrhea among men who 
have sex with men and the level of repeat infections.  
Limitations: GISP uses a convenience sample of men at public STD clinics to obtain patient 
isolates. Thus, inferences concerning the general population of men with urethral gonorrhea 
cannot be drawn. Depending upon the level of gonorrhea morbidity, the 25 men may represent 
all or a fraction of the patients seen in the public clinic. In addition, men who seek care from 
STD public clinics may not be representative of men who seek care elsewhere.  
Where available: Albuquerque; Atlanta*; Baltimore; Birmingham*; Chicago; Cincinnati; 
Cleveland*; Dallas; Denver; Detroit; Greensboro; Honolulu; Kansas City (Missouri); Las Vegas; 
Los Angeles; Miami; Minneapolis; New Orleans; New York; Orange County; Oklahoma City; 
Philadelphia; Phoenix; Portland (Oregon); Richmond; San Diego; San Francisco; Seattle*; and 
Tripler Army Medical Center, Honolulu. [* indicates regional laboratories] 
Contact: State or local STD program manager; CDC, Division of STD Prevention, 
Epidemiology and Surveillance Branch  
Hepatitis C Surveillance  
Overview: Surveillance for hepatitis C includes reporting of acute hepatitis C and hepatitis C 
virus (HCV) infection (past or present) to CDC’s National Notifiable Diseases Surveillance 
System. The purpose of hepatitis C surveillance is to identify new cases, determine risk factors 
for infection, identify infected persons who can be counseled and referred for medical follow-up, 
and evaluate prevention efforts.  
Population: All persons whose reported cases of acute hepatitis C, or HCV, infection meet the 
case definitions approved by the Council of State and Territorial Epidemiologists  
Strengths: Surveillance for acute hepatitis C provides information needed to determine 
incidence trends, transmission patterns, and persons at highest risk for infection. Persons can be 
characterized by gender, race/ethnicity, age, and risk behavior for HCV. Surveillance for HCV 
infection can be used to provide infected persons with information on how to reduce both their 
risk of transmitting HCV to others and their risk for further liver injury and to provide them with 
referral for medical evaluation. It also can be used to evaluate prevention efforts by providing 
estimates of the proportion and characteristics of persons with HCV infection.  
Limitations: Hepatitis C surveillance data should be interpreted cautiously because many 
reporting areas do not have the resources required for case investigations to determine whether a 
laboratory report represents acute infection, chronic infection, resolved infection, repeated 
testing of a person previously reported, or a false-positive result.  
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Where available: All 50 states and U.S. territories  
Contact: State or local hepatitis C (if available) or hepatitis B coordinator; CDC, Division of 
Viral Hepatitis  
References  
CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and 
HCV-related chronic disease. MMWR 1998;47(RR-19):1–39.  
CDC. Guidelines for Viral Hepatitis Surveillance and Case Management. Atlanta: CDC; 2005. 
http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm. Accessed February 7, 2013. 
HIV Testing System 
Overview: All states, territories, and selected cities receive funding to support HIV counseling, 
testing, and referral services as part of HIV prevention cooperative agreements with CDC. These 
services are provided at sexually transmitted disease (STD) clinics, family planning clinics, 
prenatal clinics, hospitals, community health centers, correctional facilities, drug treatment 
centers, tuberculosis (TB) clinics, HIV testing centers, and field (including street outreach) 
settings. Staff at these sites collect information about the persons tested (e.g., demographic 
information, behavioral risk factors), test type (i.e., anonymous or confidential), current and prior 
test results, and receipt of test results and posttest counseling. On a quarterly basis, health 
departments submit to CDC test-level data (i.e., data files with data on individual tests, not 
client-based). Personal identifying information is not provided to CDC. Some locations may 
collect client-based HIV testing data by using a code to link test results so that client-based data 
can be calculated. 
Population: All clients who receive confidential or anonymous HIV testing services at a site 
funded through a CDC cooperative agreement. 
Strengths: Standardized data on clients; data on both negative and positive results. 
Limitations: First, data findings may be influenced by whether testing sites promoted and 
followed policies of routine or targeted HIV testing. For example, the number of tests may be 
smaller in geographic locations or sites with targeted testing; and correspondingly, the HIV 
positivity in these locations or sites may be higher. Second, the population of persons using 
CDC-funded sites for HIV CTR is not representative of all persons who are tested in the United 
States. Third, data are test-level and not client-level. Fourth, the HIV testing data result from a 
program activity and are collected in conjunction with a health service delivery, which means the 
information collected by service providers is not routinely validated through research or 
epidemiologic investigation.  
Where available: State and local health departments and community-based organizations. 
Contact: State, territorial, or local HIV program manager or HIV/AIDS director. 
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HIV Incidence Surveillance  
Overview: As an extension of HIV case surveillance, state and local health departments that 
conduct HIV incidence surveillance collect additional information about HIV testing and 
treatment history as part of routine surveillance activities. Health department incidence 
surveillance personnel work with commercial, private, public, and hospital-based laboratories to 
obtain remnants of the diagnostic blood specimens to test for recent infection. Remnant 
specimens are tested as part of a serologic testing algorithm for recent HIV seroconversion 
(STARHS) to determine, at the population level, how many of the HIV-positive test results 
indicate new HIV infections. HIV testing and treatment history information and results from 
STARHS are used in a complex statistical model to calculate population-based estimates of HIV 
incidence.  
Population: All persons with newly reported HIV infections who do not have advanced disease, 
such as stage 3 (AIDS), and who are not taking antiretroviral medications for HIV prevention or 
to treat or try to prevent hepatitis B.  
Strengths: Estimates of HIV incidence can be used to monitor emerging trends in HIV, to assess 
progress in decreasing the number of new HIV infections that occur each year, to evaluate the 
effectiveness of prevention programs, and to allocate program resources.  
Limitations: Any significant recent changes in HIV testing behavior may impact the underlying 
assumption inherent in the statistical model that HIV testing behavior be constant over the recent 
2-year period, which may lead to bias in incidence estimates. The estimation model does not 
currently address individual motivation to be tested for HIV infection, which may lead to slight 
overestimates of HIV incidence if a significant number of individuals are motivated to be tested 
due to a recent exposure. STARHS may misclassify some persons with long-standing HIV 
infection as recent. Although this potential for misclassification is minimized in the statistical 
model by classifying all cases diagnosed with stage 3 (AIDS) at or within 6 months of HIV 
diagnosis as long-standing HIV infection, there may be some cases that are diagnosed late in 
infection but not as close to a stage 3 (AIDS) diagnosis that could still be misclassified, 
potentially adding to uncertainty in the estimates.  
Where available: Since 2008, 25 jurisdictions have conducted HIV incidence surveillance: 
Alabama, Arizona, California, Chicago, Colorado, Connecticut, District of Columbia, Florida, 
Houston, Indiana, Los Angeles, Louisiana, Massachusetts, Michigan, Mississippi, New Jersey, 
New York, New York City, North Carolina, Philadelphia, San Francisco, South Carolina, Texas, 
Virginia, and Washington. Additional areas were previously funded for HIV incidence 
surveillance, including: Maryland, Missouri, Ohio, Oklahoma, Tennessee, Puerto Rico, and 
Seattle.  
Contact: Local HIV incidence surveillance site coordinator; CDC, Division of HIV/AIDS 
Prevention, HIV Incidence and Case Surveillance Branch  
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Hospital Outpatient Study (HOPS)  
Overview: HOPS is a longitudinal cohort study established in 1993 to describe and monitor 
trends in demographics, symptoms, diagnoses, and treatments in a population of HIV-infected 
outpatients in clinics across the United States. HOPS abstracts clinical, immunologic, and 
virologic information through periodic reviews of medical records to enhance the understanding 
of prolonged survival, the metabolic problems associated with highly active antiretroviral 
therapy (HAART), adherence to HAART, and the occurrence of comorbidities. At baseline, 
HOPS collects demographic information and information on risk behaviors such as smoking, 
alcohol consumption, and drug use.  
Population: HIV-positive outpatients seeking care at HIV clinics  
Strengths: Because HOPS uses a longitudinal study design and collects extensive clinical 
information and laboratory clinical markers, the data illustrate patterns of clinical outcomes over 
time, particularly among long-term survivors of HIV disease and patients who are taking 
HAART. In addition, HOPS data have been used to document adverse outcomes from HAART.  
Limitations: HOPS is not a population-based study of HIV-infected persons. Thus, information 
from this study may not be representative of all HIV-infected patients in a service area. The 
quality of the data depends upon the completeness of documentation in the medical chart and the 
ability of abstractors to locate the chart.  
Where available: Chicago, Denver, District of Columbia, New York City, Oakland (California), 
Philadelphia, and Tampa  
Contact: Local study investigators; CDC, Division of HIV/AIDS Prevention, Epidemiology 
Branch  
Molecular HIV Surveillance (MHS)  
Overview: As a part of the routine HIV case reporting, data are collected on HIV-1 nucleotide 
sequences to assess prevalence and trends in acquired and transmitted HIV drug resistance; 
evaluate HIV genetic diversity; and describe HIV transmission patterns to help evaluate the 
impact of HIV prevention strategies, guide public health action, and estimate the burden of HIV 
in the United States. 
Population: HIV-1–infected persons residing in jurisdictions conducting MHS. 
Strengths: MHS is built on the strength of the HIV surveillance system in the United States and 
merges demographic and transmission risk data of persons diagnosed with HIV-1 infection and 
HIV-1 nucleotide sequence data to assemble epidemiologic profiles of HIV-1 at the molecular 
level, including mutations associated with drug resistance, subtypes, and transmission cluster 
networks. 
Limitations: Not all surveillance jurisdictions collect HIV-1 nucleotide sequence data. 
Contact: State or local health department MHS Coordinator; CDC, Division of HIV/AIDS 
Prevention, HIV Incidence and Case Surveillance Branch, MHS Coordinator. 
Data Sources 
Page 102 of 132—8/25/2014 
National Death Index (NDI)  
Overview: This national database of state death record information cannot be accessed directly; 
however, NCHS performs searches for health investigators (for a fee) to determine whether their 
study subjects’ records are potential matches to records in the NDI. If the match is accepted by 
the investigator as a true match, the database provides the following information: the fact that the 
person has died, the date of death, the U.S. state of death, and the death certificate number. For 
an additional fee, an enhanced service, named NDI-Plus, provides the International Classification 
of Diseases (ICD-9 or ICD-10) codes for the causes of death (e.g., underlying cause, multiple 
causes).  
Population: Deaths since 1979 in the entire United States, Puerto Rico, and the U.S. Virgin 
Islands  
Strengths: NDI is a nationwide, population-based index in which the causes of death are 
properly classified using ICD-9 or ICD-10 codes according to the rules of NCHS.  
Limitations: This database cannot be searched to look for deaths of, or with, particular causes of 
death, such as HIV infection. It can be searched only for potential matches with the 
investigator’s records, which the investigator must identify by variables such as name, date of 
birth, and Social Security number. If information on such identifiers is missing, it may be 
impossible to know for certain whether a partial match is a true match. The identifying variables 
of the potential matches will not be revealed directly—only the extent to which they match or do 
not match. The data are available from 1979 onward.  
Where available:  National Center for Health Statistics  
Contact:  
National Death Index  
National Center for Health Statistics  
Division of Vital Statistics  
6525 Belcrest Road, Room 820  
Hyattsville, MD 20782  
Phone: 301-458-4101  
Fax: 301-458-4034  
National Household Survey of Drug Abuse (NHSDA)  
Overview: The NHSDA is a source of statistical information on the use of illicit drugs by the 
U.S. civilian population ≥12 years of age. The survey collects data by administering 
questionnaires to a representative sample of the population through face-to-face computer-
assisted interviewing at the respondent’s residence. The information includes use of cocaine, 
receipt of treatment for illicit drugs, and need for treatment for illicit drug use during the past 
year; use of alcohol, tobacco, or marijuana during the past month; and perceived risk for binge 
drinking, marijuana use, or smoking during the past month.  
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The NHSDA uses a 50-state sampling design; for the 8 states with the largest populations, the 
sampling design provides a sample large enough to support direct state estimates. For the 42 
remaining states and the District of Columbia, small-area estimation techniques are used to 
calculate state estimates. Youths and young adults are oversampled so that each state’s sample is 
approximately equally distributed among 3 age groups: 12–17 years, 18–25 years, and ≥26 years.  
Population: Noninstitutionalized, civilian U.S. population aged ≥12 years  
Strengths: National standardized survey of drug use behaviors of the general population. To 
increase the level of honest reporting, information since 1999 has been collected by using a 
combination of computer-assisted interviewing methods to provide respondents with highly 
private and confidential means of responding to questions about substance use and other 
sensitive behaviors.  
Limitations: Direct state-level estimates are available for only 8 states; other states must rely on 
statistical estimates. NHSDA estimates represent behaviors in the general population; thus, the 
survey may underestimate the level of substance use in the population at highest risk for HIV. 
Further, data from the NHSDA are self-reported and thus subject to recall bias and 
underreporting of the level of a sensitive behavior.  
Where available: Annual nationwide survey conducted by the Substance Abuse and Mental 
Health Services Administration (SAMHSA)  
Reference 
Substance Abuse and Mental Health Services Administration. http://www.samhsa.gov/. 
Accessed February 7, 2013.  
National Neighborhood Indicators Partnership (NNIP)  
Overview: The NNIP is a collaborative effort by the Urban Institute and local partners to further 
the development and use of neighborhood-level information systems in local policymaking and 
community building.  
All local partners have built locally self-sustaining information systems with integrated and 
recurrently updated information on neighborhood conditions in their cities. These systems 
facilitate the direct use of information by local government and community leaders to build the 
capacities of distressed urban neighborhoods. Current NNIP activities are sponsored by the 
Annie E. Casey Foundation, the John D. and Catherine T. MacArthur Foundation, the Open 
Society Foundations, and the Rockefeller Foundation.  
Strengths: NNIP partners maintain a large warehouse of local administrative data that include 
vital statistics, law enforcement, taxes, education, public housing, and public assistance 
information. Much of the information is geocoded. NNIP offers materials on how to access and 
analyze the warehoused data.  
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Limitations: NNIP data come primarily from administrative data systems. The accuracy of 
nonessential information that is not required for program eligibility may be less accurate than 
other sources of data (e.g., education attainment in public assistance records). Reporting bias 
may affect specific records (e.g., crime—many crimes are underreported, and reporting practices 
may differ by jurisdiction).  
Where available: Atlanta, Baltimore, Boston, Camden, Chattanooga, Chicago, Cleveland, 
Columbus, Des Moines, Detroit, Dallas, Denver, Grand Rapids, Hartford, Indianapolis, Kansas 
City, Louisville, Memphis, Miami, Milwaukee, Minneapolis-St. Paul, Nashville, New Haven, 
New Orleans, New York, Oakland (California), Philadelphia, Pittsburg, Portland, Providence 
(Rhode Island), Sacramento, St. Louis, San Antonio, Seattle, Washington, and Urban Institute  
Reference 
National Neighborhood Indicators Partnership. http://www.neighborhoodindicators.org. 
Accessed June 12, 2014. 
Pregnancy Risk Assessment Monitoring System (PRAMS)  
Overview: A population-based survey that collects perinatal information, including information 
on prenatal HIV prevention through counseling and testing. Each month, a random sample (from 
state birth certificate files) of state-resident mothers are mailed a standardized 14-page 
questionnaire to gauge the extent of prenatal care, including counseling and testing of all 
pregnant women who delivered a live-born infant. Repeated questionnaire mailings are sent to 
the mother to encourage participation. Attempts to interview the mother by telephone are made 
soon thereafter. A Spanish translation of the mailed questionnaire and telephone interview are 
available. Since 1996, mothers who received any prenatal care were asked whether their health 
care provider discussed getting tested for HIV with them during a prenatal care visit. Since 2000, 
all mothers were asked whether they were tested for HIV during prenatal care or at the time of 
delivery.  
Population: All state-resident women who have given birth to a live-born infant are eligible for 
the PRAMS sample.  
Strengths: Population-based survey that collects information on prenatal HIV test counseling, 
along with other perinatal information. Estimates from PRAMS can be used to gauge the extent 
of provider HIV test counseling of all pregnant women who gave birth to a live-born infant. The 
level of HIV testing can also be assessed in this population.  
Limitations: PRAMS data rely on self-reported information; thus, the information is subject to 
recall bias. PRAMS data are representative only of mothers who gave birth to a live-born infant; 
pregnancies that were terminated or ended in fetal loss are not represented. Because PRAMS 
samples all mothers in a state with no explicit oversample of mothers at high risk for HIV 
infection or HIV-positive mothers, these groups are not guaranteed to have sufficient sample size 
with which to make reliable inferences. Mothers who did not seek prenatal care will not have 
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information on prenatal HIV counseling. Finally, information on HIV test result, posttest 
counseling, and HIV prophylaxis for HIV-infected women is not gathered.  
Where available: 37 states (Alabama, Alaska, Arkansas, Colorado, Delaware, Florida, Georgia, 
Hawaii, Illinois, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Missouri, North Carolina, Nebraska, New Jersey, New Mexico, New York, Ohio, Oklahoma, 
Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, 
Virginia, Washington, West Virginia, Wisconsin, Wyoming) and New York City.  
Contact: PRAMS coordinator for your state. Additional background and information on whom 
to contact in your area available at http://www.cdc.gov/prams.  
Reference 
Gilbert B, Shulman HB, Fischer LA, Rogers MM. The pregnancy risk assessment monitoring 
system (PRAMS): methods and 1996 response rates from 11 states. Maternal and Child Health 
Journal 1999;3(4):199–209.  
Ryan White HIV/AIDS Program Services Report (RSR) 
Overview: Beginning in 2009, Ryan White Program grantees and service providers started using 
a new data collection and reporting system to report information on their programs and the 
clients they serve to the HIV/AIDS Bureau.  
The Ryan White HIV/AIDS Program Services Report, or the RSR for short, is comprised of:  
• The Grantee Report. Grantees completes this report online through the HRSA 
Electronic Handbooks (EHBs) using a Web-based data entry system. Besides providing 
basic information about their organization, they will view, update, and verify a pre-filled 
list of their service provider contracts that were active in the most recent reporting period. 
For each of the contracts, grantees will view a list of Ryan White Program services and 
then check the boxes next to all services that their organization funded under the contract.  
• The Service Provider Report. Service providers will complete this report online. In 
addition to providing some basic information about their organization, providers will 
view a pre-filled list of their active service provider contracts for the most recent 
reporting period. For each of the service contracts, providers will view a list of Ryan 
White Program services and check the boxes next to all services that their organization 
delivered to RW Program clients during the reporting period.  
• The Client Report. Each service provider will submit this report online as an electronic 
file upload using a standard format. Each upload file will contain one record per client. 
Each client record will include information on demographic status, HIV clinical 
information, HIV-care medical and support services received, and the client's 'UCI', an 
encrypted, unique client identifier. 
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Strengths: The RSR data set is well-defined (see the HRSA Web site). The Ryan White grantee 
has the source data that was submitted to HRSA’s HIV/AIDS Bureau. The “Client Report” can 
be used by the Ryan White grantee for their own needs, include preparation of the “Epi Profile” 
to meet, in part, the funding requirements of the Ryan White HIV/AIDS Program. 
Limitations: The quality of the source data is determined by the Ryan White grantee. So issues 
related to data collection, data completeness, and data quality must be addressed by the Ryan 
White grantee prior to submission to HRSA. 
Where available: All Ryan White grantees and first-level provider (through grantees). 
Contact: Local Ryan White HIV/AIDS Program grantees. 
School Health Profiles  
Overview: The School Health Profiles (Profiles) is a system of surveys assessing school health 
policies and practices in states, large urban school districts, territories, and tribal governments. 
Profiles are conducted biennially by education and health agencies among middle and high 
school principals and lead health education teachers. Profiles include questions about school 
health education requirements and content; physical education requirements; school health 
policies related to HIV infection, tobacco-use prevention, and nutrition; asthma management 
activities; and family and community involvement in school health programs. Data from 
jurisdictions with overall response rates of ≥70% are statistically weighted, enabling population-
based inferences.  
Population: High schools and middle schools in a jurisdiction are eligible for sampling. The 
surveys use a systematic equal-probability sampling strategy. At a sampled school, the principal 
and the lead health education teacher each complete a questionnaire. Profile surveys have been 
conducted biennially since 1996.  
Strengths: The surveys provide population-based information on the provision of school health 
education, collecting information on whether HIV prevention is taught in a required course, 
whether specific topics related to HIV prevention are taught in a required course, whether 
teachers have received and want professional development on HIV prevention topics, the extent 
to which schools follow policies related to HIV infection, and other topics. Survey results serve 
as a springboard for enhancing activities in the school system. A minimum 70% response rate is 
required.  
Limitations: Data are self-reported and available in selected areas. Information collected is not 
in-depth on any specific topic. The profiles are unable to evaluate the effect of the school health 
practices are applicable only to students in school. In addition, the unit of analysis is the schools, 
not the students.  
Where available: In 2010, 49 states, 20 large urban school districts, 5 territories, and 2 tribal 
governments obtained the minimum response rate for their data to be weighted for the principal 
questionnaire, the lead health education teacher questionnaire, or both. 
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Contact: Departments of education in states, large urban school districts, territories, and tribal 
governments; CDC, Division of Adolescent and School Health  
Reference 
CDC. Adolescent and School Health: School Health Profiles. 
http://www.cdc.gov/healthyyouth/profiles/. Accessed February 7, 2013. 
Sexually Transmitted Disease Surveillance  
Overview: CDC conducts surveillance to monitor the levels of syphilis, gonorrhea, chancroid, 
and, more recently, chlamydia, in the United States in order to establish prevention programs, 
develop and revise treatment guidelines, and identify populations at risk for sexually transmitted 
diseases (STDs). States, local areas, and U.S. territories submit to CDC (weekly, monthly, or 
annually) case reports of STDs that have met the respective case definition for the infection. 
Case report forms include information on patient demographics, type of infection, and source of 
report (private or public sector). Service areas conduct both passive and active surveillance of 
STDs to monitor the STD transmission in their area.  
Population: All persons with a diagnosis of an infection that meets the CDC surveillance case 
definition for the infection and who are reported to local health department  
Strengths: STD surveillance data can serve as a surrogate marker for unsafe sexual practices or 
demonstrate the prevalence of changes in a specific behavior (e.g., rectal gonorrhea). STD data 
are widely available at the state and local level and because of shorter incubation periods 
between exposure and infection, STDs can serve as a marker of recent unsafe sexual behavior. In 
addition, certain STDs (e.g., ulcerative STDs) can facilitate transmission or acquisition of HIV 
infection. Finally, changes in trends of STDs may indicate changes in community sexual norms 
(e.g., unprotected sex).  
Limitations: STDs are reportable, but requirements for reporting differ by state. Reporting of 
STDs from private-sector providers may be less complete. Although STD risk behaviors result 
from unsafe sexual behavior, they do not necessarily correlate with HIV risk. Trends in 
chlamydia infections may reflect changes in reporting and screening practices rather than actual 
trends in disease.  
Where available: All 50 states, District of Columbia, and U.S. territories  
Contact: State or city STD program manager  
Reference 
CDC. Case definitions for infectious conditions under public health surveillance. MMWR 
1997;46(RR-10):1–56.  
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STD Surveillance Network (SSuN) 
Overview: SSuN was established to improve national capacity to detect, monitor and respond to 
emerging trends in STDs. SSuN collects data from 42 STD clinics and has implemented various 
projects for which STD clinic-based data are collected including (1) genital wart surveillance, 
(2) demographic and clinical characteristics of MSM attending STD clinics to assess the 
prevalence and trends in STDs, HIV and risk behaviors among MSM, and (3) STD clinic data to 
determine the proportion of patients screened for HIV and the prevalence of HIV. SSuN also 
conducts enhanced gonorrhea surveillance, where extensive data on demographics, risk and 
sexual behaviors, anatomic site of infection, and treatment are collected from interviews of a 
random sample of gonorrhea morbidity cases.  
Population: All clinic patients attending participating STD clinics; persons with a laboratory-
confirmed diagnosis of gonorrhea within SSuN jurisdictions. 
Strengths: Provides project sites with additional resources to conduct active surveillance of 
STDs and HIV risk behaviors. This surveillance can help fill critical gaps in the ability to 
understand STD and HIV trends as well as guide local, state and national STD programs and 
policies and evaluate the effectiveness of public health interventions to reduce STD morbidity. 
Limitations: Surveillance in STD clinics may not reflect STDs in the general population. 
Principal limitations of the enhanced gonorrhea surveillance component are risk and behavior 
data are self-reported, reporting of sensitive behavioral information may be subject to 
underreporting, and responses to questions may be subject to recall bias.  
Where available: Alabama, Baltimore, Chicago, Colorado, Connecticut, Los Angeles/ 
California, Louisiana, New York City, Philadelphia, San Francisco, Virginia, Washington. 
Contact person: Local or state STD program manager; CDC, Division of STD Prevention, 
Epidemiology and Surveillance Branch, Surveillance and Special Studies Team  
Tuberculosis Surveillance  
Overview: Reporting areas (the 50 states, the District of Columbia, Puerto Rico, and other U.S. 
jurisdictions in the Pacific and Caribbean) report tuberculosis (TB) cases to CDC using a 
standard case report form, Report of Verified Case of Tuberculosis (RVCT). Reported TB cases 
are verified according to the TB case definition for public health surveillance. In 1993, the 
surveillance of TB was expanded to collect information on occupation, initial drug regimen, HIV 
test results, history of substance abuse and homelessness, and residence in correctional or long-
term care facilities at the time of diagnosis. TB surveillance was again expanded in 2009 and the 
RVCT was modified to include 11 additional variables. These modifications accommodate the 
changing epidemiology of TB in terms of risk factors, new drug treatments, and enhanced 
laboratory capacity for diagnostic tests.  
Population: All persons whose case of TB meets the public health surveillance definition  
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Strengths: As a result of the 1993 and 2009 expansions of surveillance activities, jurisdictions 
have been able to evaluate the success of TB control efforts including drug susceptibility results 
and successful completion of therapy. Additionally, TB surveillance data provide a minimum 
estimate of the level of HIV comorbidity.  
Limitations: Data on HIV infection status of reported TB cases should be interpreted with 
caution. Reporting of HIV test results is incomplete due to concerns about confidentiality, laws 
and regulations in some jurisdictions that have been interpreted as prohibiting the HIV/AIDS 
program from sharing HIV status of TB patients, and reluctance of health providers to report 
HIV results to TB program staff. Furthermore, some TB patients may decline or not be offered 
HIV testing and TB patients who have been tested anonymously may not share their HIV test 
results with their health care provider.  
Where available: All 50 states, the District of Columbia, Puerto Rico, and other U.S. 
jurisdictions in the Pacific and Caribbean.  
Contact: State or territorial TB Control Offices: http://www.cdc.gov/tb/links/tboffices.htm. 
Accessed February 7, 2013. 
Reference 
CDC. Reported Tuberculosis in the United States, 2009. Atlanta, GA: U.S. Department of Health 
and Human Services, CDC, October 2010. 
http://www.cdc.gov/tb/statistics/reports/2009/default.htm. Accessed February 7, 2013. 
U.S. Bureau of the Census (Census Bureau)  
Overview: The Census Bureau collects and provides timely information about the people and the 
economy of the United States. The Web site for the Census Bureau includes data on 
demographic characteristics (e.g., age, race, Hispanic ethnicity, sex) of the population, family 
structure, educational attainment, income level, housing status, and the percentage of persons 
living at or below the poverty level. Tables and maps of census data are available for all 
geographic areas to the block level. Summaries of the most requested data for states and counties 
are provided, as well as analytical reports on population change, race, age, family structure, and 
apportionment. Links to other census-related sites are included.  
Population: United States population  
Strengths: A wide range of online statistical data on the United States population is available in 
different formats (e.g., tables, maps). State- and county-specific information is easily accessible, 
and links to other census Web sites are provided.  
Limitations: Some files may not download quickly.  
Where available: All states and U.S. jurisdictions. 
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Contact: http://www.census.gov/aboutus/contacts.html 
Reference 
U.S. Census Bureau. http://www.census.gov. Accessed June 12, 2014. 
Vital Records—Birth Data  
Overview: In the United States, state laws require that birth certificates be completed for all 
births, and federal law mandates the national collection and publication of births and other vital 
statistics data. The National Vital Statistics System is the federal compilation of the data, in 
cooperation with the National Center for Health Statistics (NCHS) and states. States use a 
standard form (U.S. Standard Certificate of Live Birth) to collect birth data and report this 
information to NCHS annually. The form collects demographic information about the newborn, 
the mother, and the father; insurance; prenatal care; prenatal risk factors; maternal morbidity; 
mode of delivery; pregnancy history; and clinical characteristics of the newborn. States have the 
option of collecting additional information on their birth certificates; some states have elected to 
include information on HIV testing.  
Population: All live births in the 50 states, the District of Columbia, and U.S. territories.  
Strengths: Vital records include all births in an area. Reporting is nearly 100% complete. 
Therefore, inferences can be made concerning the population of live births in a service area. The 
revised birth certificate collects additional information on the mother’s insurance, smoking, and 
morbidity—information that may be useful for focusing prevention resources.  
Limitations: Data obtained from patient medical records (i.e., smoking history, morbidity) are 
often not complete.  
Where available: All states and local areas maintain birth registries. Tabulated state birth tables 
are available at the Web site. 
Contact: State vital records registrar; CDC, National Center for Health Statistics  
Reference 
CDC. National Center for Health Statistics. http://www.cdc.gov/nchs. Accessed February 7, 
2013.  
Vital Records—Death Data  
Overview: In the United States, state laws require that death certificates be completed for all 
deaths, and federal law mandates the collection and publication of deaths. The National Vital 
Statistics System produces a federal compilation of death data reported to the National Center for 
Health Statistics by states. A standard certificate of death is used to record death information on 
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each decedent. The death certificate includes demographic information on the decedent, 
underlying cause of death (using an International Classification of Diseases [ICD-10] code), and 
contributions of selected factors to the death (i.e., smoking, accident, or injury).  
Population: All deaths in the 50 states, the District of Columbia, and U.S. territories  
Strengths: Reporting of deaths in the United States is universal and 100% complete. The data 
are widely available and can be used to determine the impact of HIV-related deaths related in a 
service area. Standardized procedures are used throughout the nation to collect death certificate 
data.  
Limitations: Deaths resulting from, or whose underlying cause was, HIV infection may be 
underreported on the death certificate. Clinical information related to HIV infection or stage 3 
(AIDS) may be missing. Death records are less timely than stage 3 (AIDS) case reports.  
Where available: All states and local areas maintain death registries. 
Contact: State vital records registrar; CDC, National Center for Health Statistics  
Reference 
CDC. National Center for Health Statistics. http://www.cdc.gov/nchs. Accessed February 7, 
2013.  
Youth Risk Behavior Surveillance System (YRBSS)  
Overview: Established to monitor 6 priority health-risk behaviors that contribute to the leading 
causes of mortality, morbidity, and social problems among youth and adults in the United States. 
YRBSS was developed to collect data that are comparable among national, state, and local 
samples of youth. The YRBSS includes a national school-based survey conducted by the Centers 
for Disease Control and Prevention (CDC) and state, territorial, tribal, and district surveys 
conducted by state, territorial, and local education and health agencies and tribal governments. 
Using a self-administered questionnaire, YRBSS collects information on 6 categories of 
behaviors, 1 of which comprises sexual behaviors that contribute to unintended pregnancy and 
sexually transmitted diseases, including HIV. Questions are also asked about exposure to HIV 
prevention education, sexual activity (age at initiation, number of partners, condom use, 
preceding drug or alcohol use), contraceptive use, and HIV testing history.  
Population: YRBSS surveys representative samples of students in grades 9–12.  
Strengths: YRBSS is a population-based survey that samples students in public and private high 
schools. The YRBSS questionnaires are self-administered, and anonymous inferences from 
YRBSS estimates can be drawn about behaviors of young people in high school, making the 
information useful for developing community-wide prevention programs focused on adolescents. 
YRBSS uses a standardized questionnaire so that participating states can be compared, and the 
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questionnaire is flexible so that state, territorial, and local agencies and tribal governments can 
ask specific questions to meet their needs.  
Limitations: YRBSS relies upon self-reported information; reporting of sensitive behavioral 
information may not be accurate (underreporting or overreporting may occur). Because the 
questionnaires are administered in schools, the data are representative only of young people who 
are enrolled in school and cannot be generalized to all young people. Answers to questions about 
behaviors during the past year may be subject to recall bias; however, this bias may be minimal 
because of the young age of the respondents.  
Where available: YRBSS surveys have been conducted since 1990 in selected areas and 
biennially since 1991. In 2011, 47 states participated. 
Contact: Departments of education or health in states, large urban school districts, territories, 
and tribal governments; CDC, Division of Adolescent and School Health 
Reference 
CDC. Adolescent and School Health: Youth Risk Behavior Surveillance System. 
http://www.cdc.gov/HealthyYouth/yrbs/. Accessed February 7, 2013. 
Youth Risk Behavior Surveillance System (YRBSS) among American 
Indian or Alaska Native Students 
Overview: The Youth Risk Behavior Surveillance System (YRBSS) was established to monitor 
6 priority health-risk behaviors that contribute to the leading causes of mortality, morbidity, and 
social problems among youth and adults in the United States. Included in the YRBSS is the 
national Youth Risk Behavior Survey (YRBS) from which the prevalence of health risk 
behaviors among different racial/ethnic groups can be determined, including American Indian or 
Alaska Native students (see http://www.cdc.gov/yrbss, then click Enter Youth Online). The 
YRBS also is conducted among some Native American populations: (a) Navajo Nation; 
(b) Cherokee Nation; (c) Bureau of Indian Education; and (d) Montana.  
Using a self-administered questionnaire, the YRBS collects information on 6 categories of 
behaviors, 1 of which comprises sexual behaviors that contribute to unintended pregnancy and 
sexually transmitted diseases, including HIV. Questions are also asked about exposure to HIV 
prevention education, sexual activity (age at initiation, number of partners, condom use, 
preceding drug or alcohol use), contraceptive use, and HIV testing history.  
Population: For the Navajo YRBS, targeted schools are all schools with at least 10 students 
enrolled in the middle or high school grades, at least 50% Navajo student enrollment, and located 
within the Navajo Nation or the Navajo Area Indian Health Service Area. All students in those 
targeted schools are asked to participate.  
For the Cherokee YRBS, a probability sample of regular public middle and high schools within 
the Cherokee Nation jurisdiction are used.  
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For the Bureau of Indian Education YRBS, targeted schools are all schools funded by the Bureau 
of Indian Education with at least 10 students enrolled in the middle or high school grades. All 
students in those targeted schools are asked to participate.  
Montana samples Native American students attending public high schools outside Montana 
Indian reservations and high school students enrolled in schools within a reservation or bordering 
one. State level YRBS data are also stratified by four racial/ethnic groups, including American 
Indian.  
Strengths: The YRBS is conducted among some Native American middle and high school 
students. The questionnaire is administered anonymously to students during school. Inferences 
from YRBS data can be drawn about the behaviors of Native American adolescents attending 
schools within the jurisdiction that the YRBS was conducted, making the information useful for 
developing community-wide prevention programs aimed at adolescents in those communities. 
The data from the Bureau of Indian Education YRBS can be generalized to Native American 
students attending Bureau-funded schools in the continental United States.  
Limitations: Limitations of the YRBS conducted among Native American populations include 
those identified with the YRBS project among the general population. Principal limitations are 
that the data are self-reported; reporting of sensitive behavioral information may not be accurate 
(underreporting or overreporting may occur); the data are representative only of children and 
adolescents who are enrolled in school; and answers to questions about behaviors during the past 
year may be subject to recall bias. The Bureau of Indian Education survey is conducted among 
students attending Bureau-funded schools; thus, survey estimates cannot be generalized to 
students who attended schools not funded by the Bureau of Indian Education. 
Where available:  
• 1997–2008—Navajo Nation and selected bordering high schools 
• 2000–2008—Navajo Nation and selected bordering middle schools 
• 2009–2011—Cherokee Nation middle and high schools 
• 1994–2008—Bureau of Indian Education high schools 
• 1997–2008—Bureau of Indian Education middle schools 
• 1999–2011—Montana high schools;  
Contact:  
• Navajo Nation Department of Health, 928-349-1385 for Navajo YRBS.  
• Bureau of Indian Education, Division of Performance and Accountability, 505-563-5266 
for the Bureau of Indian Education YRBS.  
• Cherokee Nation Community Health Promotion 918-453-5616 for Cherokee YRBS.  
• Montana Office of Public Instruction 406-444-3178 and available online at 
www.opi.mt.gov/yrbs. Accessed February 7, 2013. 
Ryan White HIV/AIDS Programs 
Page 114 of 132—8/25/2014 
Appendix D. 
Ryan White HIV/AIDS Programs 
The Ryan White HIV/AIDS Program is divided into several “Parts,” following from the 
authorizing legislation.  
PART A 
Part A provides grant funding for medical and support services to Eligible Metropolitan Areas 
(EMAs) and Transitional Grant Areas (TGAs)—population centers that are most severely 
affected by HIV. EMA eligibility requires an area to report more than 2,000 stage 3 (AIDS) 
cases in the most recent 5 years and to have a population of at least 50,000. To be eligible as a 
TGA, an area must have at least 1,000 reported but fewer than 2,000 new stage 3 (AIDS) cases 
in the most recent 5 years. The FY 2010 Part A appropriation was approximately $679.1 million.  
PART B 
Part B provides grants to States and Territories to improve the quality, availability, and 
organization of HIV health care and support services. Part B grants include a base grant; the 
AIDS Drug Assistance Program (ADAP) award; ADAP Supplemental Drug Treatment Program 
funds; and supplemental grants to States with “emerging communities,” defined as jurisdictions 
reporting between 500 and 999 cumulative stage 3 (AIDS) cases over the most recent 5 years. 
Congress designates, or “earmarks,” a portion of the Part B appropriation for ADAP. With the 
dramatic increase in the cost of pharmaceutical treatment, the ADAP earmark is now the largest 
portion of Part B spending.  
The FY 2010 Part B appropriation was approximately $1.25 billion of that, $835 million was for 
ADAP. Five percent of the ADAP earmark is set aside for the ADAP Supplemental Drug 
Treatment Program, which assists States needing additional ADAP funds.  
• Part B provides $5 million in supplemental grants to States for Emerging Communities.  
• In 2009, $50,000 awards were made to 2 newly eligible U.S. Pacific Territories 
(American Samoa and the Commonwealth of the Northern Mariana Islands) and 3 
Associated Jurisdictions (the Republic of the Marshall Islands, the Federated States of 
Micronesia, and the Republic of Palau).  
PART C 
Part C supports outpatient HIV early intervention services and ambulatory care. Unlike Part A 
and Part B grants, which are awarded to local and State governments that contract with 
organizations to deliver services, Part C grants are awarded directly to service providers, such as 
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ambulatory medical clinics. Part C also funds planning grants, which help organizations more 
effectively deliver HIV care and services. The FY 2010 Part C appropriation was approximately 
$206.8 million. 
PART D 
Part D grants provide family-centered comprehensive care to children, youth, and women and 
their families and help improve access to clinical trials and research. In FY 2010, Part D 
programs received approximately $77.8 million in appropriations. 
PART F  
Part F grants support several research, technical assistance, and access to care programs. 
• The Special Projects of National Significance (SPNS) Program supports the 
demonstration and evaluation of innovative models of HIV care delivery for hard-to-
reach populations. SPNS also funds special programs to support the development of 
standard electronic client information data systems by Ryan White HIV/AIDS Program 
grantees. A total of $25 million was set aside for the SPNS Program in FY 2010. 
• The AIDS Education and Training Centers (AETC) Program supports education and 
training of health care providers through a network of 11 regional and 4 national centers. 
In FY 2010, the AETC appropriation was approximately $34.8 million. 
• Minority AIDS Initiative (MAI) was established initially in FY 1999 via the 
Congressional appropriations process to provide funding to improve access to HIV care 
and health outcomes for disproportionately impacted minority populations, under Parts A, 
B, C and D. The types of MAI-funded services provided under Parts A, C and D were 
consistent with their ‘base’ programs, while the Part B MAI focused on education and 
outreach to improve minority access to State ADAP’s. The MAI was then codified with 
respect to each Part by the Ryan White HIV/AIDS Treatment Modernization Act of 2006, 
which also made the Part A and B MAI separate, competitive grant programs for 
EMA/TGA’s and States respectively. However, under the Ryan White HIV/AIDS 
Treatment Extension Act of 2009, the Congress directed that both be returned to a 
formula grant basis and ‘synchronized’ with the Part A and B grant awards, similar to the 
Parts C and D MAI.  
All grant programs of the Ryan White HIV/AIDS Treatment Extension Act of 2009 can support 
the provision of oral health services. Two Part F programs, however, specifically focus on 
funding oral health care for people with HIV:  
• The HIV/AIDS Dental Reimbursement Program reimburses dental schools, hospitals 
with postdoctoral dental education programs, and community colleges with dental 
hygiene programs for a portion of uncompensated costs incurred in providing oral health 
treatment to patients with HIV disease.  
• The Community-Based Dental Partnership Program supports increased access to oral 
health care services for people who are HIV positive while providing education and 
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clinical training for dental care providers, especially those practicing in community-based 
settings.  
In total, the Dental Program receives a combined $13.6 million in appropriations in FY2010. 
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Appendix E.  
Preparing Oral Presentations of Your Profile 
You may be called upon to present part or all of your HIV epidemiologic profile to your HPG. 
Reducing the contents of the profile to a meaningful presentation is challenging, but an effective 
oral presentation can be a key element in communicating the information in the profile. 
Developing an effective presentation involves several elements. 
KNOW YOUR AUDIENCE AND DETERMINE YOUR PURPOSE 
AND OBJECTIVES  
You have an advantage because you know that your audience is the HPG. In writing your profile, 
you have already thought about who they are, what information they need, and their level of 
familiarity with the content and terminology. You know your audience members have differing 
levels of experience in working with data.  
The objectives of the presentation are defined by the profile.  
• Explain the purpose of the profile (e.g., to help planning groups set priorities among 
populations who need prevention and care services and determine current and future 
needs for programs such as counseling and testing services).  
• Describe the major trends of HIV in the service area and the implications of those trends.  
ORGANIZE YOUR PRESENTATION 
The Opening  
The opening is intended to get the attention of your audience and prepare them for what is to 
come. Depending on the context of the presentation and your audience, you may want to  
• describe the benefit of the presentation to the audience—why they should care  
• build rapport with the audience—make eye contact; if the audience is small, try to 
address people by name  
• establish your credibility by briefly explaining your background, position, and experience  
• review the agenda or topics you will cover  
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The Body  
Structure your presentation so that you tell your audience what you are going to tell them, tell 
them what you want them to know, and then summarize what you’ve told them.  
Find out how much time you will have for the presentation. Typically, you will have 30 minutes 
in a meeting that includes other important topics. Plan your presentation to fit the time allotted. 
Avoid the common mistake of trying to pack too much information into a limited time.  
Keep the presentation concise and focused on the needs and interests of your audience. Present 
what they need to know, not what you know. If you have a lot of material, consider presenting it 
at several meetings.  
Try not to read your presentation. Your audience will be far more engaged if you speak naturally.  
Use techniques for holding your audience’s interest:  
• Keep the pace brisk by making a point and then moving quickly to the next point.  
• Consider making your presentation interactive by asking a question or soliciting opinions.  
• Include visual aids, such as overheads, handouts, or slides. Allow 1 minute per slide 
(more if your tables and figures require detailed explanation).  
• Focus on your delivery. Vary the inflection and tone of your voice (avoid speaking in a 
monotone).  
• If appropriate, include descriptions specific to your service area. For example, describe 
the kind of clients a particular clinic might see, or recount a description of high-risk drug 
injection practices gleaned from an ethnographic study conducted in the service area.  
The Closing  
Many speakers lose their audience during the closing, missing an opportunity to reinforce key 
points. Clue the audience that you are closing: “In closing, …” or “To summarize, ….” 
Restate your key points and main ideas.  
FOCUS YOUR CONTENT  
Keep the presentation simple and give the results first. Focus on the major points in the executive 
summary. For example, more persons are currently living with HIV in the service area than at 
any other time, stage 3 (AIDS) incidence and mortality have decreased or increased, or the 
highest HIV infection rates are among MSM who also inject drugs.  
Explain the confidentiality standards for your data and how the data are protected. Describe the 
strengths and weaknesses of the results so that users know the implications when making 
prevention and care program decisions.  
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Point out national trends. Much of the media coverage of HIV is based on national data. Help the 
audience differentiate the information from the media and the information they need to check 
locally to see whether the distribution of HIV locally is showing the same trends.  
If you have surprising or puzzling results, point them out. It is possible that someone in the 
audience will have an interpretation. Also, be explicit about what you do not know (it is a good 
way to increase your credibility).  
EXPLAIN EPIDEMIOLOGIC TERMS AND PRESENTATION METHODS  
Depending on the expertise and experience of your audience, you may need to explain 
epidemiologic terms. Use simple language and provide examples. For instance, here are a 
definition and an example of incidence:  
Term Explanation Example 
Incidence The number of new infections 
during a specified time, often 
a year. 
The incidence of heterosexually acquired HIV 
infection remained stable among women in the 
United States, from 5,500 infections in 2007 to 
5,700 cases infections in 2010. 
You may also need to explain how to read and interpret the tables and figures. Table E-1 
illustrates an aid that could accompany an explanation of how to read a table.  
Table E-1. Example of aid to help explain how to read a table  
 
If you have time and it is appropriate to your audience, also consider explaining  
• Your data sources. Show an actual HIV case report form (blank or fake data) or other 
data source, such as a report containing statewide hospital discharge data or a report from 
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the Youth Risk Behavior Surveillance System. The audience members are less likely to 
ask for information you do not have if they can see the data you collect.  
• Your research methods and data analyses. However, do not focus too much on the 
methods or the data analysis. Remember that end users need to make decisions based on 
the profile’s results, not the analyses.  
PROVIDE HANDOUTS  
Consider providing the following material for your audience to take home from the meeting:  
• copies of your slides or other visuals  
• handouts summarizing your main points and conclusions  
Depending on your resources and service area, you may wish to make your presentation 
available later by creating a Microsoft PowerPoint presentation.  
ADDITIONAL TIPS  
• Practice delivering the presentation to persons with no background in epidemiology. Ask 
for feedback about the clarity of your presentation, explanation of terms, and discussion 
of pertinent data.  
• Schedule additional presentations or orientations to address more detailed issues related 
to 1 or more specific behavioral risk groups or to particular care issues that may be of 
interest to stakeholders, advocates, or planners.  
• Make yourself available to attend other meetings at which users will discuss 
epidemiologic issues or use the profile.  
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Appendix F. 
Epidemiologic Profile Feedback Form for Planning Groups 
The purpose of this form is to provide the writers of HIV epidemiologic profiles feedback from 
their end users regarding the ease of use and applicability of the profile to prevention and care 
planning activities.  
Please complete this feedback form and send it to the writer or lead writer of your HIV 
epidemiologic profile.  
1. What is your role on the planning group?  
___________________________________________________________________________ 
2. Did planning group members have a role in creating the epidemiologic profile? 
 Yes  No  




3. Was the epidemiologic profile easy to read?  
 Yes  No   Somewhat 
4. How were the findings of the epidemiologic profile communicated to you? 
 Print copy only  
 Profile writers presented epidemiologic profile to planning group  
 Other type of presentation  
___________________________________________________________________________ 
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5. Were the findings of the epidemiologic profile clear to you?  
 Yes  No   Somewhat 




6. Was the epidemiologic profile useful to your planning process?  
 Yes  No   Somewhat 
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Appendix G. 
Terms, Definitions, and Calculations  
adjustments. Statistical calculations that allow the comparison of different groups (when the 
difference may affect what you are studying) as though they are alike. Differences in populations 
or subgroups make it difficult to make comparisons; adjustments remove the influence of a 
specific factor (e.g., age, gender, race, or disease status) from the analysis.  
aggregated data. Information, usually summary statistics, that is summed or presented together 
to prevent the identification of individuals.  
Stage 3 (AIDS) (acquired immunodeficiency syndrome). The condition that results from HIV 
infection and is marked by the presence of opportunistic infections or either a CD4count of <200 
cells/µL or a CD4 percentage of total lymphocytes of <14.  
bar graph (vertical). A type of figure in which categories of variables (displayed on a horizontal 
baseline) are compared by amount, frequency, or magnitude (labeled on a vertical axis). (Bar 
graphs may also be horizontal.)  
behavioral data. Data collected from studies of human behavior that is relevant to disease risk. 
Relevant behaviors for HIV risk may include sexual activity, substance use, sharing of drug 
paraphernalia, condom use, or responses to primary and secondary prevention messages.  
capability. The extent to which a provider’s services are geographically and physically 
accessible, culturally appropriate, and available at convenient times.  
capacity. The amount of services a provider can deliver (i.e., the number of service units and the 
estimated number of clients who can be served).  
case. A condition, such as HIV infection (e.g., an HIV case) diagnosed according to a standard 
case definition.  
case fatality. The number of deaths among persons with a diagnosis of the disease of interest. 
Usually expressed as a rate (number of deaths after disease onset or diagnosis divided by the 
number of persons with the disease); measures the effect of the disease on persons with a 
diagnosis.  
chief elected official (CEO). The official recipient of Title 1 funds within the EMA, usually the 
mayor or the chair of the county governing unit (e.g., board of supervisors).  
community-based organization (CBO). An organization that provides services to locally 
defined populations, which may include persons infected with, or affected by, HIV.  
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HIV planning group (HPG). A group of persons who represent, or have interests in, a given 
community and who work in partnership with health departments to design local prevention 
plans to meet the needs of persons at risk for, or infected with, HIV.  
comorbidity. The coexistence of a disease or illness and HIV infection in one person (e.g., an 
HIV-infected person who also has TB).  
comprehensive planning. The process used to determine how HIV services will be organized 
and delivered. Comprehensive HIV services planning requires planning councils and consortia to 
answer 4 questions: (1) Where are we now? (2) Where should we be going? (3) How will we get 
there? (4) How will we monitor our progress?  
confidence interval (CI). A range of values for a measure that is believed to contain the true 
value at a specified level of certainty (e.g., 95%).  
confidentiality. The treatment of information that an individual or institution has disclosed in a 
relationship of trust, with the expectation that the information will not be divulged to others in 
ways that are inconsistent with the individual’s or institution’s understanding when the 
individual or institution provided the information. It encompasses access to, and disclosure of, 
information in accordance with requirements of state law or official policy. For HIV surveillance 
data, confidentiality refers to the protection of private information collected by the HIV 
surveillance system.  
continuum of care. A coordinated delivery system, encompassing a comprehensive range of 
health and social services that meet the needs of people living with HIV at all stages of illness.  
convenience sampling. A sampling technique that relies upon selecting people who are more 
easily accessible at the time (e.g., persons at a group meeting or in a clinic when a researcher 
happens to be there). The advantage of convenience sampling is that it is easy to carry out. The 
weakness is that the findings may not be representative of the entire community.  
core epidemiologic questions. The questions in an epidemiologic profile that must be answered 
by all prevention and care grantees, regardless of HIV morbidity in their areas.  
cumulative cases: The total number of cases of a disease reported or diagnosed during a 
specified time regardless of current vital status. Cumulative cases therefore include cases in 
persons who have already died.  
Example: Assume that 9,000 HIV infections had been diagnosed in a state from 1985 through 
the year 2010. Of the 9,000 persons with HIV, 4,000 had died. The cumulative number of 
HIV infection diagnoses in that state through 2010 would be 9,000.  
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cumulative incidence: The proportion of a group of people who experience the onset of a 
health-related event during a specified period of time. Cumulative incidence is calculated by 
dividing the number of new infections during a specified period by the population at risk for the 
health-related event during that period.  
cumulative incidence = 
number of new infections during a given period of time
population at risk
 
It is important to pay attention to the time period to which the cumulative incidence relates. 
Cumulative incidence is commonly calculated for annual time periods, but it can also be 
calculated for shorter or longer periods. Use caution when comparing incidence calculations for 
differing periods.  
eligible metropolitan area (EMA). A metropolitan statistical area that qualifies for Title I 
funding by reaching a certain threshold of stage 3 (AIDS) cases. EMAs may cover 1 city, several 
cities or counties, or more than 1 state.  
epidemic curve. A type of line graph that shows the distribution of disease onset. Time is plotted 
on the horizontal (x) axis; the number of cases is plotted on the vertical (y) axis.  
epidemiologic profile. A document that describes the distribution of HIV in various populations 
and identifies characteristics both of HIV-infected and HIV-negative persons in defined 
geographic areas. It is composed of information gathered to describe the effect of HIV on an area 
in terms of sociodemographic, geographic, behavioral, and clinical characteristics. The 
epidemiologic profile serves as the scientific basis from which HIV prevention and care needs 
are identified and prioritized for a jurisdiction.  
epidemiology. The study of the distribution and determinants of health-related states or events in 
specified populations and the application of this study to the control of health problems.  
estimate. In situations in which precise data are not available, an estimate may be made on the 
basis of available data and an understanding of how the data can be generalized to larger 
populations. In some instances, national or state data may be statistically adjusted to estimate 
local conditions. Good estimates are accompanied by statistical estimates of error (a confidence 
interval), which describe the limitations of the estimate.  
grantee. The recipient of HIV prevention or Ryan White HIV/AIDS Program funds. For HIV 
prevention funds, the state or local health department is referred to as the grantee. For Ryan 
White HIV/AIDS Program funds, the chief elected official (CEO) of each EMA is the official 
grantee for Title I funds. Under Title II, the governor designates a state agency (usually the state 
health department) as the grantee.  
HIV (human immunodeficiency virus). The virus that causes HIV infection. Persons with HIV 
in their system are referred to as HIV infected.  
HIV Care Consortium. An association of public and private nonprofit providers of health 
support services and community-based organizations that plans, develops, and delivers services 
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for people living with HIV. The Ryan White HIV/AIDS Program authorizes states to use Title II 
funds to establish consortia in “areas most affected by HIV disease.”  
HIV infection, stage 1. No AIDS-defining condition and either CD4 count of ≥500 cells/µL or 
CD4 percentage of total lymphocytes of ≥29. 
HIV infection, stage 2. No AIDS-defining condition and either CD4 count of 200–499 cells/µL 
or CD4 percentage of total lymphocytes of 14–28. 
HIV infection, stage 3. Documentation of an AIDS-defining condition or either CD4 count of 
<200 cells/µL or CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-
defining condition supersedes a CD4 count or percentage that would not, by itself, be the basis 
for stage 3 (AIDS) classification. 
HIV infection, stage unknown. No reported information on AIDS-defining conditions and no 
information available on CD4 count or percentage. 
HIV primary medical care. Medical evaluation and clinical care that is consistent with U.S. 
Public Health Service guidelines for the treatment of HIV.  
HIV surveillance. The systematic collection, analysis, interpretation, dissemination, and 
evaluation of population-based information about persons with a diagnosis of HIV.  
incidence. The number of new infections in a defined population during a specific period, often 
1 year, which can be used to measure disease frequency. There is an important difference 
between HIV incidence and a new diagnosis of HIV infection: HIV incidence refers to persons 
newly infected with HIV, whereas persons newly diagnosed with HIV may have been infected 
years before the diagnosis. Population-based incidence estimates include new infections that 
have been diagnosed as well as new infections that have not been diagnosed. HIV incidence data 
may be used to monitor emerging trends and guide prevention activities.  
Program areas that collect HIV testing and treatment information and STARHS (serologic testing 
algorithm for recent HIV seroconversion) results may estimate incidence using the stratified 
extrapolation approach.  
CDC is currently funding selected surveillance programs to conduct HIV incidence surveillance. 
Data from these areas will be used to provide national estimates of new HIV infections (not just 
the number of cases newly diagnosed and reported to surveillance).  
interpretation. The explanation of the meaning of the data. For example, interpreting a trend in 
the number of HIV cases diagnosed during a 5-year period enables a planning group to assess 
whether the number of cases has increased or decreased. However, groups should use caution in 
interpreting trends that are based upon small increases or decreases.  
jurisdiction. A geographic area in which a government agency conducts surveillance or provides 
public health services.  
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line graph. A type of figure used to display the changes in a particular variable over time. 
Values are recorded periodically as points on a graph and then connected as a line to show a 
trend.  
mean: The sum of values for a variable, a group, or other category divided by the total number 
of values (e.g., in a data set). The mean is what many people refer to as an average.  
Example: Assume that people in a given service area in 2010 are the following ages at 
diagnosis of HIV infection: 18, 18, 19, 20, 22, 23, 26, 31, 41. The total of the 9 ages = 218 
years.  
218 years ÷ 9 people = mean age 24.2 years 
median: The middle value in a data set: approximately half the values will be higher and half 
will be lower. The median is useful when a data set contains a few unusually high or unusually 
low values, which can affect the mean. It is also useful when data are skewed, meaning that most 
of the values are at one extreme or the other.  
Example: Assume the following ages at diagnosis of HIV in the year 2010 data for a given 
service area: 18, 18, 19, 20, 22, 23, 26, 31, 99. Although the mean age is 30.7, the median 
age is 22. In this instance, the median age better reflects the central value of age for the 
population.  
morbidity. The presence of illness in the population.  
mortality. The total number of persons who have died of the disease of interest. Usually 
expressed as a rate, mortality (total number of deaths over the total population) measures the 
effect of the disease on the population as a whole.  
needs assessment. The process of gathering and analyzing information from a variety of sources 
to determine the current status and the unmet needs for HIV prevention or care among a defined 
population or in a geographic area.  
no identified risk (NIR). Cases in which epidemiologic follow-up has been conducted, sources 
of data have been reviewed—which may include an interview with the patient or provider—and 
no mode of exposure has been identified. Any case that continues to have no reported risk 12 or 
more months after the report date is considered NIR.  
percentage. A proportion of the whole, in which the whole is 100.  
Example: Assume that 15 of the 60 cases of AIDS in a given year in a state occurred in 
women.  
15 ÷ 60 = .25 x 100 = 25% 
planning group. Refers to CDC- and HRSA-sponsored groups, such as HIV prevention 
planning groups (HPGs) and Ryan White HIV/AIDS planning councils and consortia.  
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prevalence. The proportion of cases of a disease in a population at risk, measured at a given 
point in time (often referred to as point prevalence). Prevalence can also be measured over a 
period of time (e.g., a year; known as period prevalence). Prevalence does not indicate how long 
a person has had a disease. It can provide an estimate of risk for a disease at a specific time. 
Prevalence data provide an indication of the extent of a condition and may have implications for 
services needed in a community. For HIV surveillance, prevalence refers to living persons with 
HIV disease, regardless of time of infection or date of diagnosis.  
prevalence = 
number of existing cases*
population at risk*
 
* during specified period 
probability sampling. A sampling technique that relies upon random selection to select persons 
from a defined population; all persons have a known chance of selection. Types of probability 
samples include simple random sample, systematic random sample, and stratified sample.  
probability (P) value. The probability that a statistical result (an observed difference or 
relationship) could have occurred by chance alone. Statistical results usually are regarded as 
significant if there is less than 5% probability that the observed difference or relationship was 
due to chance alone. In such situations, the P value is said to be less than .05 (P <.05).  
proportion: A portion of a population or a data set, usually expressed as a fraction or a 
percentage of the population or the data set.  
Example: Assume that 12 of 20 HIV prevention programs in a given service area are school-
based programs. Calculation of the proportion as a fraction:  
12 ÷ 20 = .6 = 6/10 = 3/5 
Calculation of the proportion as a percentage:  
12 ÷ 20 = .6 x 100% = 60% 
public health surveillance. The continuous, systematic collection, analysis, and interpretation of 
data essential to the planning, implementation, and evaluation of public health practices, all of 
which are closely integrated with the timely dissemination of these data to those responsible for 
disease prevention and control. HIV surveillance is one example of public health surveillance.  
qualitative data. Information from sources such as narrative behavior studies, focus group 
interviews, open-ended interviews, direct observations, ethnographic studies, and documents. 
Findings from these sources are usually described in terms of common themes and patterns of 
response rather than by numeric or statistical analysis. Qualitative data often complement and 
help explain quantitative data.  
quality of life. A subjective measure of the degree to which persons affected by a specific 
disease, injury, or form of treatment perceive themselves to be able to function physically, 
emotionally, and socially. Quality of life is useful for the planning of health services.  
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quantitative data. Numeric information (e.g., numbers, rates, and percentages).  
range. The smallest and the largest values in a series.  
Example: Assume the following ages at diagnosis of HIV in the year 2010 in a given service 
area: 18, 18, 19, 20, 22, 23, 26, 31, and 41. The range in values is 18–41.  
rate: A measure of the frequency of an event compared with the number of persons at risk for 
the event. When rates are being calculated, it is usual for the denominator to be the general 
population rather than the population potentially exposed to HIV infection by various high-risk 
behaviors. The size of the general population is known from data from the U.S Census Bureau, 
whereas the size of a population at high risk is usually not known.  
number of HIV diagnoses*
population*
 × 100,000 = population rate of HIV diagnoses 
* during a given period  
For ease of comparison, the multiplier (100,000) is used to convert the resulting fraction to 
number of cases per 100,000 population. Although arbitrary, the choice of 100,000 is standard 
practice.  
Example: Assume that 16 cases of HIV disease were diagnosed during 2010 in a service area 
and that 400,000 persons lived in the area in 2010.  
Calculation of the rate: 
16 ÷ 400,000 × 100,000 = 4 per 100,000 
ratio. A way of showing the relative size of 2 numbers. The first number is divided by the other 
number to derive the ratio. The ratio may be expressed as a fraction (e.g., 3/4), or the 2 numbers 
may be separated by a colon (e.g., 3:4).  
raw data. Data that are in their original form (i.e., not coded or analyzed).  
reliability. Refers to the consistency and dependability of a data-collection instrument or 
measure. For example, if you repeat a blood test 3 times on the same specimen and the results are 
the same each time, the test is said to be reliable.  
reporting delay. Reporting delays (time between diagnosis or death and the reporting of 
diagnosis or death to state/local surveillance program) may differ among demographic and 
geographic categories; for some, delays in reporting have been as long as several years. 
representative. A sample that is similar to the population from which it is drawn and thus can be 
used to draw conclusions about the population.  
Ryan White HIV/AIDS Program. The primary federal legislation created to address the needs 
for health and support services among persons living with HIV and their families in the United 
States; enacted in 1990 and reauthorized in 1996, 2000, 2006, and 2009.  
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sample. A group of people selected from a total population with the expectation that studying 
this group will provide important information about the total population.  
seroprevalence. The number of persons in a defined population who test positive for HIV based 
on HIV testing of blood specimens. (Seroprevalence is often presented either as a percentage of 
the total specimens tested or as a rate per 100,000 persons tested.)  
service area. The jurisdictions of CDC HPGs and the service areas or planning regions of HRSA 
planning groups.  
sociodemographic factors. Background information about the population of interest (e.g., age, 
sex, race, educational status, income, geographic location). These factors are often thought of as 
explanatory because they help us to make sense of the results of our analyses.  
socioeconomic status (SES). A measure of social and economic factors that helps to describe a 
person’s standing in society (e.g., income level, relationship to the national poverty line, 
educational achievement, neighborhood of residence, home ownership).  
stratification. A technique for dividing data into homogenous groups (strata).  
trend. A long-term movement or change in frequency, usually upward or downward; may be 
presented as a line graph.  
triangulation. Synthesis of data to compare and contrast the results of different kinds of research 
that address the same topic.  
validity. The extent to which a measurement is appropriate for the question being addressed or 
measures what it is intended to measure (may be applied, for example, to an instrument for data 
collection or specific questions in a survey).  
year of diagnosis. The year in which a diagnosis of HIV infection was made.  
years of potential life lost (YPLL). The number of years that persons would have lived if they 
had not died of the disease of interest. Calculated by summing the years that persons would have 
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